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ABSTRACT
Chronic ulceration of the lower limb represents a significant clinical 
challenge in today’s aging society. Depletion of growth factors at the chronic wound 
site by proteinases and reactive oxygen species, can lead to a protracted non-healing 
wound. Growth factors are known to act in concert to promote wound repair, but 
their topical application rarely leads to a significant clinical improvement in chronic 
wounds, due to premature inactivation in the wound environment. The aim of this 
Study was to synthesise and characterise a polymer-growth factor conjugate and to 
investigate whether the novel concept, called Polymer-masking-UnMasking-Protein 
Therapy (PUMPT), may be used to generate bioresponsive, polymer therapeutics, 
promoting tissue repair. Dextrin and recombinant human epidermal growth factor 
(rhEGF) were chosen as a first model combination.
Dextrin was first modified by succinoylation and conjugated to rhEGF. The 
synthesised dextrin-rhEGF conjugate exhibited increased stability towards 
proteolytic degradation by the clinically relevant enzyme, neutrophil elastase. The 
dextrin component was degraded on exposure to physiological levels of a-amylase, 
leading to sustained release of free rhEGF. Biological activity was assessed in 
proliferation assays in vitro, using cells involved in the normal healing response. 
Polymer conjugation reduced rhEGF bioactivity, however, after exposure to 
physiological concentrations of a-amylase, dextrin degradation led to restoration of 
bioactivity of rhEGF, to the level observed with unmodified rhEGF. Dextrin-rhEGF 
was demonstrated to induce phosphorylation of the epidermal growth factor receptor 
(EGFR), and confirmed a mechanism of action by stimulation of classical signal 
transduction pathways.
Analysis of ex vivo acute and chronic wound fluids, confirmed the presence 
of a-amylase, at levels similar to those used in vitro. Chronic wound fluid also 
contained active neutrophil elastase. In an ex vivo organotypic model of acute 
corneal wound healing, a-amylase-exposed dextrin-rhEGF was demonstrated to 
enhance wound healing, above that of free rhEGF. In an in vivo model of impaired 
wound healing in the genetically diabetic (db/db) mouse, dextrin-rhEGF was 
observed to significantly enhance dermal wound healing, on topical application, at 
delayed intervals. This is the first application of the PUMPT hypothesis in vivo, and 
supports the further development of polymer-protein conjugates as bioresponsive 
nanomedicines for tissue repair.
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Chapter 1 General Introduction
1.1 Introduction
Chronic ulceration of the skin presents a major clinical challenge. In Western 
countries, the incidence of ulceration is rising as a result of the aging population and 
the increase in risk factors, such as smoking, obesity and diabetes (Mekkes et al, 
2003). The prevalence in the UK population aged > 60 years is 3% (Davies et al, 
2007), while recent US figures predict the current figure at 15% of the elderly, rising 
to 25% by 2050 (Harlin et al, 2008). The lack of adequate treatments can result in an 
extremely poor quality of life (Price and Harding, 2004).
Growth factors are known to act in concert to promote wound repair, but their 
topical application rarely leads to a significant clinical improvement in chronic 
wounds, due to premature growth factor inactivation in the wound environment. The 
aims of this Study were to synthesise a polymer-growth factor conjugate and 
investigate whether the novel concept, Polymer-masking-UnMasking-Protein 
Therapy (PUMPT), may be used to generate bioresponsive, polymer therapeutics as 
nanomedicines, capable of promoting tissue repair.
1.2 Structure of the skin
The skin is the largest organ system in the human body. It provides a tough 
protective barrier between the individual and the environment. It consists of three 
distinct layers (Figure 1.1).
1.2.1 The epidermis
The outer, keratinised layer of the skin (epidermis) is composed of a series of 
distinct layers. The multilayer stratified squamous epidermis consists of stratum 
germinativum (basal cell layer), stratum spinosum, stratum granulosum, stratum 
lucidem and stratum corneum, the outermost keratinized layer (Underwood, 1994). 
The different layers represent progressive cellular differentiation and proliferation. 
The cells migrate from the basal layer in an immature form, to the stratum corneum 
where they become flattened, differentiated, keratin-filled cells, prior to their 
shedding. The epidermis contains no blood vessels and the cells rely on the 
underlying dermis for nutritional support. Other cell types present, include 
Langerhans cells (immune-derived), melanocytes (pigment producing) and Merkel 
cells (sensory nerve endings) (Fuchs, 2007; Boulais and Misery, 2008).
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Figure 1.1 The structure of human skin, (a) The outer epidermis (magnified), 
consists of distinct layers of keratinocytes. As the cells mature, there 
is outward progression through the stratified epithelium ((D - (D). (b) 
The epidermis is supported on the dermis, in which the dermal neuro­
vascular plexus is located, in addition to dermal and epidermal 
derivatives, such as hair follicles and sweat glands (Skin Care Forum, 
2001a and 2001b).
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The proliferation and differentiation of basal keratinocytes is regulated by a 
number of factors, including the extracellular matrix (ECM) (Even-Ram and 
Yamada, 2005), hormones, cytokines and growth factors (Werner et al, 1994; auf 
dem Keller et al, 2004; Sivamani et al, 2007).
1.2.2 The basement membrane
The basement membrane (BM), is a specialized basal lamellar structure that 
separates the basal layer of keratinocytes from the dermis. It is attached to the basal 
keratinocytes by hemidesmosomes, and to the dermis by anchoring fibrils of type VII 
collagen. It consists of two layers, the upper lamina lucida, containing laminin and 
entactin, and the lower lamina densa, rich in type IV collagen (Borradori and 
Sonnenberg, 1996; Chan, 1997; Shimizu, 1998; Ghohestani et al, 2001; Masanuga,
2006). The BM acts as a barrier to large molecules, between the dermis and 
epidermis.
1.2.3 The dermis
The dermis is the inner layer of the skin, consisting of the upper papillary 
zone and lower reticular zone. The papillary dermis consists of mainly type I 
collagen, with some type II collagen and elastin. These connective tissue fibres are 
embedded in an ECM rich in proteoglycans and glycoproteins (Carrino et al, 2003). 
The reticular dermis consists of a more dense arrangement of collagen and elastin 
and contains blood vessels, nerves and skin appendages (hair follicles, sweat glands). 
The cells of the dermis are mainly fibroblasts, located in the papillary zone (Sorrell et 
al, 2007).
The papillary dermis is the interface between the dermis and the epidermis 
(the dermo-epidermal junction, DED). It consists of irregular papillae, which project 
into the epidermis, providing a large surface area for the transfer of nutrients. Nerves 
also traverse the DED, via these papillae. The amorphous ECM, which comprises the 
bulk of the dermal tissue, binds water, allowing nutrients, hormones and waste 
products to pass through the dermis (Burgeson and Christiano, 1997).
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1.2.4 The hypodermis
The hypodermis, or subcutis, is not strictly part of the skin, but it does 
provide support for the overlying structures and attachment for deeper tissues. It 
contains adipose tissue, fibrous tissue, blood vessels, lymphatics and nerves, to and 
from the skin (Kanitakis, 2002).
1.3 Wound healing
Wound healing is a dynamic pathway that optimally leads to restoration of 
tissue integrity and function. Under normal conditions, it is a complex process 
involving a highly regulated cascade of biochemical and cellular events, designed to 
achieve a healed wound over a predictable time-frame. Healing can occur by 
regeneration of the damaged tissues, such as in hepatic injury (Fausto, 2000); or 
more commonly by repair, in which damaged tissues are replaced by collagenous 
scar tissue, which acts to restore tissue continuity and function (Gurtner et al, 2008). 
Over time, this scar can mature to be almost clinically indistinguishable from the 
surrounding undamaged tissue.
1.3.1 Normal wound healing
Normal wound healing occurs in three phases, an inflammatory phase, a 
proliferative phase and a maturational phase. The inflammatory phase is 
characterised by haemostasis and inflammation. It is clinically characterised by the 
cardinal signs of redness {rubor), heat (calor), swelling {tumour), pain {dolor) and 
loss of function (Underwood, 1994).
1.3.2 Inflammatory phase
The inflammatory phase begins at the time of wounding and lasts 24-48 
hours. Collagen exposed during wounding activates the clotting cascade (both 
intrinsic and extrinsic pathways), via clotting factors, kinins, tissue factor and 
platelets. This in turn initiates the inflammatory phase. Injured cells release 
thromboxane A2, causing local vasoconstriction to stem the flow of blood, followed 
by the release of histamine, which produces a vasodilatory action, increasing the 
concentration of inflammatory and wound repair mediators (Andrews et al, 1997; 
Martin, 1997). The complement cascade of plasma proteins is also activated to aid
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coagulation and combat infection. These immediate vascular responses allow the 
next step of cellular responses to occur in the vicinity of the wound.
The coagulation cascade produces a cross-linked fibrin plug at the wound 
site. This provides the provisional matrix for cellular migration (Martin, 1997; 
Broughton et al, 2006a; Broughton et al, 2006b; Werner et al, 2007). The initial 
platelet response involves degranulation and the release of multiple chemokines, 
including epidermal growth factor (EGF) and platelet-derived growth factor (PDGF); 
fibronectin; fibrinogen; histamine; serotonin and von Willebrand’s factor (vWF) 
(Martin, 1997; Goldman, 2004; Li et al, 2007). These factors help to stabilize the 
wound through clot formation and act to control bleeding and limit the extent of 
injury. Platelet degranulation also activates the complement cascade, specifically via 
C5a, which is a potent chemoattractant for neutrophils, the second cellular type to 
enter the wound. The neutrophil is responsible for debris scavenging, the 
complement-mediated opsonisation of bacteria and bacterial phagocytosis, via 
reactive oxygen species (ROS) production in the form of superoxide radical species 
(O2 ’ ~) and hydrogen peroxide (H2O2) (Wlaschek and Scharfetter-Kochanek, 2005). 
The neutrophils decontaminate the wound, removing bacteria and foreign debris 
(Moseley et al, 2004). Local disruption of blood flow, due to the vasoactive 
mediators, produces margination of the neutrophils, allowing them to attach to the 
vascular endothelium. This is aided by interleukin-1 (IL-1); tumour necrosis factor-a 
(TNF-a); histamine; bradykinin; and the complement and coagulation cascade 
proteins (Gillitzer and Goebeler, 2001; Oberyszyn, 2007). Neutrophils can directly 
kill bacteria, but also release potent chemokines and immunoglobulins (Hubner et al, 
1996; Wetzler et al, 2000).
The next cellular types to enter the wound are monocytes/macrophages. The 
macrophage plays a critical role in removing debris and bacteria, but most 
importantly, orchestrates the subsequent events in wound healing (DiPietro, 1995; 
Martin and Leibovich, 2005). These are a primary source of cytokines and growth 
factors, such as TNF-a, PDGF, and transforming growth factor-p (TGF-B), that in 
addition to the stimulation of ECM production by fibroblasts, promote angiogenesis 
and the stimulation of keratinocytes (Sunderkotter et al, 1994; Tredget et al, 2005; 
Bandyopadhyay et al, 2006; Werner et al, 2007). These growth factors also act in an 
autocrine fashion to dramatically amplify their expression tremendously (Holman
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and Kalaaji, 2006). This step marks the transition between inflammation and cellular 
proliferation.
1.3.3 Proliferative phase
The second stage of normal wound healing is the proliferative phase that 
typically begins at day three, following wounding. Re-epithelialisation, angiogenesis, 
granulation tissue formation and collagen deposition, are the principle steps in this 
anabolic phase of wound healing. The previously dominant neutrophils and 
macrophages are also replaced by fibroblasts (Clark, 1993).
The fibroblasts from the adjoining, undamaged tissues, migrate into the 
wound matrix, under the influence of cytokines. The movement of cells is possible, 
due to their ability to bind and release fibronectin, fibrin and vitronectin (constituents 
of the thrombus) (Greilling and Clark, 1997; Clark et al, 2004; Briggs, 2005; Lygoe 
et al, 2007) and the action of proteolytic enzymes (matrix metalloproteinases, MMP - 
1, -2, and -3) (Sasaki et al, 2000; Brown et al, 2007). The MMPs permit cell 
migration through the matrix. There is also proliferation of native, as well as newly 
arrived mesenchymal cells. These fibroblasts synthesise and secrete collagen and 
proteoglycans (Hardingham and Fosang, 1992; Yanagishita, 1993; McGrath and 
Eady, 1997; Lee et al, 2004; Meshel et al, 2005; Larsen et al, 2006) of the 
connective tissue ECM that unites wound edges together, by assuming the polymeric 
form (Sottile and Hocking, 2002; Gildner et al, 2004). Normal layers of epidermis 
are restored in 2-3 days. If the basement membrane has been destroyed, similar to 
deep-dermal and full-thickness bums, then the wound is re-epithelialised from the 
normal cells in the periphery and from skin appendages, if intact (e.g. sweat glands, 
hair follicles) (Martin, 1997; Fuchs, 2007; Sivamani et al, 2007; Woo et al, 2007).
Angiogenesis can be initiated by multiple stimuli, including raised lactate 
levels, a decreased pH, and growth factors, such as vascular endothelial growth 
factor (VEGF) (Madri et al, 1996; Carmeliet and Jain, 2000). These capillary sprouts 
grow by proliferation of their endothelial cells. During wound healing, the new 
vessels soon adjoin with their counterparts and recanalisation occurs, thus restoring 
blood flow. In wounds healing by secondary closure, or secondary intention (i.e. 
wound edges not directly apposed by surgical sutures), the new capillaries fuse with 
their neighbours migrating in a similar direction, so forming granulation tissue. The 
granulation phase and tissue deposition require nutrients supplied by the capillaries,
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although failure for this to occur may result in a chronically unhealed wound. In this 
granulation sub-phase, fibroblasts differentiate to synthesise the ECM (Martin, 1997; 
Desmouliere et al, 2005). The ECM is deposited into the wound bed, whilst collagen 
is then deposited as the wound goes under the final stages of repair. Cytokines and 
growth factors, such as insulin-like growth factor (IGF), EGF and PDGF, are 
involved in this process (Gillitzer and Goebeler, 2001; Edmondson et al, 2003; 
Grazul-Bilska et al, 2003).
Re-epithelialisation can be divided into separate cellular events, including 
cell differentiation, mitosis, migration and proliferation, which begin within hours of 
injury and results in the resurfacing of the denuded area (Martin, 1997). The earliest 
aspect of this process is the thickening of the basal layer at the wound edge. The 
marginal basal layer then elongates and detaches from the basement membrane, with 
subsequent migration into the wound. These keratinocytes migrate in a single layer in 
a “sliding sheet” fashion (Zhao et al, 2003), exhibiting contact guidance, usually 
along the orientation of the collagen fibres, until they meet similar cell types and the 
process reverts to a resting phase, due to contact inhibition (Sivamani, 2007). Cells 
from this monolayer subsequently differentiate into the multilayer, stratified 
squamous epidermis. Subsequently, new surface cells begin to keratinise. This 
process occurs under the influence of hepatocyte growth factor (HGF), keratinocyte 
growth factor (KGF), EGF, TGF-a, IGF and members of the fibroblast growth factor 
(FGF) family (Werner et al, 1994; Toyoda et al, 2001).
1.3.4 Maturational phase
The final phase of normal wound healing is the maturational phase. This 
commences at about 8 days, post-injury, and continues over the following months or 
years (Broughton et al, 2006b). Once the fibroblast has migrated into the wound, it 
switches its main function to that of protein synthesis. Collagen is the major 
component of the skin, granulation tissue and mature scar and is synthesised 
primarily by fibroblasts (Van der Rest and Garrone, 1991; Prockop and Kivirikko, 
1995). The rate of production increases rapidly over the initial 2-4 weeks, until 
collagen production and collagen degradation, due to MMPs and other mediators of 
ECM turnover become equal (Tyrone and Mustoe, 1999). This balance occurs 
between the action of MMPs and tissue inhibitors of MMPs (TIMPs), which
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regulates the dynamic remodelling of the dermal ECM (Bode et al, 1999; Lauer- 
Fields et al, 2002; Bode and Maskos, 2003; Visse and Nagase, 2003; Nagase et al,
2006). After 4 weeks, the production of collagen begins to decline. Collagen is 
deposited randomly in the acute wound granulation tissue. Initially, type III collagen 
is deposited, but becomes replaced by type I collagen fibrils, which are laid down in 
a more well-aligned formation, to increase the tensile strength of the wound. This 
progresses until the ratio of type I: type III collagen is restored to that of normal skin. 
With remodelling, there is a dynamic turnover of collagen, in response to tensile 
forces, where collagen synthesis equals collagenolysis (Chiquet et al, 2003; Silver et 
al, 2003).
Replacement of the dermal ECM is complex, as it contains components other 
than collagen. These include proteoglycans, fibronectin and elastin. Proteoglycans 
are synthesised primarily by fibroblasts and consist of a protein core, covalently 
linked to glycosaminoglycans (GAG), including chondroitin sulphate or dermatan 
sulphate (Sugahara et al, 2003; Raman et al, 2005; Taylor and Gallo, 2006). 
Hyaluronan is also an important structural and functional component of the ECM 
wherever there is rapid tissue proliferation, regeneration and repair (Chen and 
Abatangelo, 1999). Hyaluronan stabilises the clot matrix, activates inflammatory 
cells, and modulates all stages of wound repair (Laurant and Fraser, 1992; Almond, 
2007; Meran et al, 2007; Price et al, 2007). Fibronectins are primarily attachment 
proteins and important in the phases or wound healing, including fibroblast migration 
(Briggs, 2005). The formation of a new ECM results in a tensile strength plateau, 
achieved after approximately 2 years, to about 80% of the normal strength of the 
surrounding undamaged tissues, past which the strength will not increase. 50% of 
this strength is gained in the first 6 weeks, post-injury (Tyrone and Mustoe, 1999).
The wound is eventually closed by the migration of epithelial cells from the 
wound edge, filling the defect until they reach other epithelial cells and halt their 
advance, by the process of contact inhibition. Although this adds nothing to wound 
strength, and remodelling continues under the epithelial cover (Martin et al, 1992). 
When wound fibroblasts reach a concentration with which their density causes 
contact inhibition, they differentiate into myofibroblasts, containing a-smooth 
muscle actin fibrils (Gabianni, 1992; Desmouliere et al, 2005; Darby and Hewitson, 
2007; Hinz, 2007; Hinz et al, 2007). This begins 4-5 days, post-injury, and is
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represented by the centripetal movement of the wound edges towards the centre of 
the wound. Myofibroblasts in the injured area are believed to be responsible for 
wound contraction. Over time, the volume of injured tissue is replaced by uninjured 
tissue. The scar becomes reduced in cell content and blood supply, represented 
clinically by the change in colour, texture and size of the scar, as the body tries to 
remodel the immature scar tissue (Bond et al, 2008).
1.3.5 Chronic impaired wound healing
A chronic wound can be clinically described as a wound that has not healed 
after 3 months (Tyrone and Mustoe, 1999). It can be more accurately diagnosed by 
the presence of high levels of chronic inflammatory cells, including neutrophils, 
macrophages and lymphocytes, a defective wound ECM, and a failure of 
epithelialisation (Herrick et al, 1992). Impaired wound healing can result from local 
or systemic causes. Local causes include trauma, infection, ischaemia, foreign bodies 
and elevated tissue pressure, whilst systemic causes, such as diabetes, advanced age, 
drug therapy and endocrine disturbance, can compound the effects of the build up of 
chronic wound metabolites (Broughton et al, 2006a).
Dermal fibroblasts play a pivotal role in controlling wound healing responses 
and variations in fibroblast phenotype have been observed, relating to the wound 
healing phenotype (i.e. the acute or chronic wound) (Sempowski et al, 1995; 
Stephens et al, 1996; Al-Khateeb et al, 1997; Stephens et al, 2001; Wall et al, 2008). 
Numerous alterations have been described in association with aging and the onset of 
cellular senescence, including increases in MMP-1 and -2 production, increased ROS 
generation, increased IL-1 and IL-15 expression, and decreased IL-6 expression 
(West et al, 1989; Mendez et al, 1998; Shelton et al, 1999) The accumulation of 
senescent fibroblasts within the chronic wound tissues, play an important role in 
mediating inflammation and impaired ECM remodelling, which is a key feature of 
the disease (Stephens et al, 2003).
A number of growth factors (e.g. EGF, PDGF, VEGF, TGF-P), act in concert 
to promote normal wound repair (Goldman, 2004; Blakytny and Jude, 2006; Li et al,
2007), but have been shown to be at reduced levels in chronic wound exudates 
(Yager et al, 1997; Trengove et al, 1999). This is likely due to rapid protein 
degradation by chronic wound proteinases, especially neutrophil elastase, and/or
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denaturation by ROS (Yager et al, 1997; Wlashek et al, 1997; James et al, 2003; 
Moseley et al, 2004; Wlashek and Scharfetterr-Kochanek, 2005).
ROS is a term encompassing oxygen free-radicals, including the O2 ’ ~~ and 
hydroxyl (*OH) radical species, as well as non-radical oxygen derivatives, such as 
H2O2 and hypochlorous acid (HOC1) (Moseley et al, 2004). Reactive nitrogen species 
(RNS) are similar, and include the nitric oxide (NO*) radical species and 
peroxynitrite (ONOO ) (Waddington et al, 2000). RNS and ROS are derived from 
both inflammatory cells and endothelial cells and possess beneficial roles in wound 
healing, enhancing bactericidal activity and modulating many functions including: 
vasodilatation, granulation tissue formation, re-epithelialisation and ECM turnover 
(Stallmeyer et al, 1999; Waddington et al, 2000; Pollock et al, 2001; Sen et al, 2002; 
Rizk et al, 2004). The overproduction of ROS and RNS in chronic wounds can lead 
to an imbalance in the oxidant/antioxidant status and cause indiscriminate damage 
to cellular constituents, including deoxyribonucleic acid (DNA), lipids and proteins. 
In addition, ROS and RNS can directly and indirectly modify and degrade the ECM 
components of the skin, including collagen, proteoglycans and hyaluronan (Moseley 
et al, 2004). Direct cellular effects of ROS and RNS include impaired migratory, 
proliferative and ECM synthetic properties of dermal fibroblasts and keratinocytes 
(Agren et al, 1997; Pfeilschifter et al, 2001; Moseley et al, 2002; Wlascheck and 
Scharffetter-Kochanek, 2005). The various roles of these biochemical markers of 
chronic wound healing are summarised in Figure 1.2.
The normal healing process is “stalled” in a chronic inflammatory process, 
high in pro-inflammatory cytokines and wound proteinases, and low in growth 
factors, which are essential for the normal progression to the proliferative phase of 
wound healing. Without such progression, the clinical entity of the non-healing 
wound, is apparent.
1.3.6 Pathophysiology of chronic wounds
The aetiology of leg ulcers, includes venous insufficiency, diabetes, arterial 
insufficiency or a combination of these factors (Mekkes et al, 2003). In these 
wounds, the structured normal healing process is frequently disrupted by an 
underlying abnormality; prolonging the inflammatory phase and limiting progression 
to the proliferative phase of wound healing. Thus, a cascade of responses are 
generated that perpetuate the non-healing state.
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Figure 1.2 Degradation of the extracellular matrix (ECM) by proteolysis and reactive oxygen species 
(ROS). In the chronic wound, the ECM is degraded, leading to a failure of re-epithelialisation 
(adapted from Moseley et al, 2004).
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1.3.7 Venous leg ulceration
Venous ulcers are the most common form of leg ulcer, accounting for about 
70% of all cases in the UK (Sarkar and Ballantyne, 2000). Overall, these ulcers affect 
approximately 1% of the population (Fowkes et al, 2001). The concept of venous 
stasis suggests that stagnant blood lying in tortuous and dilated, superficial veins 
close to the skin, can cause tissue anoxia and cell death. There is usually an 
underlying causative factor, leading to the rise in venous pressure, which affects the 
capillary network, preventing the normal arterio-venous flow of blood. Nearly half of 
patients affected have a previous history of deep vein thrombosis (DVT), while the 
remainder have evidence of incompetent perforating veins that connect the deep and 
superficial venous systems of the leg (Valencia et al, 2001; Rajendran et al, 2007).
There is usually a preceding stage to ulceration, called lipodermatosclerosis 
(Herouy et al, 1999). Excessive proteolytic activity by proteinases, especially MMP- 
1, -2, -8 and -9, and fibrinolytic factors of the plasminogen activation system, lead to 
an abnormal ECM. There is also reduced expression of TIMPs and TGF-fi, leading to 
an imbalance in normal wound healing (Moseley et al, 2004). After the initial trigger 
and disruption of the epidermis, wound healing has already taken a pathological path.
Venous stagnation can cause ulceration, via tissue anoxia, resulting in cell 
damage/death. Other propagating factors can include, the leakage of macromolecules 
into the ECM, that leads to an accumulation of fibrin that can create a barrier for 
oxygen and nutrient transfer (Dormandy, 1997; Stacey et al, 2000; Brown, 2005). 
Trapped neutrophils can also block superficial lymphatics, further impeding the flow 
of toxins from the skin and surrounding area (Scott, et al, 1991; Falanga and 
Eaglestein, 1993). Other systemic diseases, that can compound a venous ulcer, 
include peripheral oedema from heart and renal failure, arthritis that limits 
mobilisation, and diabetes, which, via various mechanisms, markedly limits 
successful wound healing.
1.3.8 Diabetic foot ulceration
Diabetic foot ulcers occur as a result of a variety of factors. These include 
mechanical changes in the conformation of the bony architecture of the foot, 
peripheral neuropathy, atherosclerotic arterial disease and a reduction in the 
propensity to heal (Leung, 2007). Diabetic foot ulcers are responsible for more
15
Chapter 1 General Introduction
hospitalisations than any other complication of diabetes. In the USA, there are 16 
million diabetics, 15% of which will develop a foot ulcer (Reiber et al, 1998).
Atherosclerosis can affect the non-diabetic population, as well as the diabetic 
population. In diabetics, the disease is more common in the infra-popliteal region, 
affecting smaller vessels and the microvasculature. This is believed to result from a 
number of metabolic abnormalities, including high low-density lipoprotein (LDL) 
and very low-density lipoprotein (VLDL) levels, elevated plasma vWF, inhibition of 
prostacyclin synthesis, increased plasma fibrinogen levels and increased platelet 
adhesion (Stillman, 2008).
Diabetics have a higher incidence of atherosclerosis, thickening of capillary 
basement membranes, arteriolar hyalinosis and endothelial proliferation (Mauer et al, 
1992). Peripheral neuropathy occurs due to a multifactorial process. It clinically 
produces decreased sensation in a “glove and stocking” distribution, usually affecting 
the feet. Initially vibration sense, proprioception and light touch are lost, but over 
time, this can progress to an insensate foot that will be prone to trauma (Sugimoto et 
al, 2000). It is believed to results from reduced blood supply to the nerve via the vasa 
nervosum, due to the microcirculatory pathology. Other possibilities involve a 
deficiency in myoinositol, altering myelin synthesis, diminishing sodium-potassium 
adenine triphosphatase activity, chronic hyperosmolarity, leading to oedema of nerve 
trunks, and increased fructose and sorbitol (Quan, 2008).
Any of these factors can initiate a wound that can become chronic, due to 
repeated trauma. There is also an interruption of the inflammatory and proliferative 
phases of wound healing (Blakytny and Jude, 2006), as neutrophils and macrophages 
cannot adequately control the bacterial load of the wound, as glycosylation is 
inhibitory to phagocytic function, due to advanced glycation end products (AGE) 
(Schmidt et al, 1993). Glycosylated haemoglobin (HbAic) also causes red cells to 
become less pliable, resulting in reduced oxygen delivery and microvascular 
sludging (Candiloros et al, 1995).
1.3.9 Pressure ulceration
Pressure ulcers have been described as decubitus ulcers and pressure sores. 
Both terms have been interchangeable in the medical literature. Pressure sores have 
mulitfactorial causation. Many factors contribute to the development of a pressure
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sore, but pressure leading to ischaemia and cell death is the final common pathway 
(Baranoski, 2006).
In the USA, the prevalence in nursing homes is 17-28%, amongst the 
neurologically impaired is 5-8% annually, and in acutely hospitalised patients, is 3- 
11% (Revis and Caffee, 2006). Anatomically, the hip and buttock region account for 
two-thirds of all pressure sores, with the ischial tuberosity, greater trochanter and 
sacral areas, most commonly affected. The lower extremity accounts for one quarter 
of pressure sores, with the malleolus, heel, knee and pre-tibial areas, usually affected. 
The remaining sores can occur at any place on the body, but with greater likelihood 
over a bony prominence (Barczak et al, 1997; Wilhelmi and Neumeister, 2008).
Pressure is exerted upon the skin, soft tissue, muscle and bone, by the weight 
of the individual onto the surface beneath. These pressures are often in excess of 
capillary filling pressure, approximately 32 mm Hg (Revis and Caffee, 2006). 
Tissues are capable of withstanding much higher pressures in short duration, with no 
lasting damage. However, sustained pressure, just above the capillary filling 
pressure, is enough to cause an ulcer. Shear forces and friction can aggravate the 
pressure effect, as can tissue maceration. Microcirculatory occlusion leads to tissue 
anoxia, cell death and ulceration. Irreversible changes can happen within 2 hours of 
uninterrupted pressure (Ryan, 2000).
In patients with normal mobility, sensation and mental faculty, pressure sores 
do not occur. Conscious and unconscious feedback allows individuals to adjust their 
weight to shift the pressure from one area to another and prevent damage. Individuals 
unable to avoid long periods of uninterrupted pressure, include the elderly, the 
neurologically impaired and patients hospitalised with acute illness. These are the 
groups most at risk of pressure sore development (Baranoski, 2006), who cannot 
protect themselves from the pressure exerted upon their bodies, unless they 
consciously change position or have assistance in doing so.
Although prolonged, uninterrupted pressure is the cause of a pressure sore, 
impaired mobility is probably the most common reason patients are exposed to it, 
Pressure effects can be augmented by bacterial contamination or macerated skin, due 
to urine and faecal incontinence, which may be high in these groups. Contractures 
and spasticity often contribute by rigidly holding a joint in flexion against a surface, 
and increasing the exposure to friction and shear forces (Klenck and Gebke, 2007).
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1.4 Current treatment strategies
Due to the prolonged and excessive inflammation that perpetuates chronic 
wounds, current treatment strategies are aimed at reducing inflammation. Surgical 
debridement and wound care are aimed at decreasing the necrotic tissue and 
proteinase burden, thus providing a virtual resetting of the wound, to an acute healing 
phase (Menke et al, 2007). Other methods of debridement can include the use of 
larval therapy and wound dressings that can promote autolysis (Mumcuoglu, 2001). 
After suppression of the inflammatory response, current strategies include methods 
to replace the lost or abnormal dermis, with a synthetic or donor equivalent. Recent 
advances in wound dressings include acellular matrices, composed of GAG and 
collagen (Biobrane™, Smith & Nephew, UK), to provide a scaffold for native 
fibroblast growth (Balasubramani et al, 2001; Jones et al, 2002). Matrices containing 
cultured skin fibroblasts and keratinocytes (TransCyte™, Smith & Nephew, USA; 
My Skin™, CellTran Ltd., UK) have also been recently introduced (Moustafa et al, 
2007; Tenenhaus et al, 2007).
To promote cellular proliferation and migration into the wound space, growth 
factors have also been studied in models of acute and chronic wound healing, both in 
vitro and in vivo. With the action of chronic wound proteinases, such as neutrophil 
elastase, and ROS, aforementioned, the levels of native growth factors are known to 
be reduced in the chronic wound environment (Yager et al, 1997; Wlashek et al, 
1997; James et al, 2003; Moseley et al, 2004; Wlashek and Scharfetterr-Kochanek, 
2005). Initial studies involving exogenous growth factors in impaired wound healing 
were initially disappointing, but as Falanga (1993) postulated “If one looks at the 
development of most drugs, it becomes evident that an extended period of time is 
necessary before the proper use and full range o f activities o f the drug in treating 
human disease become apparent. In many cases, initial treatment failures are due to 
faulty expectations, as well as inadequate dosing and delivery systems. It is my 
opinion that growth factor therapy will follow a similar course but that it ultimately 
will have a role in the modulation of wound repair”.
1.4.1 Growth factors
In 1992, Pittelkow proposed seven growth factors - EGF, basic and acidic 
FGF, TGF-a and TGF-p, PDGF isoforms AA, -AB and -BB, and IGF, as being the
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most promising as potential wound-healing agents (Pittelkow, 1992). To date, the 
only growth factor currently licensed for the treatment of chronic wounds in the UK 
and USA, is PDGF-BB (bacaplermin), in the form of a topical gel (Regranex™ 
0.01% PDGF-BB; Johnson & Johnson, UK). In the UK, it is licensed as an adjunct 
treatment for fiill-thickness, neuropathic, diabetic ulcers (British National Formulary,
2008)
The pre-clinical development of Regranex™ involved multiple in vitro and in 
vivo studies (LeGrand, 1998). Regranex™ was shown to be a potent chemotactic, 
mitogenic, and activation agent for cell types (fibroblasts) thought to be essential in 
normal soft-tissue repair (Grotendorst et al, 1981; Deuel and Huang, 1982; Seppa et 
al, 1982). In animal models (rat, rabbit, pig, guinea pig, diabetic mouse), Regranex™ 
greatly accelerated normal tissue repair and reversed deficient repair in 
experimentally inflicted wounds, via the deposition of an enhanced provisional 
matrix and collagen (Pierce et al, 1988; 1989; Mustoe et al, 1989, 1991; Lynch et al, 
1989; Senter etal, 1995; LeGrand, 1998).
Phase I/II clinical trials showed promising, but not significant, effects on 
wound healing in pressure ulcers, and no toxic effects were observed (Robson et al, 
1992a; 1992b). Phase III studies of topical becaplermin in diabetic ulcers, in 
conjunction with good wound care, showed a significant decrease in the time for 
complete wound closure, with a safety profile similar to the placebo (Wieman et al, 
1998). A meta-analysis of four phase III trials, involving 922 patients with diabetic 
ulcers, identified significant outcomes in small ulcers (<1.5 cm2), with enhanced 
wound closure, in conjunction with good wound care (Smiell et al, 1999). A phase 
IV clinical trial concluded that topical becaplermin should be used in diabetic ulcers 
that have not healed by more than 50 % after 4 weeks, using an appropriate wound 
treatment (Steed, 2006).
More recently, in March 2008, the Federal Drug Administration (FDA) 
reported an ongoing safety review of Regranex™, concluding that people who have 
used three or more tubes of becaplermin gel, and who have or develop cancer, are 
more likely to die from the cancer than people who have cancer, and who have not 
used becaplermin gel (Federal Drug Administration, 2008). However, despite these 
concerns, the product still remains licensed for use, at present.
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The first clinical trials involving recombinant growth factors examined 
treatment with recombinant human EGF (rhEGF) of donor sites in patients who 
required skin grafting for either bums or reconstructive surgery (Brown et al, 1989). 
The topical effect of rhEGF, on wound healing, has been studied extensively in the 
literature (Figure 1.3). The topical application to acute wounds (Franklin and Lynch, 
1979; Brown et al, 1989; Hong et al, 2006), has been shown to enhance healing. 
RhEGF has been available since 1984 (Brake et al, 1984), which led to a rapid 
upsurge in the wound healing research, relating to EGF. In the early 1990’s, no 
significant effects of rhEGF in the treatment of chronic wounds was shown (Falanga 
et al, 1992), potentially due to growth factor degradation by chronic wound 
proteinases and ROS, thereby limiting rhEGF efficacy and bioactivity (Tamuzzer et 
al, 1997; Wlascheck et al, 1997; Yager et al, 1997; Moseley et al, 2004; Wlaschek 
and Scharffetter-Kochanek, 2005).
rhEGF-containing topical gels for the treatment of diabetic foot ulcers are 
currently being marketed in India (ReGen-D™ 150; Bharat Biotech International, 
India), Cuba (Hebermin; Cuban Biotechnology, Cuba) and South Korea (E.G.F. Plus; 
Medikims Ltd., South Korea) (Mola et al, 2003; Frew et al, 2007). Although these 
products are gel matrices containing rhEGF, there is no chemical modification of the 
growth factor, or conjugation to the carrier matrix. In essence, these gels are a topical 
formulation of rhEGF that may be susceptible to the action of chronic wound 
proteinases. A phase IV clinical study (Krishna Mohan, 2007), has shown increased 
efficacy of one of the products (ReGen-D™ 150), in selected diabetic foot ulcers (< 
200 cm3, remaining unhealed after 2 weeks from diagnosis). A significant rate for 
wound size reduction was recorded, although time for total wound closure was 
similar to controls. This effect may be due to the short duration of rhEGF action, 
prior to possible proteolytic/ oxidative degradation. Stimulation of granulation tissue 
formation was noted to occur, but the rate of wound closure slowed as the study 
progressed (by the time 100% of the treated group had healed, over 90% of the 
control group had also healed without treatment). The study was also performed by 
the company that produced ReGen-D™, so a conflict of interest may exist, but such 
results are encouraging. Another rhEGF-related product (ReGen-D™ 60; Bharat 
Biotech International, India), is recommended for use in bum injury, but clinical 
trials are still in progress.
/
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Figure 1.3 The development of epidermal growth factor (EGF) in wound 
healing research. A PubMed search was performed using the 
keywords [epidermal growth factor] + [EGF] + [wound] + [healing] 
and the number of articles per year published recorded. Seminal 
papers during this progression are noted.
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1.4.2 Hypothesis of a polymer-rhEGF conjugate, as a novel therapy for 
chronic wounds
In this present Study, it is proposed that, by conjugating rhEGF to a polymer 
via reactive amine groups, the production of a polymer therapeutic agent could be a 
novel therapy for chronic wounds. Conjugation to a polymer may protect the rhEGF 
from proteolytic/oxidative degradation and allow the site-specific, controlled release 
of the growth factor. With the possibly enhanced stability of the protein, a reduced 
dose may be utilised to reduce unwanted side effects while, via the Enhanced 
Permeability and Retention (EPR) effect (Matsumura and Maeda, 1986) (vide infra), 
both systemic and topical delivery of the polymer therapeutic may be employed. The 
development of the conjugate will follow a similar stepwise plan as Regranex™, with 
initial in vitro studies leading to ex vivo and in vivo models of normal and impaired 
wound repair.
1.5 Polymer therapeutics as novel wound healing agents
The proposed polymer-rhEGF conjugate is a polymer therapeutic. This term 
encompasses many structures, including polymeric drugs, polymer-drug conjugates, 
polyplexes, polymer-protein conjugates and polymeric micelles. Figure 1.4 shows 
schematics for each of these polymer therapeutics.
Polymeric drugs are entities, which are biologically active in their own right. 
In this context, polymeric micelles are micelles in which a drug is covalently bound 
to the core of the micelle. Polymer-drug conjugates consist of a bioactive drug, 
covalently attached to a water-soluble polymer, through a spacer group. In order to 
target specific locations in the body, it is also possible to attach a targeting residue, 
which enhances receptor-mediated pinocytosis of the conjugate. Polymer-protein 
conjugates consist of a protein, conjugated to a water-soluble polymer (Duncan, 
2003). These polymeric macromolecules are in the size range of one to hundreds of 
nanometres and are hence, referred to as nanomedicines (European Science 
Foundation, 2005).
1.5.1 Nanomedicines and wound healing
In recent years, there has been little published in relation to nanomedicines 
and wound healing. The majority of articles focus on non-dermal wound healing, for
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Figure 1.4 Polymer therapeutics, (a) The different classes of polymer 
therapeutics, with examples of entities that are either in clinical 
trials, or are licensed for use in the UK (adapted from Duncan, 
2003). (b) Examples of the benefits of polymer therapeutics over 
traditional pharmaceutics.
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example, spinal injury repair (Ellis-Behnke et al, 2006; Guo et al, 2007; Hampton,
2007). Nano-sized particles containing antibiotics or antimicrobials (Tian et al, 2005; 
Kim et al, 2007) can be applied to wound healing. Indeed, the use of silver 
nanoparticles, in vivo, has been shown to promote wound repair (Fong and Wood, 
2006; Wong et al, 2006; Sibbald et al, 2007; Vlachou et al, 2007; Bhattacharyya and 
Bradley, 2008). A composite ECM (Han and Gouma, 2006), synthesised from 
cellulose acetate, has been electrospun to produce a urinary bladder matrix. Similar 
principles could be applied to the dermal ECM, as has been shown with 
electrospinning of various macromolecules (collagen, gelatins, chitosan) (Rho et al, 
2006; Chong et al, 2007; Zhou et al, 2008). Accelerated wound healing has also been 
demonstrated using a self-assembling peptide nanoscaffold, in conjunction with 
rhEGF (Schneider et al, 2008). The reduction of scar tissue formation has also been 
noted with a variety of nanoscale materials (Shaunak et al, 2004; Webster, 2006).
1.5.2 Rationale for designing nanomedicines: The EPR effect
The underlying principle for attaching a protein to a polymer is that 
conjugation can extend the plasma half-life, reduce immunogenicity, mask protein 
charge, reduce toxicity, and can also allow passive targeting by the EPR effect 
(Matsumara and Maeda, 1986). Although originally described in the context of 
tumours, which tend to have an extensive and disorganised vasculature, compared to 
normal tissues, the process of neovascularisation that occurs in some wound healing 
states may mimic this (Nagy et al, 2008). The pathophysiology responsible for 
increased permeability can be attributed to an increase in fenestrae, a discontinuous 
basement membrane, enlarged inter-endothelial junctions and an increased number 
of vesicles (Hashizume et al, 2000; McDonald and Foss, 2000). Thus, the EPR effect 
can be exploited in the delivery of polymer therapeutics. While conventional, low 
molecular weight drugs, can pass readily through the bloodstream, into the tissue or 
be excreted, polymer therapeutics can accumulate in target tissues, due to the EPR 
effect (Seymour et al, 2002; Reddy, 2005). Although, initial studies will focus upon 
the topical application of polymer conjugates to the wound bed, the possible benefits 
of the EPR effect must also be considered in the drug design process.
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1.5.3 Polymer-protein conjugates
Ever since dextran-streptokinase (Streptodekase®) was first used clinically 
(Torchilin et al, 1982), polymer therapeutics have become increasingly popular for 
delivering proteins, peptides and antibody-based therapeutics, with polymer-protein 
conjugates being the first polymer therapeutics to be used in practice. An ideal 
polymer-protein conjugate should be water-soluble, stable and bioactive. In addition, 
the polymer needs to be excreted safely following delivery of the protein payload 
(Veronese and Morpurgo, 1999).
1.5.4 Clinical development of polymer-protein conjugates
PEGylation was first proposed by Davis and Abuchowski in the 1970s 
(Abuchowski et al, 1977), and has since been used to deliver an extensive range of 
therapeutic proteins, enzymes, cytokines and monoclonal antibody (mAb) fragments. 
PEG is a pharmaceutical excipient that has been extensively studied as a protein 
conjugate. It is a flexible, water-soluble chain, which can extend to give a 
hydrodynamic radius many times greater than a globular protein of equal molecular 
weight. As such, PEG can conceal the protein to which it is bound (Veronese and 
Pasut, 2005).
In 1990, PEG-adenosine deaminase (Adagen™; Enzon Pharmaceuticals, 
USA) became the first polymer-protein conjugate to receive FDA approval. It is used 
for the treatment of severe combined immunodeficiency disease (SCID). Studies 
have demonstrated improved efficacy and reduced immunogenicity of Adagen®, than 
previous therapies, involving blood transfusion or administration of native enzyme 
(Hershfield et al, 1987; Chaffee et al, 1992). In Japan, in the 1980s, Maeda and 
colleagues synthesised styrene maleic anhydride neocarzinostatin (SMANCS), as an 
anticancer agent for localised administration via the hepatic artery, by covalently 
linking two styrene maleic anhydride chains (SMA) to neocarzinostatin (NCS), an 
anti-tumour protein (Maeda and Matsumara, 1989). Previously, NCS had proved to 
be too toxic for clinical use. However, following conjugation to SMA and 
subsequent dispersion in Lipiodol®, a phase contrast agent, it was possible to 
administer it specifically to liver tumour tissue, using visualisation by x-ray. It was 
licensed for use in Japan in 1993 (Duncan, 2003). Shortly after, a PEG-L- 
asparaginase conjugate (Oncaspar™; Enzon Pharmaceuticals, USA), received
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approval by the FDA for the treatment of acute lymphoblastic leukaemia (ALL). 
Asparaginase is also available in a non-conjugated formulation, but Oncaspar™ 
demonstrates longer retention time in plasma, reduced immunogenicity and requires 
only a weekly administration, while unconjugated L-asparaginase requires daily 
administration and can induce anaphylaxis and other hypersensitivity reactions 
(Duncan, 2006; Pasut et al, 2008).
PEG has also been used to deliver cytokines, such as recombinant 
granulocyte colony-stimulating factor (GCSF) (Pegfilgrastim: Neulasta™, Amgen, 
UK; Kinstler et al, 2002), for the treatment of chemotherapy-induced neutropaenia. 
The PEGylated form of GCSF need only be administered as a single subcutaneous 
injection, while native GCSF requires daily dosing by injection for two weeks, to 
obtain equivalent prevention of neutropenia. Other polymer-protein conjugates that 
have come to the market are PEG-a-interferon 2a (Peginterferon alfa: Pegasys™, 
Roche Products Ltd., UK; Reddy et al, 2002) and PEG-a-interferon 2b 
(Peginterferon alfa: ViraferonPeg™, Shering-Plough, USA), for the treatment of both 
hepatitis B and hepatitis C, and PEG-human growth hormone antagonist, for the 
treatment of acromegaly (Pegvisomant: Somavert™, Pfizer, UK). Currently, all of the 
polymer-protein conjugates licensed for use in the UK (Neulasta™, Pegasys™, 
ViraferonPeg™ and Somavert™), are based on PEG conjugation.
Initially, polymer-protein conjugates were developed for the treatment of 
cancer and life-threatening, immunological and haematological disorders. More 
recently, their development has moved to the treatment of chronic diseases. 
However, there are presently no products in the wound management sector that are 
designed around a polymer therapeutic.
1.6 Rationale for design of polymer-rhEGF conjugates
From the viewpoint of the present Study, it was important to select the most 
appropriate polymer for conjugation to rhEGF, in order to fully achieve the 
therapeutic aim. Polymers are high molecular weight substances made from one or 
more small repeating units (monomers). There are many structures of polymers; and 
size, 3-D shape (including crosslinking) and asymmetry determine the properties of 
them. Homopolymers are chains of polymers containing one type of repeating 
monomer. Copolymers contain more than one monomer, and may be an alternating
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copolymer chain, a block copolymer or a graft copolymer. The structure of the 
polymer also varies. It may be linear, star, branched or dendrimer (Duncan, 2005).
1.6.1 Biodegradable polymers for the masking/unmasking of rhEGF activity
Over recent years, the concept of using biodegradable polymers for the 
delivery of therapeutic proteins, has become increasingly attractive. The use of non- 
or slowly biodegradable polymers in macromolecular therapeutics, for an extended 
length of time, have the potential to cause the development of lysosomal storage 
disease (Chi et al, 2006), and, at high concentrations, may lead to other pathological 
metabolic changes (Miyasaki, 1975). In response to these issues, a number of 
polymers have been investigated as biodegradable carriers, including naturally 
occurring polysaccharides, such as dextran and dextrin (Schacht et al, 1987), and 
synthetic polymers, including polyglutamic acid (PGA) (Singer et al, 2003).
The aim of coupling a biodegradable polymer to rhEGF, via reactive amine 
groups, was to create a conjugate, which would not only benefit from the advantages 
of PEGylation, but also render rhEGF inactive, and thus, protect the active binding 
site from degradation by chronic wound proteinases and ROS, yet enable bioactivity 
to be reinstated at an appropriate rate, by triggered polymer degradation. 
Furthermore, since historical polymers for protein delivery were usually required to 
have a molecular weight of < 40,000 g/mol, to permit renal excretion, biodegradable 
polymers allow the selection of much larger polymers (Duncan, 2003).
1.6.2 Polymer masking UnMasking Protein Therapy (PUMPT)
The concept of PUMPT has recently been coined, using dextrin as a model 
polymer (Duncan et al, 2008). The hypothesis is that the conjugation of a 
biodegradable polymer to a biologically active protein can mask activity and enhance 
stability in the bloodstream, while subsequent regeneration of bioactivity can be 
achieved, by the triggered degradation of the polymer, at the target site. The main 
advantages, supporting the use of dextrin, are its multifunctionality and 
biodegradability. Multifunctionality allows the polymer to surround the protein, to 
“mask” protein activity and reduce immunogenicity, prior to “unmasking” of the 
protein, via degradation of the dextrin polymer at the site of action (Figure 1.5).
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Figure 1.5 The Polymer masking-UnMasking Protein Therapy (PUMPT) 
hypothesis. Panel (a) shows conjugate delivery to the chronic wound by 
either topical, or systemic application, with passive accumulation by the 
EPR effect. Panel (b) shows the protection of rhEGF from proteolysis 
by the polymer, the release of rhEGF following exposure to wound fluid 
a-amylase, and the binding to the EGF receptor, with subsequent 
activation of intracellular pathways, leading to cellular proliferation and 
migration.
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1.6.3 Dextrin
The polymer chosen as a model in the present Study was dextrin, a 
biodegradable polysaccharide produced from the enzymatic hydrolysis of cornstarch. 
Dextrin is a a-1,4 polymer of D-glucose, with less than 5 % a-1,6 links, resulting in 
minimal branching of the polymer. It is rapidly degraded by a-amylase, to yield the 
disaccharides maltose and iso-maltose, in just a few minutes (Hreczuk-Hirst et al, 
2001a; 2001b). The amylases are a group of enzymes found in all living organisms, 
that breakdown starches into disaccharides, by acting upon a-l,4-glycosidic bonds, 
a-amylase is found in humans, although not exclusively, whereas p- and 
glucoamylase are found exclusively in plants and microorganisms (Janacek, 1997; 
Pandey et al, 2000). Studies on the a-amylase-mediated degradation of dextrin, have 
revealed that altering the degree of modification to the backbone by succinoylation 
can control the rate of enzymatic degradation (Hreczuk-Hirst et al, 2001a).
Dextrin was chosen as a model for these studies, as it has been used clinically 
for many years, is FDA approved and is Generally Recognised As Safe (GRAS), 
proving it to be non-toxic and non-immunogenic. Caloreen™ is composed of 
maltodextrin, and has been used as a dietary supplement in patients with renal and 
hepatic failure (Woolfson et al, 1976). Following successful clinical safety trials, 
icodextrin (Extraneal®, Baxter International, USA), a dextrin with a MW of ~ 20,000 
g/mol, was approved for routine use as an intraperitoneal dialysis solution for chronic 
renal failure (Davies, 2006). Moreover, dextrin has also been used as a carrier for the 
delivery of 5-fluorouracil to the intraperitoneal cavity (Kerr et al, 1996; Hosie et al, 
2003), and recent reports also describe dextrin’s conjugation to various drugs, 
including doxorubicin, tyrosinamide and biotin (Hreczuk-Hirst et al, 2001b), and 
proteins, including trypsin and melanocyte-stimulating hormone (Duncan et al,
2008).
1.7 Aims of the study
The aim of this Study is to determine the potential of a novel polymer 
therapeutic strategy (PUMPT) for further development as a new treatment for 
chronic wounds. Dextrin has been selected as the most suitable polymer, and rhEGF 
selected as an appropriate growth factor, as it is known to promote wound repair, 
both in vitro and in vivo. A PUMPT agent will be synthesised and evaluated as
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2.1 Chemicals
2.1.1 General chemicals, polymers and reagents
Recombinant human epidermal growth factor (rhEGF) was obtained from 
Prospec-Tany Technogene Ltd, (Rehovot, Israel) and type 1 dextrin from com, was 
supplied by ML Laboratories (Liverpool, UK). Alexa Fluor® 488 dye-labeled EGF 
(EGF-Alexa488) was purchased from Molecular Probes (Invitrogen). 4- 
dimethylaminopyridine (DMAP), ethanol, methanol, acetic acid (glacial), anhydrous 
N,N-dimethylformamide (DMF), sodium chloride, diethyl ether, succinic anhydride, 
sodium dodecyl sulphate (SDS), anhydrous dimethylsulfoxide (DMSO), Tris 
hydrochloride (Tris-HCl), 1-ethyl-3- [3-dimethylaminopropyl] carbodiimide 
hydrochloride (EDC), Triton XI00, tween 20, glycerol, dithiothreitol (DTT), 
ethylenediaminetetraacetic acid (EDTA), copper (II) sulphate pentahydrate (4% w/v 
solution), human neutrophil elastase, human salivary a-amylase, ninhydrin, 
hydrindantin, paraformaldehyde, lithium acetate dihydrate, 98% sodium hydroxide 
(NaOH), bicinchoninic acid solution (BCA), carboxymethylcellulose sodium salt, 
leupeptin, aprotinin (from bovine lung), cytochrome C (from bovine heart), carbonic 
anhydrase (from bovine erythrocytes), bovine serum albumin (BSA), and alcohol 
dehydrogenase (from Saccharomyces cerevisiae), were all purchased from Sigma- 
Aldrich (Poole, UK). Bromothymol blue was purchased from BDH Chemicals Ltd. 
(Poole, UK). V-hydroxysulfosuccinimide (sulfo-NHS) was obtained from Fluka 
(Gillingham, UK). DL-amino-2-propanol was purchased from Acros 
(Loughborough, UK). Marvel® dried skimmed milk powder was purchased from 
Cadbury (Birmingham, UK). Vectashield® mounting medium ± DAPI, was 
purchased from Vector Laboratories Ltd. (Peterborough, UK). Methoxy-alanine- 
alanine-proline-valine-7-amino-4-methylcoumarin was purchased from Bachem UK 
Ltd. (Liverpool, UK). 10% buffered formalin was obtained from Bios Europe, 
Skelmersdale, UK. Nitrogen gas was purchased from BOC (Guildford, UK). Unless 
otherwise stated, all chemicals were of analytical grade.
2.1.2 Chemicals for cell culture
Tissue culture grade DMSO, 3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyltetrazolium bromide (MTT) and 0.02% trypan blue solution, were purchased 
from Sigma-Aldrich.
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2.2 Cells and tissue culture media
Human epidermoid carcinoma (HEp2) (ATCC No: CCL-23) and Eagle’s 
minimum essential media (EMEM), with L-glutamine and Earle’s balanced salt 
solution, adjusted to contain 1.5 g/L sodium bicarbonate, non-essential amino acids, 
and sodium pyruvate, were purchased from LGC Promochem (Teddington, UK). 
Human HaCaT keratinocytes (Boukamp et al, 1988) and hTERT-immortalised, 
chronic wound fibroblast cell lines and patient-matched, normal dermal fibroblasts 
were donated by Dr. Ivan Wall and Dr. Mathew Caley (Wound Biology Group, 
Tissue Engineering and Reparative Dentistry, School of Dentistry, Cardiff 
University). Epilife® medium and HKGS kit (bovine pituitary extract, bovine insulin, 
hydrocortisone, bovine transferrin), were obtained from Cascade Biologies 
(Mansfield, UK). Dulbecco’s minimum essential media (DMEM), Ham’s FI2 
nutrient media, Trypsin-EDTA, penicillin G, streptomycin sulphate, amphotericin B, 
hydrocortisone, adenine, cholera toxin, insulin and foetal calf serum (FCS) were 
purchased from Invitrogen (Paisley, UK). Balanced salt solution (BSS Plus®) was 
purchased from Alcon Laboratories (Hemel Hemstead, UK).
2.3 Antibodies and enzyme-linked immunosorbant assay (ELISA)
The antibodies, anti-EGFR (phosphoY1173; anti-human, polyclonal IgG 
antibody, raised in rabbit), anti-STAT3 (phospho Y705; anti-human, polyclonal IgG 
antibody, raised in rabbit) and anti-CD31 (anti-mouse, polyclonal IgG antibody, 
raised in rabbit), were purchased from Abeam (Cambridge, UK). The antibodies, 
anti-actin (C-2; anti-human, monoclonal IgG antibody, raised in mouse), and anti- 
EGFR (F4; anti-human, monoclonal IgG, raised in mouse) and K562 and A431 
whole cell lysates, were purchased from Santa Cruz Biotechnology (Santa Cruz, 
USA). Horseradish peroxidase-conjugated secondary antibodies (anti-rabbit, 
polyclonal IgG antibody, raised in goat; and anti-mouse, polyclonal IgG antibody, 
raised in goat) were obtained from Dako UK Ltd. (Ely, UK). A human EGF-ELISA 
kit was purchased from R&D Systems (Abingdon, UK).
2.4 Animals
Two-month old male Wistar Han rats were purchased from Charles River 
Laboratories (Margate, UK) and male diabetic mice (C57BLKs/Bom db/db; 12-13 
weeks old) were purchased from The Jackson Laboratory (Bar Harbor, USA).
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2.5 Equipment
2.5.1 Equipment for cell culture
With the exception of centrifugation steps, all cell culture was performed 
under sterile conditions, in a Class II, laminar flow Astec Microflow 2 cabinet 
(Bioquell UK, Andover, UK). All flasks and plates were maintained in a NuAire air- 
jacketed DH autoflow automatic CO2 incubator, at 37°C/5% CO2 (NuAire, Plymouth, 
USA). For general cell culture, an Olympus CK2 inverted bright field microscope 
was used (Olympus UK Ltd., Watford, UK). For routine cell counting, a Marienfield 
silver stained Neubauer haemocytometer (Lauda-Konigshofen, Germany) was used. 
Tissue culture flasks (25, 75 and 175 cm3), tissue culture sterile plates (12-well and 
96-well), sterile pipettes (5, 10 and 25 mL), 100 mm Petri dishes, cryovials, sterile 
cell scrapers, kwills, universal containers, sterile centrifuge tubes (15 and 60 mL) and 
7mL bijoux, were all purchased from Greiner Bio-One (Stonehouse, UK).
2.5.2 Analytical Equipment
2.5.2.1 Spectrophotometry: Ultraviolet-visible.
A UV-visible plate reader (Sunrise Touchscreen) was purchased from Tecan 
(Reading, UK). A UV-visible spectrophotometer (Cary 1G) was purchased from 
Varian Inc. (Walton-on-Thames, UK), with software version 2.0. A Dynex MRX 
Spectrophotometer (Dynex Technologies, Billinghurst, UK), equipped with a 540 nm 
filter, and a Fluostar Optima Microplate Reader (BMG Labtech, Aylesbury, UK), 
equipped with 520 nm and 620 nm filters, were also used.
2.5.2.2 Infrared (IR) spectroscopy
The FT-IR spectrophotometer (Avatar 360) was obtained from Thermo- 
Nicolet (Hemel Hemstead, UK), fitted with a Nicolet Smart Arc diffuse reflectance 
accessory. Nicolet E-Z Omnic ESP 5.2 software was used for data collection.
2.5.2.3 Fluorescence
A Fluostar Optima Microplate Reader (BMG Labtech), equipped with an 
excitation and emission filters, at 485 nm and 520 nm, respectively, was used for 
fluorescence analysis.
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2.5.2.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE)
All electrophoresis equipment, including a Power Pac 300, Protean II 
electrophoresis tank and GelAir Drying Frame, were purchased from Bio-Rad 
Laboratories Ltd. (Hemel Hemstead, UK).
2.5.2.4 Gel permeation chromatography (GPC)
The aqueous GPC was equipped with a JASCO HPLC pump and two TSK- 
gel columns in series (4000 PW, followed by 3000 PW) and a guard column (progel 
PWXL), were purchased from Polymer Laboratories (Church Stretton, UK). The 
eluate was monitored using a differential refractometer (Gilson 153, Gilson, Inc., 
Middleton, USA) and a UV-vis spectrophotometer at 279 nm (UV Severn Analytical 
SA6504, Severn Analytical, Gloucester, UK), in series. PL Caliber Instrument 
software, version 7.0.4, obtained from Polymer laboratories (Church Stretton, UK), 
was used for data analysis.
2.5.2.6 Fast protein liquid chromatography (FPLC)
An AKTA FPLC system, purchased from GE Healthcare (Amersham, UK), 
was used. The unit was connected to a pre-packed Superdex 75 10/300 GL column 
and a Frac-950 fraction collector (GE Healthcare). The UV detector data was 
collected using Unicom 3.20 software and analysed using FPLC director®, version
1.10 software.
2.5.2.7 Flow cytometry
Receptor-binding and uptake studies were performed using a Becton 
Dickinson FACSCalibur cytometer (Oxford, UK) equipped with an argon laser (488 
nm) and emission filter (550 nm). Data were acquired in 1024 channels, with band 
pass filters (FL-1 530 nm ± 30 nm; FL-2 585 ± 42 nm; FL-3 670 nm long pass filter). 
Data were processed using CELLQuest®, version 3.3 software.
2.5.2.8 Centrifugation
A Precision Durafuge 200 (Thermo Fisher Scientific, Waltham, USA) was 
used for centrifugation at 1500 g; a Varifuge 3.0 (Heraeus Sepatech GmbH,
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Osterode, Germany) at 4000 g; and an Eppendorf 5415-R (Eppendorf, Hamburg, 
Germany), at 15,000 g  / 4°C.
2.5.2.9 Microscopy
Confocal microscopy was performed with a Leica TCS SP5 work-station, 
equipped with Leica DMI4000B Microscope, a 400-700 nm laser, a 350-700 nm 
laser and a 350-1050 nm laser, and run with Leica Application Suite Advanced 
Fluorescence (LAS AF) software (Leica Microsystems (UK) Ltd., Milton Keynes, 
UK). A microtome was also purchased from Leica Microsystems (UK). Time-lapse 
microscopy was performed using automated time-lapse microscope (Zeiss Axiovert 
200M Inverted Microscope with XL-3 Incubator Housing, Carl Zeiss Ltd., Welwyn 
Garden City, UK; using Openlab 5 software, Improvision Ltd., Coventry, UK). An 
operating microscope (Stemi 2000-C) was also obtained from Carl Zeiss Ltd., and 
images recorded with a Nikon Coolpix 4500 digital camera (Nikon UK, Kingston- 
upon-Thames, UK). Fluorescein staining of specimens was performed with a 
Fluorets® Sterile Ophthalmic Strip (Chauvin Pharmaceutics, Kingston-upon-Thames, 
UK), and images recorded, under an ultraviolet light source, at 365nm (UVP Ltd., 
Cambridge, UK). BD Falcon CultureSlides® were obtained from BD Biosciences 
(London, UK).
2.5.2.10 Miscellaneous equipment
The pH meter (3150 pH meter) was purchased from Jenway (Leeds, UK). 
The Flexi Dry FD-1.540 freezer-dryer was obtained from FTS Systems (Stone 
Ridge, NY, USA), connected to a high vacuum pump (DD75 double stage), 
purchased from Javac (Middlesbrough, UK). Dialysis membranes Spectra/POR® 
CE (Cellulose Ester, molecular weight cut-off; MWCO = 10,000 g/mol) and 
Universed Closures were purchased from Pierce & Warriner (Chester, UK). 
Polyvinyl difluoride (PVDF) dialysis membrane (MWCO = 250,000 g/mol) was 
purchased from Fisher Scientific (Loughborough, UK). Black 96-well analytical 
plates were from Greiner Bio-One. Vivaspin 6 centrifugal concentrators were 
obtained from Sigma-Aldrich. Filters (0.2 pm) were purchased from Millipore 
(Watford, UK). Ready Gel® 4-15% Tris-HCl electrophoresis gels, Kaleidoscope 
Pre-stained Standards, a Trans-Blot Semi-Dry Electrophoretic Transfer Cell System
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and the Bio-Rad DC Protein Assay were obtained from Bio-Rad Laboratories Ltd. 
A W-220F sonicator was obtained from Misonix, Farmingdale, USA. Amersham 
Hybond-P PVDF membrane, ECL Plus Western Blotting Detection Reagents and 
Hyperfilm ECL were purchased from G.E. Healthcare. A Curix 60 autodeveloper 
was obtained from Agfa-Gevaert (Mortsel, Belgium). Release® non-adherent and 
Bioclusive® film dressings were purchased from Johnson & Johnson Wound 
Management (Gargrave, UK). The Phadebas® Amylase Assay Kit was purchased 
from Magle Life Sciences (Lund, Sweden) and the EnzChek® Elastase Assay Kit 
was obtained from Molecular Probes (Invitrogen). An ultra-fine micro-knife (15° 
cutting angle, 5mm blade) was obtained from Fine Science Tools (Heidelberg, 
Germany). Cyanoacrylate adhesive gel was purchased from Henkel Loctite 
Adhesives Ltd. (Hemel Hemstead, UK). Surgical scalpels (15-blade) were 
purchased from Swann-Morton (Sheffield, UK). Cotton swabs were purchased from 
Medical Wire and Equipment Co. Ltd. (Corsham UK). Needles and syringes were 
purchased from Tyco Healthcare (Gosport, UK). Jackson-Pratt® surgical drains 
were purchased from Cardinal Health (Basingstoke, UK).
2.5.2.11 Image analysis software
Images (movies and stills) were processed and analysed using QuickTime® 
(version 7.1.5, Apple Computer, Inc, Cupertino, USA), Adobe Photoshop® (CS3; 
Adobe Systems Incorporated, San Jose, USA), and ImageJ® (1.37v; 
http://rsb.info.nih.gov/ij/), including MTrackJ plugin software (Erik Meijering; 
http://www.imagescience.org/meijering/ software/mtrackj/). Image Pro® image 
analysis software (version 4.1.0.0, Media Cybernetics, Bethesda, USA) was used for 
in vivo wound closure analysis.
2.6 Methods
This Section provides a detailed description of the general methods used in 
these Studies. Specific methods are described, as they are utilised in each Chapter. 
Methods used for conjugate synthesis and purification are described in detail in 
Chapter 3 (Section 3.2). However, the methods used for conjugate characterisation 
are described here, as these techniques apply for all the methods explored for 
polymer-protein conjugation.
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2.6.1 Purification of the dextrin-rhEGF conjugate
Several methods were used to purify the dextrin-rhEGF conjugate to remove 
salts, unreacted protein and linking agents (Chapter 3). FPLC, in conjunction with 
ultra-filtration, was later chosen as the method of choice.
2.6.1.1 Purification of the dextrin-rhEGF conjugate, by FPLC
An AKTA FPLC system was used to separate free rhEGF and conjugated 
dextrin-rhEGF, according to their respective molecular weights. A pre-packed 
Superdex 75 10/300 GL column was washed with 2 column volumes (~ 48 mL) of 
filtered (0.2 pm) and degassed double-distilled water (ddlLO). Next, the column was 
equilibrated with 3 column volumes (~ 72 mL) of filtered and degassed mobile 
phase, phosphate buffered saline (PBS, pH 7.4), prior to use. First, the column was 
calibrated (0.5 mL/min flow rate), using standardised proteins of various molecular 
weight: rhEGF, 6,200 g/mol; cytochrome C (from bovine heart), 12,400 g/mol; 
carbonic anhydrase (from bovine erythrocytes), 29,000 g/mol; albumin (from bovine 
serum), 66,000 g/mol; and alcohol dehydrogenase (from Saccharomyces cerevisiae),
150,000 g/mol (Figure 2.1a). A typical calibration curve is shown in Figure 2.1b. 
Dextrin-rhEGF samples (1 mL) were subsequently injected into a 2 mL loop (“partial 
fill” method) and allowed to run at a flow rate of 0.5 mL/min. When the conjugates 
were being purified, fractions (1 mL) were collected, corresponding to the dextrin- 
rhEGF fractions (6-9 mL), which were further purified by ultra-filtration, using 
Vivaspin 6 centrifugal concentrators. Other reactant fractions: free rhEGF (14-16 
mL), DMAP (19-21 mL), sulfo-NHS (15-17 mL), were discarded.
The dextrin-rhEGF conjugate fractions were transferred to the Vivaspin 6 
centrifugal concentrator, using a pipette and centrifuged at 4000 g  for 10 min. The 
resulting sample was resuspended in 5 mL ddH20 and the process repeated 5 times. 
Finally, the ultra-filtered sample was lyophilised over night, and stored at 4 °C, until 
required for further characterisation.
The limiLof detection of rhEGF was determined using serial dilutions of 
rhEGF (40, 8, 1.6 and 0.32 pg/mL, in PBS). Peak heights were recorded and the limit 
of detection determined when no visible peak was detected, corresponding to free
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Figure 2.1 Fast protein liquid chromatography (FPLC). Panel (a) shows the 
calibration chromatogram, using protein standards: alcohol
dehydrogenase, 150,000 g/mol; bovine serum albumin (BSA),
66,000 g/mol; carbonic anhydrase, 29,000 g/mol; cytochrome C, 
12,400 g/mol; recombinant human epidermal growth factor 
(rhEGF), 6,200 g/mol. V0 denotes the void volume and Vb, the bed 
volume. Panel (b) shows a typical calibration curve using the 
protein standards. Panel (c) shows the limit of detection for rhEGF, 
by FPLC, calculated to be approximately 0.7 pg/mL.
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rhEGF (Figure 2.1c). The rhEGF limit of detection was 0.7 pg/mL. After use, the 
column was thoroughly washed with eluant, followed by ddH2 0 , and finally stored 
in 20 % v/v ethanol.
2.6.2 Characterisation of the dextrin-rhEGF conjugate
Once synthesised, it was necessary to characterise the dextrin-rhEGF 
conjugates, in respect of their conjugate protein content, free protein content, 
molecular weight and polydispersity.
2.6.2.1 GPC and FPLC characterisation of the conjugate molecular weight
Polymer-protein conjugates are notoriously difficult to characterise, as they 
are neither protein nor polymer. Therefore, while it was not possible to accurately 
assign the molecular weight of the synthesised conjugates, GPC and FPLC were used 
in combination with SDS-PAGE, to quantitatively define the molecular weight of the 
conjugates and their purity, in respect of free rhEGF. The BCA assay was used to 
quantify the total protein content of the conjugates.
2.6.2.1.1 Characterisation by GPC
GPC, with a refractive index (RI) detector, is commonly used to separate 
polymers, according to their size and shape (hydrodynamic radius). Polysaccharide 
(pullulan) standards (molecular weights ranging from 11,800 to 210,000 g/mol), 
were used to produce a calibration curve (Figure 2.2). All samples were prepared in 
PBS (3 mg/mL). Of these solutions, approximately 60 pL was injected into the 
sample loop. PBS (filtered and degassed) was used as the mobile phase (flow rate 1.0 
mL/min). Both RI and UV detection (at 279 nm) were used and the data analysed 
using PL Caliber Instrument software.
2.6.2.1.2 Characterisation by FPLC
FPLC, with a UV detector, was also used to estimate the dextrin-rhEGF 
conjugate molecular weight, in comparison to protein standards of various molecular 
weights (detailed in Section 2.6.1.1) and to measure the ratio of free and bound 
protein. The same FPLC system, used for purification, was used for characterisation.
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rhEGF (Figure 2.1c). The rhEGF limit of detection was 0.7 pg/mL. After use, the 
column was thoroughly washed with eluant, followed by ddlLO, and finally stored 
in 20 % v/v ethanol.
2.6.2 Characterisation of the dextrin-rhEGF conjugate
Once synthesised, it was necessary to characterise the dextrin-rhEGF 
conjugates, in respect of their conjugate protein content, free protein content, 
molecular weight and polydispersity.
2.6.2.1 GPC and FPLC characterisation of the conjugate molecular weight 
Polymer-protein conjugates are notoriously difficult to characterise, as they
are neither protein nor polymer. Therefore, while it was not possible to accurately 
assign the molecular weight of the synthesised conjugates, GPC and FPLC were used 
in combination with SDS-PAGE, to quantitatively define the molecular weight of the 
conjugates and their purity, in respect of free rhEGF. The BCA assay was used to 
quantify the total protein content of the conjugates.
2.6.2.1.1 Characterisation by GPC
GPC, with a refractive index (RI) detector, is commonly used to separate 
polymers, according to their size and shape (hydrodynamic radius). Polysaccharide 
(pullulan) standards (molecular weights ranging from 11,800 to 210,000 g/mol), 
were used to produce a calibration curve (Figure 2.2). All samples were prepared in 
PBS (3 mg/mL). Of these solutions, approximately 60 pL was injected into the 
sample loop. PBS (filtered and degassed) was used as the mobile phase (flow rate 1.0 
mL/min). Both RI and UV detection (at 279 nm) were used and the data analysed 
using PL Caliber Instrument software.
2.6.2.1.2 Characterisation by FPLC
FPLC, with a UV detector, was also used to estimate the dextrin-rhEGF 
conjugate molecular weight, in comparison to protein standards of various molecular 
weights (detailed in Section 2.6.1.1) and to measure the ratio of free and bound 
protein. The same FPLC system, used for purification, was used for characterisation.
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Figure 2.2 GPC analysis of pullulan molecular weight standards, using 
TSK gel columns G4000 PWXL and G3000 PWXL in series. 
Panel (a) shows the chromatogram of the pullulan standards 
(5,900 - 788,000 g/mol). Panel (b) represents a typical calibration 
curve for the estimation of sample molecular weight.
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After appropriate equilibration and calibration, samples of purified conjugate (200 
pL) were injected into the sample loop and allowed to run at a flow rate of 0.5 
mL/min.
2.6.2.2 SDS-PAGE
The method was adapted from one described by Laemmli (1970). This 
method was used for both characterisation of the dextrin-rhEGF conjugate and for 
electrophoresis of cell lysates, prior to Western blot analysis (Chapter 5). Pre-cast, 4- 
15% Tris-HCl electrophoresis gels were used, in conjuction with Kaleidoscope Pre­
stained standards (myosin, 197,211 g/mol; p-galactosidase, 125,275 g/mol; BSA, 
83,426 g/mol; carbonic anhydrase, 37,095 g/mol; soybean trypsin inhibitor, 31,168 
g/mol; lysozyme, 17,154 g/mol; and aprotinin, 6,990 g/mol).
Gels were prepared, as per the manufacturer’s instructions, transferred to the 
electrophoresis tank and the tank filled with running buffer (0.25 M Tris-HCl, 1.92 
M glycine in dcUHfeO, 1 % SDS, pH 8.3). rhEGF (1 mg/ml) and dextrin-rhEGF 
conjugate (1 mg/mL rhEGF equivalent) were snap frozen, lyophilised, reconstituted 
in 20 pL of denaturing buffer (4 % SDS, 20 % glycine, 10 % 2-mercaptoethanol, 
0.004 % bromophenol blue, 0.125 M Tris-HCl, in ddH20, pH 6.8), heated (100 °C, 5 
min) and microcentrifuged (10 s). The prepared samples and molecular weight 
standards (10 pL) were added to the sample wells, using a microsyringe and 
separated by electrophoresis, at 200 V for 1 h. The gels were removed from the glass 
templates, rinsed with dcfflbO and stained (1 h) with 200mL of 1 % Coomassie 
Blue solution (in 50 % methanol, 10 % acetic acid). After destaining in 35 % 
methanol/5 % acetic acid solution and rehydration in 5 % methanol/7 % acetic acid 
solution, the gels were rinsed in dtfflhO and air-dried (2 days) between cellophane 
sheets, clamped in a GelAir Drying Frame. The limit of detection of rhEGF by SDS- 
PAGE was further determined with lyophilised samples of rhEGF (10, 5, 2.5, 1.25, 
0.63, 0.31, 0.16, 0.08 pg), reconstituted in 20 pL of denaturing buffer, described 
above. The limit of detection was determined when no visible band, corresponding to 
rhEGF, was detected. This was estimated to occur at 200 ng rhEGF.
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2.6.2.3 BCA protein assay
The BCA assay was used to determine the total protein content of the 
polymer-protein conjugates (Smith et al, 1985). The assay consists of two steps. 
First, the protein reduces the Cu2+ to Cu+ by the biuret reaction. The resulting Cu+ 
forms a coloured coordination complex with four to six nearby peptide bonds. Next, 
the BCA forms complexes with the remaining Cu2+, which produces a purple 
coloured solution, detectable at 562 nm. The intensity of the colour is directly 
proportional to the number of peptide bonds participating in the reaction (Figure 2.3).
In a 96-well microtitre plate, calibration curves, using BSA and rhEGF as 
standards, were constructed over a range of concentrations (0.05-1 % w/v) (Figure 
2.4a). Conversion of [BSA] to [rhEGF] was performed using a standard conversion 
factor, to allow calibration curves to be utilised with BSA, rather than rhEGF, 
typically using the equation below:
[rhEGF] = ([BSA] x 0.6477) + 0.004
Reference wells of 20 pL volume were established in triplicate, using a range 
of BSA concentrations, diluted in PBS (0-1 mg/mL BSA). Samples of the dextrin- 
rhEGF conjugate (20 pL, 1 mg/mL) and rhEGF (20 pL, 1 mg/mL) were used for 
analysis. BCA reagent (200 pL; ratio 1 mL BCA: 20 pL CUSO4) was added to each 
well. Each plate was lightly agitated and incubated in the dark, for 20 min at 37°C. 
The absorbance of each well was quantified using a Tecan Spectrophotometer, 
equipped with a 550 nm filter. The limit of detection of rhEGF by the BCA assay 
was determined by serial dilution of a rhEGF sample (50 pg/mL). At the point where 
there was no significant difference between a blank well and a sample well, the 
detection limit was said to have been reached (1.56 pg/mL; Fig. 2.4b).
2.6.2.4 Bio-Rad DC protein assay
The Bio-Rad DC protein assay was used as an alternative to the BCA assay, 
for protein quantification of cell lysate samples (Chapter 5), where a high 
concentration of DTT (1 mM), in the protein extraction buffer, would give false 
positive readings. This is a colourimetric assay based upon the reaction of protein 
with an alkaline copper tartrate solution and folin reagent. Colour development (pale
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Figure 2.3 Mechanism of action for the BCA assay for protein quantification
(adapted from the Pierce Chemical Protein Assay Technical Handbook, 
2005).
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yellow to blue) is primarily due to the amino acids, tyrosine and tryptophan, and to a 
lesser extent, cystine, cysteine and histidine (Lowry et al, 1951).
The protein content of the cell lysates was determined, using BSA as a 
standard. Stock solutions of extraction buffer, containing BSA (2 mg/mL), were 
prepared and diluted to a range of concentrations (0.2 - 2 mg/mL BSA). Standards 
and samples (5 pL) were added in triplicate to a 96-well microtitre plate. A stock 
solution consisting of 98 % DC protein assay reagent A, and 2 % DC protein assay 
reagent S, was prepared, as per the manufacturer’s instructions. This solution (25 
pL), and DC protein assay reagent B (200 pL), was added to the sample and 
calibration wells. Plates were incubated at room temperature, for 15 min. Absorbance 
was measured at 620 nm and a calibration curve constructed (Figure 2.5).
2.6.2.5 ELISA
For quantification of rhEGF, both liberated from the dextrin-rhEGF conjugate, 
and present in mouse plasma, a human EGF-ELISA kit was employed. A 96-well plate 
was supplied, pre-coated with a monoclonal antibody to human EGF. Samples (200 
pL) were added and assayed against standards of rhEGF of known concentration (0 - 
250 pg/mL) for 2 h. The supernatant was aspirated and the wells washed (x 3) with 
wash buffer (400 pL x 3; R&D Systems). A polyclonal antibody to human EGF, which 
has been conjugated to horseradish peroxidase, was added to the wells (200 pL; R&D 
Systems) for 1 h. The samples were washed (x 3), as described above. Substrate solution 
(200 pL; R&D Systems), was added for 20 min. A colour change from clear to blue 
occurred, with the reaction being terminated by the addition of stop solution (50 pL; 
R&D Systems). A blue to yellow colour change occurred, in proportion to the 
concentration of EGF. The absorbance of each well was measured using a Tecan plate- 
reader, at 450 nm, with correction at 540 nm (absorbance at 450 nm -  absorbance at 540 
nm). A typical calibration curve is shown in Figure 2.6.
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Figure 2.5 Bio-Rad DC protein assay. A typical Bio Rad DC protein assay standard 
calibration curve for BSA (mean ± S.D., n = 3).
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2.6.2.6 EnzChek® elastase assay
For quantification Of neutrophil elastase activity in wound fluid samples, and 
exogenous elastase to which the dextrin-rhEGF conjugate was exposed, the EnzChek® 
elastase assay was utilised (Abdel-Latif et al, 2004). The assay was performed in 
accordance with the manufacturer’s instructions: Reaction buffer (50 pL; Molecular 
Probes) and substrate (50 pL; DQ elastin, 100 pg/mL; Molecular Probes) were added to 
a black, 96-well analytical plate. A porcine pancreatic elastase standard (50 U/mL; 
Molecular Probes) was diluted to 0.250, 0.063, 0.016, 0.004 U/mL, in ddH20, and 
added (100 pL) to the reaction mixture. Analytical samples (100 pL) were also added, 
as necessary. Fluorescence was measured with a Fluostar Optima Microplate Reader 
(excitation 485 nm, emission 520 nm), at timed intervals, over a 1 h period. A typical 
calibration curve is shown in Figure 2.7.
2.6.3 Biological characterisation of the dextrin-rhEGF conjugate
Detailed methods for these bioactivity assays are fully described in Chapters 
4 and 5.
2.6.3.1 Cell culture
In order to ensure sterility of the incubator, the safety cabinets and equipment 
were sprayed with 70 % v/v ethanol, in water. Those items not supplied pre-sterilised 
were sterilised by (a) autoclaving (120 °C, 15 lb/m2, 15 min) for glassware, certain 
plastics, PBS and dcfflbO; (b) microfiltration (0.2 pm) for solutions; or (c) UV 
irradiation (30 min). Cells were maintained at 37 °C/5% CO2 , unless required.
2.6.3.2 HEp2 culture
HEp2 cells were seeded at 1.5x10s cells/75 cm2 tissue culture flask and 
incubated in 10 mL HEp2-serum containing medium (H-SCM 10 %: EMEM with 
penicillin G (100 U/mL), streptomycin sulphate (100 pg/mL), amphotericin B (0.25 
pg/mL) and 10 % v/v FCS). Upon reaching 80-90 % confluence, the cells were sub- 
cultured, as follows. The cells were washed (x 2) with PBS and detached from the 
plastic by incubation with 1 mL of trypsin/EDTA (0.05 % trypsin, 0.53 mM EDTA), 
for approximately 5 min at 37 °C. Each flask was washed with H-SCM (9 mL), to
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Figure 2.7 EnzChek® elastase assay. Panel (a) shows the typical fluorescence 
obtained, from a flurogenic substrate, in response to porcine 
pancreatic elastase standards, over a 1 h period (mean ± S.D., n = 
3). Panel (b) shows a typical calibration curve of these standards at 
60 min. The fluorescence was measured at 485 nm excitation and 
520 nm emission, and background fluorescence subtracted (relative 
fluorescence units; RFU).
52
Chapter 2 General Materials And Methods
collect trypsinised cells. The cell suspension was then transferred to a 15 mL 
centrifuge tube and centrifuged at 1500 g  for 5 min. The supernatant was aspirated 
and the resulting pellet was re-suspended in lmL H-SCM 10 %. Viable cells were 
assessed with trypan blue staining (Section 2.6.3.6) and cells counted prior to sub­
culture. The cell culture medium was changed twice weekly.
2.6.3.3 Keratinocyte culture
HaCaT keratinocytes were seeded at 1.5x10s cells/75 cm2 tissue culture flask 
and incubated in 10 mL keratinocyte-serum containing medium (K-SCM 10 %: 
consisting of 67.5 % DMEM / 22.5 % Ham’s F12 nutrient media, supplemented with 
penicillin G (100 U/mL), streptomycin sulphate (100 pg/mL), amphotericin B (0.25 
pg/mL), hydrocortisone (400 ng/mL), adenine (0.089 mM), cholera toxin (0.08 
pg/mL), insulin (5 pg/mL), and 10 % v/v FCS). Upon reaching 80-90 % confluence, 
keratinocytes were sub-cultured, as described above (Section 2.6.3.2), resuspended in 
K-SCM 10 % and counted (Section 2.6.3.6). The cell culture medium was changed 
every 48 hours.
2.6.3.4 Fibroblast culture
Human normal dermal and chronic wound fibroblasts were seeded at
K *51.5x10 /75cm tissue culture flask and incubated in lOmL fibroblast-serum 
containing medium (F-SCM 10 %: DMEM with penicillin G (100 U/mL), 
streptomycin sulphate (100 pg/mL), amphotericin B (0.25 pg/mL), L-glutamine (2 
mM), puromycin (1 pg/mL) and 10 % v/v FCS). Upon reaching 80-90 % confluence, 
the fibroblasts were sub-cultured, as described above (Section 2.6.3.2), resuspended 
in F-SCM 10 % and counted (Section 2.6.3.6). Cell culture medium was changed 
twice weekly.
2.6.3.5 Cryopreservation and cell retrieval
For cryopreservation, all cell-types were resuspended in a mixture of 10 % 
(v/v) DMSO and 90 % (v/v) FCS and placed in cryogenic vials. These vials were 
then stored in liquid nitrogen, at -196 °C, for long-term cell storage.
Cryopreserved cells were retrieved from the storage in liquid nitrogen by 
rapid thawing at 37 °C. The cells were washed with serum-containing media 
(SCM10 %; cell-type specific) and following centrifugation (1500 g) for 5 min, the
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pellets obtained were resuspended in lmL of SCM and re-seeded at a density of 1.5 x 
105 cells/75 cm2 tissue culture flask.
2.6.3.6 Assessment of cell viability
At sub-culture, the viability of the cells was assayed using the Trypan Blue 
dye exclusion test (Tennant, 1964). An aliquot of the resuspended cells (25 pL) was 
mixed with an equal volume of 0.02 % (w/v) Trypan Blue solution, with 8 pL of the 
resulting solution being transferred to a Neubauer haemocytometer and the number 
of stained and non-stained cells was determined. Cells from two 0.1 mm3 squares 
(one taken from the top chamber, and one taken from the bottom chamber of the 
haemocytometer) were counted. Non-viable cells (stained with trypan blue) were not 
included in the viable cell count. The following formula was used to determine cell 
concentrations:
cells/mL = mean cell count x 2 x 104
Where: mean is the arithmetic mean of the 2 values
2 takes into account the trypan blue dilution 
104 accounts for the conversion from 0.1 mm3 to mL
Typically, 80-90 % of cells (from each cell line) were viable, after cryo-retrieval.
2.6.3.7 MTT assay as a means to assess cell viability and proliferation
Cellular viability and proliferation were assessed using the MTT dye- 
reduction assay (Mosmann, 1983). MTT assay involves a redox reaction of the 
yellow substrate solution (MTT), with mitochondrial respiration products, NADH 
and NADPH, resulting in the formation of insoluble blue, formazan crystals. This 
reduction takes place only when mitochondrial reductase enzymes are active, and 
therefore, this conversion can be directly related to the number of viable cells. When 
the amount of purple formazan produced by cells treated with an agent is compared 
with the amount of formazan produced by untreated control cells, the effectiveness of 
the agent in causing cell proliferation can be quantified.
Cells were seeded into 96-well plates at densities of 10, 5, 2.5 and 1 x 103 
cells/well and cell-specific, SCM added (250 pL). In the case of the HEp2 cells,
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culture was performed in parallel with both SCM and serum-free media (SFM). Cells 
were cultured, as described above, and daily MTT assays performed over a 7 day 
period. MTT (5 mg/mL in PBS; 25 pL) was added to the cell media and incubated at 
37 °C, for 5 h. The media was then removed and lysis buffer added (DMF (50 %) in 
dcfflfeO, containing SDS (20 %), glacial acetic acid (2.5 %) and HC1 (1M, 2.5 %), pH 
4.7; 50 pL) and further incubated for 3 h at 37 °C. The absorbance of each sample 
were determined at 540 nm. Growth curves were constructed and presented as 
absorbance at 540 nm and as percentage increase in absorbance compared to day 0, 
as shown in Figures 2.8 -  2.10.
The results from the growth curve analysis would be used for optimisation of 
future cell proliferation assays:
• MTT assays were performed after 72 h, whilst all of the cell types were in the 
logarithmic growth phase.
• HEp2 cells were cultured in serum-free media, as a cell proliferation model, 
to exclude the influence of endogenous EGF within FCS.
• HEp2 cell culture was extended to 8 days, in SFM, to investigate the 
sustained release effects of rhEGF, from the dextrin-rhEGF conjugate.
• Cells were universally seeded at 2.5 x 103 cells/well, as this was either the 
optimum density, or showed no significant difference to other cell densities.
2.6.3.8 Determination of relative epidermal growth factor receptor (EGFR) 
density, by flow cytometry
Flow cytometry was used to study the receptor binding and uptake of EGF- 
Alexa488. EGF-Alexa488 was added to cells (Section 4.2.2) and at the end of the 
experiment, cells were suspended in cold PBS (200 pL) and analysed using a Becton 
Dickinson FACSCalibur Cytometer. Data were collected, with 10,000 total cell 
counts per sample, and processed using CELLQuest® version 3.3 software. Control 
cells (incubated with medium only), were used in all cases to account for background 
fluorescence output (M l). Data were acquired in 1024 channels with band pass filter 
FL-1 (530 nm ± 15 nm). Results were expressed as geometric mean x % positive 
cells / 100.
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Figure 2.8 Human epidermoid carcinoma (HEp2) cellular growth curves.
Panel (a) shows absorbance values from the MTT assay, performed 
over an 8 day period, and panel (b) shows absorbance as a percentage 
of the value at day 0, in response to 10% foetal calf serum-containing 
media (H-SCM 10 %). Panel (c) shows absorbance values from the 
MTT assay, again over 8 days, and panel (d) shows absorbance as a 
percentage of the value on day 0, in serum-free conditions (H-SFM) 
(mean ± S.D., n = 6, * 2.5 x 103 cells/well > all other cell densities,/? < 
0.05; ** 2.5 x 103 cells/well > 5 or 10 x 103 cells/well,/? < 0.001; *** 
2.5 x 103 cells/well > 1 or 10 x 103 cells/well,/? < 0.01; ANOVA and 
Bonferroni post-hoc test).
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Figure 2.9 Patient- and passage-matched normal dermal and chronic wound 
fibroblast cellular growth curves. Panel (a) shows absorbance 
values from the MTT assay performed over an 8 day period, and panel 
(b) shows absorbance as a percentage of the value at day 0, of normal 
dermal fibroblasts, in response to 10% foetal calf serum-containing 
media (F-SCM 10 %). Panel (c) shows absorbance values from the 
MTT assay, over an 8 day period, for chronic wound fibroblasts, and 
panel (d) shows absorbance as a percentage of the value at day 0, in F- 
SCM 10% (mean ± S.D., n = 6 * 2.5 x 103 cells/well > 1 x 103 
cells/well, p  < 0.05; ** 2.5 x 103 cells/well not significantly different 
from other cell densities; ANOVA and Bonferroni post-hoc test).
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Figure 2.10 Spontaneously immortalised keratinocyte (HaCaT) cellular 
growth curves. Panel (a) shows absorbance values from the MTT 
assay performed over an 8 day period, and panel (b) shows 
absorbance as a percentage of the value at day 0, in response to 10% 
foetal calf serum-containing media (K-SCM 10 %) (mean ± S.D., n 
= 6, * 2.5 x 103 cells/well > other cell densities, p  < 0.05, ANOVA 
and Bonferroni post-hoc test).
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Several methods were used to interpret the flow cytometry data. An increase 
in fluorescence of the cell population can be estimated using two methods. Firstly, by 
measuring the increase in average fluorescence of the population using the mean, 
geometric mean or median. The second method involves analysis of the number of 
cells that have taken up the fluorescently-labelled compound. In this instance, control 
cells were compared to cells exposed to EGF-Alexa488, to account for background 
fluorescence. From this data, two regions were arbitrarily set (Figure 2.11). Region 
Ml corresponds to a region covering 98 % of the control population events, while 
M2 relates to any area with higher fluorescence than M l. As cell-associated 
fluorescence increased, so did the number of events in the M2 region.
2.7 Statistical analysis
Statistical analyses were undertaken using GraphPad Prism®, version 4.00 
(GraphPad Software, San Diego, USA). Data were compared using a Student's t-test, 
a one-way ANOVA, with a Bonferroni post-test (parametric methods), and Kruskal- 
Wallace multivariate analysis, followed by ad hoc two sample Mann Whitney U-test 
(non-parametric methods). Results were expressed as a mean and standard deviation 
(S.D.), or standard error of the mean (S.E.M.). Statistical significance was considered 
at a probability ofp <  0.05.
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Typical flow cytometry distribution. Region Ml corresponds to a 
region covering 98 % of the control population events, while M2 
relates to any area with higher fluorescence than M l.
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3.1 Introduction
To explore the hypothesis that a polymer-protein conjugate would be a viable 
therapy for chronic wounds, as part of the Polymer-masking UnMasking Protein 
Therapy (PUMPT) concept, it was first necessary to select an appropriate polymer, to 
be used in conjunction with the bioactive protein or peptide of interest (Ferguson et 
al, 2006r Duncan et al, 2008). The choice of polymer was important to ensure 
biocompatibility, to allow conjugation to the protein of choice, and to be degradable 
by an endogenous human enzyme, that would be present in the wound environment, 
without the presence of toxic breakdown products. It was also important to generate 
a stable conjugate, which would mask the protein activity, when conjugated, but still 
allow the release of a bioactive agent, following polymer degradation.
The bioactive, recombinant protein, that would be the other component of the 
conjugate, should have been an established mediator of the normal wound healing 
response, and furthermore, should be commercially available, well-characterised and 
ideally, be found to be depleted in the chronic wound environment, by the action of 
proteinases. Vitally, this protein should also possess the chemistry to allow 
conjugation to the chosen polymer. It is well known that conjugation of a polymer to 
a protein can significantly improve biological efficacy in vivo, by reducing 
proteolytic degradation, extending plasma circulation time and reducing protein 
immunogenicity (Roberts et al, 2002; Sato, 2002; Harris and Chess, 2003; Werle and 
Bemkop-Schnurch, 2006).
3.1.1 Choice of polymer
Synthetic and natural polymers have been explored as drug carriers, but 
almost all polymers used clinically are non-biodegradable synthetic polymers, e.g. 
poly(ethyleneglycol) (PEG) (Veronese and Harris, 2002; Veronese and Pasut, 2005) 
and V-(2-hydroxypropyl) methacrylamide (HPMA) co-polymers (Vasey et al, 1999). 
Although well tolerated in man, such polymers are not biodegradable, and may lead 
to progressive accumulation after repeated doses (Dunn et al, 1998). Systemic 
administration of high molecular weight, non-degradable polymers (e.g. 
polyvinylpyrolidone; PVP), has been shown to cause bone marrow suppression and 
myelofibrosis, leading to the withdrawal from clinical use of PVP-based plasma 
expanders (Moffitt, 1975; Dunn et al, 1998). In order to ensure renal excretion, 
polymers of a molecular weight below the renal threshold (-40,000 g/mol), must be
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utilised (Duncan, 2003). Although natural polymers, such as dextran and poly(amino 
acids), are frequently of high molecular weight and biodegradable, even low levels of 
modification to facilitate drug conjugation, can lead to a non-degradable adduct 
(Vercauteren et al, 1990). Dextrin, an a -1,4 polyglucose, derived from the enzymatic 
hydrolysis of com or potato starch, has been selected for use in the present Study. It 
contains few (< 5%) a -1,6 links, so displays minimal branching, and is degraded by 
a-amylase (at a -1,4 glucosidic linkages), to produce the disaccharides maltose (a- 
1,4-linked) and iso-maltose (a -l,6 -linked) (Roberts and Whelan, 1960; Davies, 
1994; Burkart, 2004; Hreczuk-Hirst et al, 2001b). A number of other naturally 
occurring polymers, such as dextran are inherently biodegradable, but low levels of 
chemical modification can results in the generation of non-degradable adducts 
(Vercauteren et al, 1990; 1992). In addition, some natural polymers are not suitable 
for repeated administration, due to their immunogenicity (Bircher, 2006; Bisaccia et 
al, 2007).
3.1.1.1 Dextrin
Dextrin was chosen as a suitable polymer for protein conjugation, as it has 
proven biocompatibility and clinical tolerability. Dextrin has been used clinically for 
several years, initially as a dietary supplement (Caloreen™), for renal and hepatic 
failure (Woolfson et al, 1976; Alsop, 1994), and later as a component of peritoneal 
dialysis solution (icodextrin, Extraneal®) (Peers and Gokal, 1998; Frampton and 
Plosker, 2003; Davies et al, 2006). It has also been utilised as a carrier for 5- 
flurouracil, in the treatment of intra-peritoneal carcinoma (Kerr et al, 1996; Hosie et 
al, 2003). The safety and pharmacokinetic data for dextrin is well-established and it 
possesses both Federal Drug Administration (FDA) approval and is Generally 
Recognised as Safe (GRAS) listed (Day, 2003).
For the preparation of polymer-protein conjugates, conversion of the 
polysaccharide into a suitable reactive derivative, is usually required (Bruneel and 
Schacht, 1994). A large number of methods have been described to activate 
polysaccharides (Schacht et al, 1987), including periodate oxidation (Bruneel and 
Schacht, 1993a), chloroformate activation (Bruneel and Schacht, 1993b) and 
cyanogen bromide (Costa and Reis, 2004) (summarised in Table 3.1). Activation by 
these methods can lead to disruption and instability of the polymer backbone and in
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Table 3.1 Methods of polysaccharide activation
Activation method
Chloroformate activation
Cyanogen bromide activation
Periodate oxidation
Succinoylation
Method overview
Introduces hydroxyl groups into 
the polymer
Primary amine groups are
introduced directly into the 
reactive intermediate
Formation of an aldehyde 
groups by oxidation of 1,2- diol 
groups
Uses succinic anhydride to 
introduce a carboxyl pendant 
group, without disturbing the 
polymer backbone
Disadvantages
Possibility of formation of intra- 
or inter-chain carbonate esters. 
Formation of five-member rings 
can interfere with polymer 
backbone.
Reactive intermediate produced 
during activation of the
hydroxyl group can disrupt the 
polymer backbone.
Hydrogen cyanide is toxic and 
must be carefully removed. 
Linkage is unstable, resulting in 
slow release of pendant groups.
Aldehyde groups can lead to 
toxicity if not completely
neutralised.
Example polysaccharides
Cellulose (Rupprich et al, 
1990)
Dextran (Chiu et al, 1999)
Hyaluronate (Mlcochova et al, 
2006)
Starch (Costa and Reis, 2004)
Dextran (Devakumar and 
Mookambeswaran, 2007) 
Mannan (Ramirez et al, 2006)
Starch (Lawal, 2004)
Chitosan (Kato et al, 2004) 
Dextrin (Hreczuck-Hirst et al, 
2001a)
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some cases, release toxic by-products, including hydrogen cyanide and 
polyaldehydes (Hreczuk-Hirst et al, 2001a). Succinoylation has been used by others 
to modify pullulan (Bruneel and Schacht, 1994), which can react with succinic 
anhydride in dimethylsulfoxide (DMSO), using 4-dimethylaminopyridine (DMAP) 
as a catalyst. Hreczuk-Hirst et al (2001a) optimised dextrin succinoylation, with 
respect to temperature and reaction time. This Study concluded that 50 °C, with a 
minimum of 8  h reaction time, was optimal for dextrin succinoylation. Using these 
conditions, it was possible to reproducibly succinoylate dextrin, with a yield of ~ 50 
%. Furthermore, it was demonstrated that different degrees of dextrin succinoylation 
could be achieved by variation of the reactant ratios, and that the rate of a-amylase 
degradation of the succinoylated dextrins could be prolonged, by increasing the 
degree of polymer modification (Hreczuk-Hirst et al, 2001a).
Dextrin is normally degraded very quickly in the body, by both salivary and 
pancreatic isoforms of a-amylase. This approach made dextrin a suitable polymer for 
use in targeted drug delivery and also, for use in protein modification, in the context 
of PUMPT. Several peptides have been conjugated to succinoylated dextrin, 
including phospholipase A2 and trypsin (Ferguson et al> 2006; Duncan et al, 2008). 
These studies utilised the crosslinking agents, 1-ethyl-3- [3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDO) and Af-hydroxysulfosuccinimide (sulfo-NHS). 
EDC reacts with the carboxyl groups of an succinoylated dextrin intermediate, 
forming an amine-reactive O-acylisourea intermediate. This can further react with 
the amine groups of lysine residues in a protein, to give a conjugate joined by a 
stable amide bond. However, EDC alone is not particularly efficient. A failure of 
rapid amine reaction results in hydrolysis and regeneration of the carboxyl group, 
making it unstable and short-lived in aqueous solution. The addition of sulfo-NHS 
stabilises the amine-reactive intermediate, by converting it to an amine-reactive, 
sulfo-NHS ester, thus increasing the efficiency of EDC-mediated, coupling reactions. 
The amine-reactive sulfo-NHS ester intermediate has sufficient stability, to permit 
two-step crosslinking procedures, which allows the carboxyl groups on the protein to 
remain unaltered (vide infra). For this Study, a dextrin-fraction of average molecular 
weight ~ 51,000 g/mol was used, to provide adequate masking of the protein, and 
thus, reduce the bioactivity of the conjugated recombinant protein.
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3.1.2 Choice of protein
The recombinant protein selected for this Study had to fulfil multiple criteria. 
It had to be an established mediator of the normal wound healing response. It should 
have a well-established and characteristic action on the cells involved in wound 
repair (i.e. the keratinocytes and fibroblasts), be commercially- and readily-available 
(at the mg quantity as required) and well-characterised structurally. The recombinant 
protein also needed to allow polymer conjugation, via accessible amino acid 
residues, be detectable by immunological and protein assays, and ideally, be of a low 
molecular weight, in comparison to the selected dextrin polymer (-51,000 g/mol). A 
recombinant growth factor was selected as the choice of protein, as their regulatory 
action is integral to the normal wound healing process and as they act upon specific 
cell surface receptors, thereby activating secondary intracellular signalling pathways 
(Martin, 1997). A selection of the recombinant growth factor candidates considered, 
is shown in Table 3.2.
3.1.2.1 Epidermal Growth Factor
Epidermal Growth Factor (EGF) is a polypeptide of 53 amino acids, 
containing three internal disulfide bridges, which was first isolated from the mouse 
submaxillary gland (Cohen, 1962). At physiological pH, EGF can exist as a dimer 
(Lu et al, 2001). EGF facilitates epidermal cell regeneration and plays an essential 
role in the process of wound healing, through stimulation of keratinocyte 
proliferation and migration (Wemer and Grose, 2003). The initial doses of EGF, as 
well as other cytokines and growth factors, are delivered at the wound environment, 
via platelet degranulation, within the provisional fibrin clot (Nanney and King, 
1996). EGF also promotes the formation of granulation tissue and stimulates 
fibroblast motility (Rheinwald and Green, 1977; Barrondon and Green, 1987). As a 
mitogen, EGF first binds with high affinity to specific cell-surface receptors 
(Carpenter and Cohen, 1990).
The EGF-receptor (EGFR; erbB-1) belongs to the family of ErbB receptor 
tyrosine kinases (Bazley and Gullick, 2005), which also includes c-erbB-2/HER2, c- 
erbB3-/HER3 and c-erbB4/HER4. All of these receptors are similar in structure, with 
a ligand-binding domain located extracellularly, a transmembrane domain and a 
cytoplasmic catalytic domain (Marques et al, 1999). The 11 ligands currently
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Table 3.2 Potential growth factors for polymer conjugation
Growth factor Molecular weight Number of amino acids 
(number of lysine groups)
Action Price (cheapest 
commercial source)
Reference
Epidermal growth factor 
(EGF)
6,200 g/mol 53(2) Motogenic and mitogenic 
influence on keratinocytes
$225/mg* Nanney and King 
(1996)
Platelet-derived growth 
factor-BB (PDGF-BB)
48,600 g/mol 218(14) Mitogenic and chemotactic 
influence on fibroblasts, 
extracellular matrix production 
Macrophage activation and 
chemotaxis
$3510/mg* Siegbahn et al (1990)
Transforming growth 
factor-^ and (32 (TGF-
Pi ^  P2)
(3j = 25,000 g/mol 
|32 = 25,000 g/mol
Pi = 112 (8)
p2 = 112 (7)
Mitogenic and chemotactic 
influence on fibroblasts 
Keratinocyte migration 
Fibroblast extracellular matrix 
synthesis and remodelling
£5600 /mg** Gordon and Blobe 
(2008)
Insulin-like growth 
factor-1 (IGF-1)
7,600 g/mol 70 (3) Mitogenic influence on endothelial 
cells and fibroblasts
$270/mg* Edmondson et al 
(2003)
Vascular endothelial 
growth factor (VEGF)
38,200 g/mol 165(11) Angiogenesis $3510/mg* Tonneson et al 
(2000)
Hepatocyte growth 
factor (HGF)
83,000 g/mol 728 (48) Motogenic and mitogenic 
influences on fibroblasts
$4400 / mg* Nakamura (1991)
*ProSpec-Tany Technogene (Rehovot, Israel) **Peprotech EC (London, UK)
(catalogues accessed, September ,2008)
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identified for these receptors in mammals are EGF, transforming growth factor-a 
(TGF-a), HB-EGF (heparin binding), betacellulin, amphiregulin, epiregulin, epigen 
and the neuregulins (NRGs) 1-4 (Olayioye et al, 2000).
In the absence of ligand, monomeric receptors reside within the cell 
membrane in an inactive state, distributed evenly over the cell membrane (Bazley 
and Gulliek, 2005). However, when ligand is present in the surrounding milieu, the 
receptor sites become occupied by monomeric EGF. Provided two stable 1:1 
EGF:EGFR intermediate complexes persist, sequential receptor dimerisation and 
oligomerisation ensue (Ferguson et al, 2003). Receptor dimers, which have greater 
stability and ligand-binding affinity than their corresponding monomers (Ben-Levy 
et al, 1992; Zhou et al, 1993), are increasingly considered to be necessary for 
activation (Alroy and Yarden, 1997). Consequent to ligand binding and receptor 
dimerisation, intracellular tyrosine kinase catalytic activity is increased (Hubbard and 
Till, 2000; Dibb et al, 2004).
Subsequent to the transphosphorylation of the receptor dimer, secondary 
messenger proteins, possessing one of the two main classes of domains that 
recognise site-specific phosphorylation (“docking sites”), can interact with the 
receptors (Bazley and Gulliek, 2005). An example of a well-characterised second 
messenger/receptor interaction, is the recruitment of the enzyme phospholipase C 
gamma (PLCy) (Wang et al, 2001). In its inactive state, PLCy is normally found in 
the cytosol. However, upon phosphorylation of the EGFR, PLCy is able to interact 
with the phosphorylated receptor. This causes, not only tyrosine phosphorylation by 
the activated receptor, but also relocation to the plasma membrane, where it 
ultimately generates the secondary messengers, inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (Falasca et al, 1998), required for calcium/calmodulin-dependent 
kinases and the stimulation of protein kinase C. Additional targets of signaling are 
the JAK-STAT pathway (Janus kinases - Signal Transducers and Activators of 
Transcription; Schindler et al, 2007). These transduce the signal carried by 
extracellular polypeptides (e.g. growth factors) to the cell nucleus, where activated 
STAT proteins modify gene expression (Henson and Gibson, 2006). This pathway 
plays a central role in principal cell fate decisions, regulating the processes of cell 
proliferation, differentiation and apoptosis (Bazley and Gulliek, 2005).
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Within the 53 amino acid polypeptide structure of EGF, are two lysine 
residues (K2 8 , KUg), which would permit conjugation to succinoylated dextrin (Figure 
3.1). Lysine 28 is located within the 3-D structure of EGF and thus, may not allow 
polymer conjugation, due to steric inhibition (Lu et al, 2001). Lysine 48, however, is 
located peripherally and may, therefore, allow site-specific conjugation to 
succinoylated dextrin. Leucine 47 is implicated in EGFR binding, so this action 
should be inhibited by conjugation of the polymeric macromolecule to the adjacent 
amino acid. This would be dependent upon the site of conjugation, as site specific 
conjugation at the N-terminus would still permit EGFR binding, due to the increased 
distance from the binding moiety (Lee et al, 2003; Zeng et al, 2006).
Chronic wound proteinases and reactive oxygen species have been shown to 
degrade growth factors, including EGF, involved in normal dermal wound healing 
(Yager et al, 1997; Wlashek et al, 1997; James et al, 2003; Moseley et al, 2004; 
Wlashek and Scharfetterr-Kochanek, 2005). Therefore, the application of the 
PUMPT concept may provide protection and stabilisation of the recombinant EGF 
(rhEGF) protein, in a simulated chronic wound environment. Indeed, the conjugation 
of macromolecules, such as poly(ethylene glycol), dextran, polyamidoamine 
dendrimers, to EGF has previously been shown in other studies, to reduce bioactivity 
and the receptor binding ability of EGF (Gedda et al, 1996; Lee et al, 2003; Zeng et 
a;, 2006; Hee Na et al, 2006; Thomas et al, 2008; summarised in Table 3.3).
3.1.2.2 Recombinant human epidermal growth factor
RhEGF was one of the first growth factors to be synthesised, using 
recombinant DNA technology, in Saccharomyces cerevisiae (Brake et al, 1984). In 
the present Study, the rhEGF that was used in the synthesis of the polymer-protein 
conjugate was purchased commercially, following expression in Escherichia coli. 
RhEGF is a single, non-glycosylated, polypeptide chain, having a molecular mass of 
6,222 g/mol. The rhEGF was purified by proprietary chromatographic techniques, 
resulting in a purity greater than 98 %, as determined by analysis by reverse-phase- 
high performance liquid chromatography (RP-HPLC) and analysis by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The sequence of 
the first five N-terminal amino acids was determined and found to be Asn-Ser-Asp- 
Ser-Glu, which agrees with the sequence of native human EGF. rhEGF quantification
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Figure 3.1 Human epidermal growth factor (EGF). Panel (a) shows the 
amino-acid sequence, panel (b) shows the protein primary structure 
with locations of potential disulfide bonds and hydrogen bonds 
(adapted from Boonstra et al, 1995), and panel (c) shows the space­
filling model of the EGF molecule, with surface residues known to be 
important in dimerization (123, A25, L26, Y13, LI5, HI6, Y37, R41, 
Q43) and receptor binding (L47), highlighted in blue, and lysine 
residues (K28, K48), highlighted in red (adapted from Lu et al, 2001).
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Table 3.3 Literature review of polymer-EGF conjugates
Polymer
(molecular weight)
Polymer: protein EGF origin In vitro model Reduction in EGF activity 
(%  of unmodified EGF)
Reference
Dextran (70,000 g/mol) 1 : 356 Mouse U343 human glioma 37 - 75% Gedda et al (1996)
Poly(ethylene glycol)
(2000 g/mol)
(5000 g/mol)
Poly(ethylene glycol )-block-
poly(6-valerolactone)
micelles
3 : 1 
3 : 1
Recombinant human NRK47F
(Rat renal interstitial 
fibroblasts)
No reduction* Lee et al (2003)
(2,000 g/mol) 1 :1552 Unknown MDA-MB-468 human 
breast cancer
No reduction* Zeng et al (2006)
Poly(ethylene glycol) 
(2000 g/mol)
(5000 g/mol)
(20,000 g/mol)
3 : 1 
3 : 1 
3 : 1
Recombinant human NRK49F
(Rat renal interstitial 
fibroblasts)
71%
67%
61%
Hee Na et al (2006)
Poly(amidoamine) 
dendrimer 
(26,530 g/mol) 1 : 3 Mouse SCC15
(Human head & neck 
squamous cell carcinoma)
25% Thomas et al (2008)
*N-terminus conjugation
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was performed by two independent methods, using ultra-violet spectroscopy at 280 
nm, using the absorbance value of 2.858, as the molar extinction coefficient for a
0.1% (1 mg/ml) solution and analysis by RP-HPLC, using a calibrated solution of 
rhEGF, as a reference standard (Manufacturer’s data sheet; Prospec-Tany 
Technogene, Rehovot, Israel).
3.1.3 Experimental aims
The aims of this Chapter were the:
1. Synthesis and characterisation of succinoylated dextrin.
2. Synthesis and characterisation of dextrin-rhEGF conjugate batches.
3. Purification of dextrin-rhEGF batches.
4. Analysis of the degradation of dextrin, succinoylated dextrin and dextrin- 
rhEGF, in response to physiologically relevant a-amylase concentrations, 
using gel permeation chromatography (GPC).
5. Assessment of the stability of dextrin-rhEGF in an a-amylase-ffee 
environment.
6 . Assessment of the stability of dextrin-rhEGF in response to proteinases, using 
fast-protein liquid chromatography (FPLC).
7. Quantification of the rate and amount of rhEGF released from the dextrin- 
rhEGF conjugate, in response to physiologically relevant a-amylase 
concentrations, using FPLC and enzyme-linked immunosorbant assay 
(ELISA).
3.2 Methods
A number of general methods (Chapter 2) were used for the characterisation 
of the dextrin-rhEGF conjugates synthesised; the BCA protein assay (Section 
2.6.2.3), SDS-PAGE (Sectipn 2.6.2.2), FPLC and GPC (Section 2.6.2.1.).
3.2.1 Succinoylation of dextrin
Succinoylated dextrin was synthesised, according to the method of Hreczuk- 
Hirst et al (2001b). The reaction scheme is summarised in Figure 3.2. Dextrin 
(51,000 g/mol; lg, 19.6 pmol) was added to DMAP (80 mg, 655 pmol) in a 50 mL
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Dextrin-rhEGF synthesis. Dextrin (A) was functionalised with 
succinic anhydride (B), in combination with DMAP and DMF, to 
produce succinoylated dextrin (C). This was reacted with EDC 
(D), to form an amine reactive, O-acylisourea intermediate (E). 
Reaction with sulfo-NHS (F) then formed an amine-reactive sulfo- 
NHS ester (G). Lysine residues within the rhEGF molecule (H), 
formed stable amide bonds, resulting in the dextrin-rhEGF 
conjugate (I).
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round bottom flask. This mixture was purged with nitrogen and anhydrous 
dimethylformamide (DMF) (75 mL), added to the stirred mixture. Succinic 
anhydride (182.5 mg, 1.825 mmol) was dissolved in DMF (2.5 mL) and added to the 
reaction mixture. The resultant mixture was stirred under nitrogen, at 50 °C for 14 h.
The DMF was evaporated under high vacuum, to leave a few drops of the 
reaction mixture. The remaining reaction mixture was added, drop-wise, to 250 mL 
of vigorously stirred, diethyl ether and left for 10 h, under continual stirring. The 
resulting mixture was filtered under vacuum and dissolved into a minimal amount of 
double-distilled water (ddHsO). This solution was purified by dialysis (molecular 
weight cut-off 10,000 g/mol), to remove free reactants (succinic anhydride, DMAP, 
DMF) in 5 L of ddFhO for approximately 8  water changes, allowing 1-2 h between 
each water change. The remaining product was then collected, froze and lyophilised 
for two days, and stored at 4 °C, for subsequent characterisation.
3.2.2 Confirmation and quantification of dextrin functionalisation
3.2.2.1 Titration
The degree of carboxylic acid group incorporation into the dextrin polymer, 
from succinic anhydride, was quantified by titration (Hreczuk-Hirst et al, 2001a). 
Solutions of succinoylated dextrins (1.5 mg/mL, 2 mL) were titrated against sodium 
hydroxide (NaOH; 50 pM), using a bromothymol blue indicator (1 % w/v in ethanol, 
pH range 6  - 7.6). The end point of the titration was indicated by a change in the 
solution colour from yellow to blue, at pH 7.6. Titrations were performed in 
triplicate, and the mean mol % modification, i.e. the number of carboxylic acid 
groups incorporated, was calculated (Figure 3.3).
3.2.2.2 Fourier transform infrared (FTIR) spectroscopy
The extent of the functionalisation of the succinoylation dextrin was 
determined by Fourier transform infrared (FTIR) spectroscopy. FTIR is a 
measurement technique, whereby spectra are collected based on measurements of the 
temporal coherence of a radiative source, using time-domain measurements of the 
electromagnetic radiation or other type of radiation. It can be applied to a variety of 
types of spectroscopy, including optical spectroscopy, infrared spectroscopy (IR),
/
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Dextrin (51,000 g/mol) = approximately 283 glucose monomers (180 g/mol)
Succinoylated dextrin is a mixture of unmodified glucose monomers (U) + succinoylated monomers (S) (280 g/mol) 0
HO \  \  / O H
OH
HO.
HO / 0 H
OH
u OH
5  -------C H j— CH2— COOH
o
molecular weight (Mw) = (180U) + (280S) U = 283 - S therefore, Mw = ((283 - S) x 180) + (280S)
succinoylated detxrin
succinoylated dextrin (mol) = mass of succinoylated dextrin (g) (SD) = SD SD
TITRATION
((283 - S) x 180) + (280S)) 50,940 + 100S
moles NaOH (A/a) = S x moles succinoylated dextrin
Mw dextrin (DEX) + 100S
Na = S
QCO therefore S = DEX
sjDEX+ 100S/ SD
J ia ,
- 100
calculate S 
by titration
Mol % succinoylation = S x 100Mw = (283 - S) x 180) + (280S) Weight % succinoylation = 280S x 100
Mw
Figure 3.3 Calculation of % modification of succinoylated dextrin. Modification was expressed as mean mol % succinoylation (n = 3).
U =  number of unmodified glucose monomers; S = number of modified (succinoylated) glucose monomers; DEX=  molecular 
weight of unmodified dextrin (g/mol); SD = mass of succinoylated dextrin (g), analysed via titration; Na = moles of sodium 
hydroxide (NaOH), used in titration; Mw = molecular weight (g/mol).
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nuclear magnetic resonance, and electron spin resonance spectroscopy (Ellis and 
Goodacre, 2006).
Succinoylated dextrins were analysed, usually using 64 scans, over the mid- 
infrared (400 -  4000 cm'1) and near-infrared (4000+ cm'1) regions, with background 
interferences being subtracted. Scanning in these two regions enabled the detection 
of both specific molecules and combination bands, respectively. Where spectra were 
unresolved, the number of scans was increased from 64 to 300. This improved the 
signal to noise ratio, to give much clearer spectra. Qualitative analysis of the 
FTIR spectra was conducted by interpretation of the peaks in the double-bond region, 
2 0 0 0 -1500 cm 1.
3.2.3 Molecular weight and polydispersity determination of succinoylated
dextrin, by GPC
Dextrin and succinoylated dextrin, solubilised in phosphate buffered saline 
(PBS; 3 mg/mL), were injected (60 pL) onto the GPC column, as described in 
Section 2.6.2.1. Elution profiles were monitored over 30 min, at a flow rate of 1 
mL/min. Weight average, the number average molecular weights and the 
polydispersity of the succinoylated dextrin samples, were derived from the 
polysaccharide molecular weight standard curve, obtained as previously described.
3.2.4 Ninhydrin assay
Prior to conjugation of rhEGF to dextrin, it was firstly important to determine 
the number of available amine groups available for conjugation. The ninhydrin assay 
was selected for this purpose. Ninhydrin is a powerful oxidising agent, with the 
ability to react with all primary amino acids, between pH 4 and 8 , resulting in a 
purple colour, which forms the basis of the quantitative measurement of amine 
content (Plummer, 1978).
A 4 M lithium acetate buffer solution was prepared by dissolving lithium 
acetate dihydrate (102.02 g) in dcfflbO (150 mL). Acetic acid (glacial) was added, 
until pH 5.2 was reached. The volume was made up to a final volume of 250 mL 
with dtfrkO. Ninhydrin (0.8 g) and hydrindantin (0.12 g) were dissolved in 30 mL 
DMSO and 10 mL lithium acetate buffer, respectively.
DL-amino-2-propanol was dissolved in dcfflfeO to provide amino acid
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standards with concentrations in the range of 12.9 -  90.4 pM. A sample of rhEGF 
(250 pg/mL in PBS) was prepared. Buffered ninhydrin reagent ( 8 6  pL) was added to 
an equal quantity of sample/standard solution and heated in a water bath, at 100 °C 
for 15 min. The mixtures were subsequently cooled to room temperature, and 130 pL 
of 50 % v/v ethanol added, prior to spectrophotometric analysis at 570 nm. A typical 
calibration curve is shown in Figure 3.4.
3.2.5 Succinoylated dextrin-rhEGF conjugation and characterisation
Conjugation of the rhEGF to succinoylated dextrin was optimally performed 
at a 2:1 molar ratio (rhEGF : succinoylated dextrin), based on preliminary data. 
rhEGF was supplied in 1 mg aliquots of lyophilised powder. Succinoylated dextrin 
(8.2 mg) was dissolved in 500 pL of ddH2 0  and added to EDC (1.12 mg), in a 10 
mL round bottomed flask and stirred for 10 min, at room temperature. To this, sulfo- 
NHS (1.2 mg) was added and stirred for a further 40 min, under identical conditions. 
rhEGF (2 mg) was dissolved in dcfflhO (300 pL) and added to the reaction mixture. 
NaOH (0.5 M) was added drop-wise, until the mixture reached pH 8 . The resulting 
mixture was stirred for 18 h. The conjugate was purified using FPLC and ultra­
filtration as described in Section 2.6.1. The purified conjugate was characterised by 
GPC, FPLC, SDS-PAGE and BCA protein assay, as described in Section 2.6.
3.2.6 Degradation of dextrin, succinoylated dextrin and the dextrin-rhEGF
conjugate, by a-amylase
Human salivary a-amylase (Type XIII-A) was supplied as units (U) per mg 
of protein. One U will liberate 1 mg of maltose from starch, in 3 min, at pH 6.9, 20 
°C. Human plasma amylase is normally quoted as international units (i.u.), or 
Somogyi units, where one i.u. will liberate 1 mg of glucose from starch, in 30 min, at 
pH 7.4, 40 °C (equivalent to 0.0167 pkatals/L). A calibration curve was constructed 
using known concentrations of salivary amylase, assayed using the Phadebas® 
amylase assay (Section 6.2.3.2) to equate U to i.u. (Figure 3.5). All values herein are 
quoted as human plasma equivalents (i.u.).
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Figure 3.4 Ninhydrin assay. Typical calibration curve obtained for the 
quantification of the number of primary amines in rhEGF, available for 
polymer-protein conjugation, using DL-amino-2-propanol standards 
(mean ± S.D., n = 3).
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Figure 3.6 Fourier transform infrared (FTIR) spectroscopy analysis of 
dextrin and succinoylated dextrin. Panel (a) shows typical 
spectrum of dextrin is shown in red, and succinoylated dextrin, in 
black. Infrared band positions for relevant chemical groups are 
arrowed. Succinoylation was confirmed by the presence of the 
non-conjugated C=0 groups at the characteristic wavenumber 
(1720 cm'1; arrowed in red). Panel (b) shows characteristic 
infrared band positions for different chemical groups (Adapted 
from Advanced Light Source, 2008).
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Figure 3.7 Gel permeation chromatography (GPC) analysis of dextrin and 
succinoylated dextrin.A typical chromatogram of dextrin is shown in 
red, and succinoylated dextrin, in black. The shift in elution volume 
results from the succinoylation, leading to an increase in 
hydrodynamic volume and approximate molecular weight (dextrin 
approximately 57,000 g/mol, succinoylated dextrin approximately
84,000 g/mol). V0 represents the void volume.
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dark smearing appearing between approximately 197,000 to 37,000 g/mol, 
corresponding to the presence of a polydisperse conjugate. Prior to purification, 
there was also a band present within the conjugate reaction mixture at approximately
6,000 g/mol, corresponding to free rhEGF (Figure 3.8a). This band was absent 
following purification, by FPLC (Figure 3.8b).
Similarly, FPLC analysis of the conjugation reaction mixture, prior to 
purification, showed a peak corresponding to the dextrin-rhEGF conjugate, in the 
void volume (V0) region (7.7 mL) (Figure 3.9a). Other peaks, corresponding to free 
rhEGF (14-16 mL) (Figure 3.9b), and the reactants DMAP (Figure 3.9c) and sulfo- 
NHS (Figure 3.9d), were also identified. Following FPLC purification, the conjugate 
was free of these reactants and free rhEGF (Figure 3.9e). Estimation of molecular 
weight by comparison to the FPLC protein standard curve, was 147, 000 ± 17, 000 
g/mol (mean ± S.D. n = 5 batches). GPC was also used to estimate molecular weight, 
by comparison to the polysaccharide standard curve, and polydispersity (106, 0 0 0  ± 
1000 g/mol and 1.53, respectively; mean ± S.D. n = 3).
Various batches of dextrin-rhEGF were synthesized and characterized to 
optimise the reaction conditions (Table 3.4). The optimum conditions for synthesis of 
the dextrin-rhEGF conjugates were concluded to be a 2:1 molar ratio of 
rhEGFidextrin, with an 18 h reaction time. Synthesis was reproducible, with the 
mean rhEGF content being 16.3 ± 4.4 wt % protein, as determined by BCA assay (n 
= 5 batches, mean ± S.D.). This equated an rhEGF incorporation of approximately 2 
moles of rhEGF to every mole of succinoylated dextrin.
3.3.2 Degradation of dextrin, succinoylated dextrin and the dextrin-rhEGF
conjugate, by a-amylase
Dextrin, succinoylated dextrin and the dextrin-rhEGF conjugate were 
degraded by physiological levels of a-amylase (93 i.u./L), which produced a shift in 
molecular weight over time, as evident by GPC (Figure 3.10a). Minimal degradation 
occurred in a-amylase-free conditions (Figure 3.10b). Succinoylated dextrin (Tm = 
79.7 h) was degraded at a much slower rate than native dextrin (T1/2 = 6  min). The 
dextrin-rhEGF conjugate was degraded in a similar fashion to succinoylated dextrin 
(T1/2 = 55.4 h) (Figure 3.10c), indicating that protein conjugation did not affect 
polymer degradation.
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Table 3.4 Dextrin-rhEGF conjugate, batch summary
Batch Reaction mixture 
(dextrin : rhEGF)
Reaction
time
% conjugation of 
rhEGF (weight %)
Estimation of molecular 
weight (FPLC)
Ratio of dextrin: 
rhEGF
% yield 
rhEGF**
JTH001 1 : 1 18 h 6% 126,000 g/mol 2 :1 12%
JTH002 2 :1 18 h 7% 137,000 g/mol 1 : 1 17.3 %
JTH003 2 : 1 ' 30 h 4% 134,000 g/mol 3 : 1 2.4 %
JTH004 2 :1 18 h 16.8% 137,000 g/mol 1 :2 47.9 %
JTH005 2 :1 18 h 14.3 % 157,000 g/mol 3 :4 37.2 %
JTH006 2 :1 18 h 11 % 172,000 g/mol 1 : 1 23.1 %
JTH007 2 :1 18 h 23.1 % 131,000 g/mol 2 :5 31.2%
JTH008 2 :1 18 h 16.5 % 140,000 g/mol 1 :2 19.8 %
* average 16.3 % 147,000 g/mol 1 :2 31.8%
*batches JTH001 - JTH003 were for reaction optimisation purposes only. Subsequent batch calculations were based upon JTH004 - JTH008 
** weight % x mass of conjugate
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Figure 3.10 GPC analysis of the degradation of dextrin, succinoylated dextrin and 
dextrin-rhEGF. Panel (a) shows the typical shift in elution volume (and 
approximate molecular weight) of dextrin, in response to a-amylase (93 
i.u./L) over a 3 h period. V0 denotes the void volume (13 mL). Panel (b) 
shows the degradation of succinoylated dextrin and dextrin, over a 24 h 
period, in the absence (PBS) and presence of a-amylase (93 i.u./L) (n = 3; 
mean ± S.D. , * P <  0 .001, ANOVA and Bonferroni post hoc test). Panel 
(c) shows the change in relative molecular weight (GPC analysis) of 
dextrin (- - ■  - -), succinoylated dextrin (—▲—■), and dextrin-rhEGF (- - 
♦  - -), in the presence of a-amylase (93 i.u./L), over a 24 h period (n = 3; 
mean ± S.D., * p  = 0.0012, ANOVA and Bonferroni post hoc test).
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3.3.3 Dextrin-rhEGF conjugate degradation assays
When the dextrin-rhEGF conjugate was exposed to a-amylase (93 i.u./L), the 
polymer was degraded and free rhEGF was released (Figure 3.11). FPLC analysis 
showed the characteristic reduction in peak area, corresponding to the dextrin-rhEGF 
conjugate (6-9 mL), when exposed to a-amylase at 37 °C, as the dextrin polymer 
was degraded. In a reciprocal fashion, the FPLC peak corresponding to free rhEGF 
(14-16 mL) increased as rhEGF was released into solution. In a-amylase-free 
conditions, at 37 °C, the conjugate remained stable, with minimal degradation of the 
dextrin-rhEGF conjugate and little or no release of free rhEGF, calculated as the ratio 
of the peak heights of rhEGF : dextrin-rhEGF. The conjugate was thus verified to be 
resistant to hydrolytic degradation. The conjugate remained stable, both in solution at 
4 °C and lyophilised with later reconstitution. Upon addition of a-amylase (93
i.u./L), rhEGF was liberated over a 168 h period. As rhEGF was released and the 
conjugate degraded, there was a shift in the rhEGF : dextrin-rhEGF ratio, in favour 
of the released growth factor. A biphasic pattern, with an episode of released rhEGF 
over 0-3h, followed by sustained release from 3 -168 h was evident.
The ELISA method was sensitive to the human isoform of EGF (including 
rhEGF). The dextrin-rhEGF conjugate that had not been exposed to a-amylase, was 
shown not to stimulate the antigen-antibody response required for the ELISA 
reaction. In contrast, following a-amylase exposure, free rhEGF released into 
solution did stimulate the antigen-antibody complex formation (Figure 3.12). After 
168 h, 61.2 % of the total rhEGF content of the conjugate was released. However, a- 
amylase and succinoylated dextrin controls did not produce a recordable response. 
Again, the biphasic pattern of rhEGF release that was noted by FPLC analysis, was 
also evident, with rhEGF release reaching a plateau after 24 h and increasing during 
the final 144 h.
3.3.4 Stability of rhEGF and the dextrin-rhEGF conjugate, in response to
proteinases
As a proof of concept study, free rhEGF was degraded at a greater rate (T1/2 = 
45min), than the dextrin-rhEGF conjugate (T1/2 > 3h), following trypsin (0.025%) 
exposure (Figure 3.13a). FPLC analysis of rhEGF and dextrin-rhEGF, in response to 
neutrophil elastase (at physiologically relevant concentrations), exhibited marked
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degradation of rhEGF (T1/2 < 2h),when compared to conjugated rhEGF (T1/2 > 24h) 
(Figure 3.13b). Indeed, nearly 70% of the dextrin-rhEGF conjugate remained, 
following 6 h exposure to neutrophil elastase.
3.4 Discussion
The Chapter aimed to synthesise and characterise a dextrin-rhEGF conjugate. 
Quantification of the amine groups available for polymer conjugation, via the 
ninhydrin assay, estimated a different number (mean = 1 .2 ), from the actual value 
(three: two lysine residues and the N-terminus). The discrepancy between the actual 
and calculated amine groups may be a consequence of the inaccessibility of the 
amine groups, within the tertiary structure of the protein. Although there appeared to 
be only one accessible amine group for conjugation, probably lysine 48 (K48), site- 
specific conjugation was still possible. Furthermore, with the close locality of K48 to 
a residue implicated in EGF-receptor binding (leucine 47) (Lu et al, 2001), it can be 
postulated that conjugation may reduce receptor-binding capability and therefore, 
permit “masking” of rhEGF bioactivity, in keeping with the PUMPT concept.
3.4.1 Dextrin-rhEGF conjugation
Succinoylation of dextrin is a reliable, reproducible and cost-effective 
mechanism for the “activation” of the dextrin polymer. The introduction of reactive 
pendant groups to the polymer chain allowed chemical modification, without 
inducing instability in the polymer, that can be associated with other forms of 
modification, involving functional group introduction into the polymer backbone 
(Hreczuk-Hirst et al, 2001a). The chemicals used in this process are also less toxic 
than those highlighted, associated with other such processes (Bruneel and Schacht, 
1993a; 1993b; Table 3.1).
The variable succinoylation of dextrin has been previously reported to be 
between 5% to 34% (Hreczuk-Hirst et al, 2001a; Ferguson et al, 2006; Duncan et al, 
2008) as determined by titration. With the introduction of biologically active 
carboxylic groups to the dextrin polymer, it was possible to form polymer-protein 
conjugates. The reaction efficiency was optimised with the use of cross-linking 
agents (EDC, sulfo-NHS), resulting in up to 23.1% incorporation of rhEGF, by 
weight.
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Reproducible conjugation was evident, using reliable methods of protein 
assay (SDS-PAGE, FPLC and the BCA protein assay), which detected both free- and 
conjugated rhEGF. The conjugate product was characterised and purified, to remove 
both free rhEGF and excess cross-linking agents from the reaction mixture, resulting 
in < 1 % contamination with free rhEGF or cross-linkers.
3.4.2 Challenges to the dextrin-rhEGF conjugate characterisation
There was a significant difference in the estimated average molecular weight 
of the dextrin-rhEGF conjugate by GPC (106, 000 ± 1000 g/mol) and FPLC (147, 
000 ± 17, 643 g/mol).
Characterisation of a polymer-protein conjugate is generally difficult, as it 
does not behave like either individual component. This is especially significant when 
using GPC to determine molecular weight. Pullulan, like dextrin, is a polysaccharide 
that would be expected to take on a random coil structure in solution (Shingel, 2004), 
and therefore, is expected to behave similarly to dextrin. For these studies, pullulan 
was deemed the most appropriate choice as a molecular weight standard. However, it 
was recognised that the estimation of the conjugate molecular weight was likely to be 
difficult, by GPC.
Similarly, it remained impossible to obtain an absolute molecular weight for 
the conjugate, using FPLC, due to the structural and chemical properties of the 
conjugate, compared to the protein standards. Proteins have a unique tertiary 
structure that is, not only, dependent on their molecular weight, but also their charge, 
thus making accurate calibration of the FPLC column difficult. The presence of the 
polymer would, therefore, influence the molecular weight and charge of the 
conjugate and the polydispersity, making accurate determinations of molecular 
weight impossible.
SDS-PAGE was used to confirm the increase in rhEGF protein molecular 
weight, suggesting successful conjugation of succinoylated dextrin and rhEGF. Free 
rhEGF was compared to the pre- and post-purification reaction products, in relation 
to a series of molecular weight markers. The smearing observed for the dextrin- 
rhEGF conjugates, indicated that polydisperse dextrin-rhEGF conjugates were 
produced, due to the random coil nature of dextrin, in addition to uneven protein 
distribution along the polymer chain and between different chains. There are 
numerous conformations ip which the dextrin-rhEGF conjugate could exist, as a
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result of the multiple binding sites on succinoylated dextrin. The potential for cross- 
linking was reduced, by the fact that rhEGF had only one potential binding site. 
Using the weight % rhEGF incorporation, in conjunction with the estimation of 
dextrin-rhEGF molecular weight (FPLC), the ratio of dextrin : rhEGF, on average 
per batch, was calculated to be 1 : 2 (dextrin : rhEGF). This matched the initial ratio 
in the optimum reaction mixture, and although free rhEGF was also noted in typical 
pre-purification FPLC chromatograms, it must also be assumed that an equivalent 
amount of unconjugated, succinoylated dextrin, must also be present.
3.4.3 Dextrin-rhEGF degradation
The present Chapter demonstrated that dextrin, succinoylated dextrin and the 
dextrin-rhEGF conjugate, are all susceptible to a-amylase-mediated degradation, and 
therefore, are suitable as the degradable carrier component of a polymer-protein 
conjugate. Modification of dextrin by succinoylation, not only allowed activation of 
the polymer chain, thus permitting conjugation to rhEGF or other proteins/peptides, 
but also reduced the rate of a-amylase-mediated degradation. Degradation was 
slowed nearly 800-fold, by the addition of carboxylic acid side chains to the dextrin 
molecule. As the polymer was degraded, the degree of polydispersity was reduced as 
the chain lengths shortened and began to normalise to limit-dextrin and smaller 
maltose and isomaltose disaccharide units.
Hreczuk-Hirst et al (2001b) demonstrated that the rate of dextrin degradation 
was proportional to the degree of succinoylation, as unmodified dextrin had a half- 
life of 1-5 min, following exposure to rat plasma-derived a-amylase (approximately 
12,000 to 23,000 i.u./L), or porcine plasma a-amylase (approximately 2,000 i.u./L). 
These findings are similar to those obtained in the present Study, even though a 
much lower concentration of human, salivary a-amylase was used (93 i.u./L; T1/2 = 6  
minutes). Hie greater the mol % carboxylic acid groups incorporated, the slower the 
degradation rate. Rapid degradation was apparent at < 15 mol %, but at greater 
degrees of succinoylation, a slower degrading polymer, capable of sustained release 
over several days was produced.
As one of the aims of this Study, was to assess the dextrin-rhEGF conjugate 
as a therapy for human chronic wounds, the majority of the subsequent studies were 
performed under physiological concentrations of human plasma a-amylase.
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Although the a-amylase employed herein was from a human source, it is not 
pancreatic in origin (as human plasma a-amylase would be). Nevertheless, any 
further experimentation using human pancreatic amylase would yield similar results.
The ELISA did not detect any free rhEGF in the purified dextrin-rhEGF 
conjugate, unless the polymer had been degraded by a-amylase. Therefore, it can be 
concluded that the succinoylated dextrin polymer is likely to reduce the 
immunogenicity of rhEGF, again increasing the potential half-life of the rhEGF 
protein, as in the conjugated form, rhEGF and the active EGF-receptor binding 
domains are “masked”. The use of a polyclonal detection system may have allowed 
the detection of the rhEGF, prior to complete polymer degradation, as sites away 
from the conjugation may be detected. However, it must be considered that without 
proteolysis, the amide bond between the polysaccharide remnant and the rhEGF 
protein will remain. The “masking” effect does have a drawback, however, in that an 
accurate measure of the quantity of rhEGF incorporated into the dextrin-rhEGF 
cannot be directly quantified by ELISA, although degradation studies, as shown 
herein, have been demonstrated to liberate over 60 % of the calculated rhEGF from 
the dextrin-rhEGF conjugate, on exposure to a-amylase, for 168 h.
The controlled release phenomenon, described here would theoretically 
enhance the stability of the rhEGF protein, in both plasma and chronic wound fluid. 
Indeed, increased resistance to proteolytic degradation, as would occur in a chronic 
wound environment, is apparent by the resistance of the dextrin-rhEGF conjugate, to 
degradation in both the trypsin, proof-of-concept model, and the neutrophil elastase 
model (a proteinase in chronic wound fluid; Trengove et al, 1999). Subsequently, the 
half-life of rhEGF, when conjugated to succinoylated dextrin, was observed to 
increase over 1 2 -fold, after exposure to neutrophil elastase.
In all studies of a-amylase-mediated degradation, a biphasic pattern was 
evident, with rapid initial enzymatic hydrolysis, followed by a slower, more 
sustained pattern of release. This phenomenon was also reported by Hreczuk-Hirst et 
al (2001b). The initial hydrolysis would quickly produce large polymer chains 
( 1 0 , 0 0 0  -  2 0 , 0 0 0  g/mol), which would then undergo slower degradation to the limit- 
dextrin, and then to maltose and isomaltose disaccharide units.
/
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3.5 Conclusions
In summary, the succinoylation of dextrin produced an activated polymer that 
allowed reversible protein conjugation, via a-amylase-mediated degradation. The 
half-life of succinoylated dextrin (and of the dextrin-rhEGF conjugate), under 
physiological concentrations of human plasma a-amylase, was sufficient to permit 
effective, controlled, rhEGF release. Whereas traditional controlled release agents 
combine the active ingredient in a carrier vehicle, there is no chemical binding 
between the vehicle and therapeutic agent. Thus, the therapeutic agent is open to 
immunogenic reactions and degradation. This Chapter has demonstrated that the 
dextrin-rhEGF conjugate can “mask” the conjugated rhEGF from both an 
immunogenic response and proteolytic degradation. Upon polymer degradation by a- 
amylase, immunogenic rhEGF is released. The inactivation (“masking”) must be 
reversible (“unmasking”) to allow delivery of bioactive rhEGF to the site of action. 
The large molecular size of dextrin-rhEGF, which has been determined by GPC and 
FPLC, may also allow targeting of specific tissues, via the enhanced permeability 
and retention (EPR) effect (Matsumura and Maeda, 1986).
The bioactivity of rhEGF and “unmasked” dextrin-rhEGF conjugate, will 
now be established, in addition to the reduction in conjugate bioactivity, when in an 
a-amylase-free environment. Samples of the dextrin-rhEGF conjugate, that have 
been exposed to wound proteinases, will also be analysed, to ensure bioactivity is 
retained and restored, as part of the PUMPT hypothesis. Further evaluation included 
assessment of the rhEGF bioactivity, with in vitro cell-based models of wound 
healing.
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4.1 Introduction
The main cell types involved in the structural process of wound healing, i.e. 
collagen synthesis, and extracellular matrix (ECM) remodelling and re- 
epithelialisation, are the fibroblasts and keratinocytes (Martin, 1997). Therefore, the 
stimulatory effects of recombinant human epidermal growth factor (rhEGF) and the 
dextrin-rhEGF conjugate on these cells, will be the focus of the present Chapter. 
Specifically, cellular migration into the wound space and cellular proliferation, to 
replace and repair lost or dysfunctional tissues, will be examined.
4.1.1 Fibroblasts
Fibroblasts synthesise and maintain the ECM of the dermis, and provide a 
structural framework for normal skin function. Embryologically, these cells are 
derived from the mesenchyme (Desmoulliere and Gabbiani, 1996). Fibroblasts are 
the most common cell type in the connective tissue of animals and secrete the 
precursors of the ECM, including collagen, elastin, proteoglycans and glycoproteins 
(Doljanski, 2004).
Morphologically, fibroblasts have a branched cytoplasm, surrounding an 
elliptical nucleus (Desmoulliere and Gabbiani, 1996). Although disjointed and 
scattered at low cellular density, fibroblasts, when at a high cellular density, often 
locally align in parallel clusters. Active fibroblasts can be recognized by their 
abundant rough endoplasmic reticulum. Inactive fibroblasts, which are also known as 
fibrocytes, are smaller and spindle shaped (Bucala et al, 1994). They have a reduced 
rough endoplasmic reticulum. Tissue injury stimulates fibrocyte activity, and the 
induction of fibroblasts mitosis (Quan et al, 2004).
Fibroblasts are morphologically heterogeneous with diverse appearances 
depending on their location and activity. While epithelial cells form the lining of 
body structures, it is fibroblasts and related connective tissues that sculpt the form of 
an organism (Grinnell et al, 2003). Although, similar in structure, such fibroblasts 
can retain their individual phenotype (Sorrell and Caplan, 2004). For example, 
chronic wound fibroblasts undergo cellular senescence (irreversible entiy into the Go 
phase of the cell cycle), at an earlier stage than their patient-matched, normal dermal 
counterparts (Telgenhoff and Shroot, 2005; Wall et al, 2008).
As an early response to injury, local dermal fibroblasts begin to proliferate 
and migrate to the site of/ injury, where they synthesise a collagen-rich ECM
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(McClain et al, 1996). Many of the growth factors present at the wound site act as 
mitogens or as chemotactic factors for fibroblasts, including platelet-derived growth 
factor (PDGF), EGF, fibroblast growth factor (FGF), insulin-like growth factor-1 
(IGF-1) and transforming growth factor-P (TGF-P) (Martin, 1997). After one week, a 
proportion of the fibroblast population will have differentiated into myofibroblasts, 
due to TGF-pi and mechanical cues, related to the forces resisting contraction 
(Desmouliere et al, 1996; Grinnell and Ho, 2002; Hinz, 2007; Hinz et al, 2007). 
Expression of a-smooth muscle actin, allows the generation of contractile forces to 
reduce the wound area.
The fibroblasts that will be used in the present Study were derived from 
biopsies of the edge of a chronic venous leg ulcer and of the ipsilateral thigh, from a 
single patient. These cells were hTERT (human telomerase, reverse transcriptase) 
immortalized and donated by Dr Ivan Wall and Dr Mathew Caley (Tissue 
Engineering and Reparative Dentistry, School of Dentistry, Cardiff University). 
These chronic wound and normal dermal fibroblast cell lines have been established 
to mimic impaired and normal wound healing responses, in vitro.
4.1.2 Keratinocytes
Keratinocytes are structured in a laminar form that makes up the five layers 
of the epidermis (strata basalis; spinosum; granulosum; lucidum; and corneum). 
Keratinocytes originate in the stratum basalis from keratinocyte stem cells, which 
migrate up through the dermis, undergoing differentiation as they progress. On 
reaching the stratum corneum, these become flattened or squamous in morphology 
and are highly keratinized (Eckert, 1989), providing the skin with it’s barrier 
characteristics to infective or toxic vectors, and minimizes moisture loss (Madison, 
2003). Keratinocytes are continuously shed from the stratum corneum and replaced 
by cells from below (Houben et al, 2007). The transit time from stratum basalis to 
stratum corneum is approximately one month, although this can be accelerated in 
hyperproliferative keratotic conditions, such as psoriasis (Weinstein et al, 1984).
Keratinocytes are responsible for the process of re-epithelialisation, which 
occurs during the late-inflammatory and proliferative phases of wound healing (Patel 
et al, 2006, Gurtner et al, 2008). Upon re-epithelialisation of the wound, the normal 
barrier function of the skin (to moisture and pathogens) is restored, allowing the
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proliferation of sub-epidermal fibroblasts and ECM remodeling (Patel et al, 2006; 
Sivamani et al, 2007). Unlike fibroblasts, the keratinocytes migrate in a group-wise 
fashion, producing a “sliding sheet” of cell migration (Zhao et al, 2003).
In unwounded skin, basal keratinocytes are attached to the specialised basal 
lamina via hemidesmosomes, which bind to laminin in the basal lamina via a 6 p4  
integrins, which have intracellular links to the keratinocyte cytoskeleton (Haapasalmi 
et al, 1996). For keratinocyte migration to occur, these hemidesmosomes are 
degraded and the expression of new integrins (a5pl), collagen receptors and 
fibronectin/tenascin receptors, allows the cells to “crawl” over the wound matrix 
(Cavani et al, 1993; Breuss et al, 1995; Haapasalmi et al, 1996). Forward locomotion 
involves the contraction of actinomysin filaments within the cytoskeleton, which 
insert into the new adhesion complexes (Mitchison and Cramer, 1996). This activity 
is not limited solely to basal cells, as suprabasal cells can “leapfrog” the basal cells, 
during migration, in combination with “sliding sheet” migration (Zhao et al, 2003).
In order to migrate through the provisional wound matrix, keratinocytes at the 
leading edge of the sheet of migration, must degrade the fibrin barrier ahead of them 
by plasmin activation (from the plasminogen precursor within the clot), via 
expression of tissue-type plasminogen activator (tPA) or urokinase-type plasminogen 
activator (uPA) (McNeill and Jensen, 1990). Various matrix metalloproteinases 
(MMPs) are up-regulated by keratinocytes. MMP-9 (gelatinase B) is believed to be 
released from basal cells from the basal lamina (Salo et al, 1994), whilst MMP-1 
(interstitial collagenase) aids degradation of collagens I and III in the wound matrix, 
allowing migration (Saarialho-Kere et al, 1994; Moseley et al, 2004). Once the skin 
defect has been covered by a cell monolayer, a new stratified epidermis is established 
from the wound edge, inwards, allowing the restoration of normal cellular activity 
(Martin, 1997).
In the present Study, a spontaneously immortalised human keratinocyte cell 
line (HaCaT; Boukamp et al, 1988) was used. The HaCaT cell line mimics many of 
the properties of normal epidermal keratinocytes, is not invasive and can 
differentiate, under appropriate experimental conditions. Indeed, cell migration 
assays with primary human keratinocytes and HaCaT cells have proved to have 
similar results (Koivisto et al, 2006). Both of these cells have been shown to be 
sensitive to EGF stimulation, at nanogram concentrations (Kim and Kim, 2008).
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4.1.3 Human epidermoid carcinoma (HEp2) cells
For proof of concept studies, a human epidermoid carcinoma (HEp2) cell line 
was used. This cell line is known to over-express EGF-receptor on the cell surface 
(Salomon et al, 1995) and be sensitive to EGF stimulation (Raspaglio et al, 2003). 
The HEp2 cell line was established in 1952 (Moore et al, 1955), from tumours that 
had been produced in irradiated-cortisonised, weanling rats, following injection with 
epidermoid carcinoma tissue, from the larynx of a 56-year-old male (Toolan, 1954). 
The HEp2 cell line has supported the growth of measles virus (Black et al, 1956), 
and it has been used for experimental studies of tumor production in rats, hamsters, 
mice, embryonated eggs and volunteer terminal cancer patients (Moore, 1958).
4.1.4 EGF stimulation
Both fibroblasts and keratinocytes are sensitive the EGF stimulation 
(Nickoloff et al, 1988; Shiraha et al, 2000). Their culture requires the addition of 
exogenous EGF, in the form of foetal calf serum (FCS). As the present Study will 
involve the addition of exogenous rhEGF, either free, or in the form of the dextrin- 
rhEGF conjugate. A cell type that was highly responsive to EGF stimulation, that 
could be maintained in serum-free media, was also implemented (HEp2), allowing 
the effects of free rhEGF, the dextrin-rhEGF conjugate or EGF present in FCS, to be 
distinguished.
4.1.5 Experimental aims
A series of assays of cell proliferation and migration, were developed, 
involving the aforementioned cell lines. The efficacy of rhEGF and the dextrin- 
rhEGF conjugate, were assessed in these models, as was the “masking” of rhEGF 
bioactivity via succinoylated dextrin conjugation, and “unmasking”, in response to 
physiological levels of a-amylase.
The aims of this Chapter were the:
1. Optimisation of the cell proliferation assay with rhEGF.
2. Assessment of cell proliferation, in response to the dextrin-rhEGF conjugate 
in HEp2 cells, keratinocytes, and patient-matched normal dermal and chronic 
wound fibroblasts.
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3. Evaluation of “masking/unmasking” of the dextrin rhEGF conjugate, by a- 
amylase, on the cellular response.
4. Optimisation of the cell migration assay with keratinocytes and fibroblasts.
4.2 Methods
Cells were cultured, as described in Section 2.6.3.1.
4.2.1 Cell viability/proliferation assay
HEp2 cells, HaCaT keratinocytes and normal and chronic wound fibroblasts 
were seeded into 96-well microtitre plates at a cell density of 2.5 x 103 cells/well in 
10 % foetal calf serum-containing media (SCM 10%). Cells were maintained at 37 
°C/5% CO2 for 24 h. Cell-type specific media was used (summarised in Table 4.1). 
The optimum cell density was determined from the cellular growth curves (Figures 
2.7 -  2.9, Section 2.6.3.7). The MTT assay (Section 2.6.3.7) used for assessment of 
cellular viability and proliferation.
4.2.1.1 Optimisation
All cell types were serum-starved, in serum-free media (SFM), for 24 h. To 
assess optimum proliferation, in response to exogenous rhEGF, cells were 
maintained in media with differing FCS content (0, 1 and 10 %), with the aim of 
determining the minimum concentration of endogenous EGF (present in FCS), to 
enable cell proliferation. It was first necessary to prepare the stock solutions of 
rhEGF. RhEGF (400 ng/mL) in either SCM 10%, SCM 1% or SFM, for each specific 
media (Table 4.1), were prepared and serially diluted, upon addition to the cells. 
Cells were maintained at 37 °C/5% CO2 for 72 h, upon which, cell proliferation was 
assayed using the MTT assay (Section 2.6.3.7).
4.2.1.2 Addition of the dextrin-rhEGF conjugate
In the case of the dextrin-rhEGF conjugate, media was prepared, as shown in 
Table 4.2, and maintained at 37 °C/5% CO2 with, or without, a-amylase (29 - 521
i.u./L) for 24 h. In parallel, samples of rhEGF or the dextrin-rhEGF conjugate were 
also exposed to trypsin-EDTA (0.025%) (Section 3.2.7), purified using FPLC 
(Section 2.6.1), and exposed to a-amylase (93 i.u./L), at 37 °C, for 24 h.
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Table 4.1 Cell culture media composition
Cell line 10% FCS-containing media 1% FCS-containing media Serum-free media
Human epidermoid carcinoma H S C M 10%: H SC M  1 %: H SFM :
(HEp2) EMEM EMEM EMEM
penicillin G (100 U/mL) penicillin G (100 U/mL) penicillin G (100 U/mL)
streptomycin sulphate (100 pg/mL) streptomycin sulphate (100 pg/mL) streptomycin sulphate (100 pg/mL)
amphotericin B (0.25 pg/mL) amphotericin B (0.25 pg/mL) amphotericin B (0.25 pg/mL)
10 % v/v FCS 1% v/v FCS
HaCaT keratinocyte K-SCM 10%: K S C M 1%: KSFM :
DMEM 67.5% DMEM 67.5% Epilife® medium, plus
Ham’s F12 nutrient media 22.5% penicillin Ham’s F12 nutrient media 22.5% penicillin HKGS kit:
G (100 U/mL) streptomycin sulphate (100 p G (100 U/mL) streptomycin sulphate (100 p bovine pituitary extract (0.2% v/v) bovine
g/mL) amphotericin B (0.25 pg/mL) g/mL) amphotericin B (0.25 pg/mL) insulin (5 pg/mL) hydrocortisone (0.18 p
hydrocortisone (400 ng/mL) hydrocortisone (400 ng/mL) g/mL)
adenine (0.089 mM) adenine (0.089 mM) bovine transferrin (5 pg/mL)
cholera toxin (0.08 pg/mL) cholera toxin (0.08 pg/mL)
insulin (5 pg/mL) insulin (5 pg/mL)
10% v/v FCS 1% v/v FCS
Normal dermal fibroblasts and F-SCM 10%: F S C M 1 %: FSFM :
chronic wound fibroblasts DMEM DMEM DMEM
penicillin G (100 U/mL) penicillin G (100 U/mL) penicillin G (100 U/mL)
streptomycin sulphate (100 pg/mL) streptomycin sulphate (100 pg/mL) streptomycin sulphate (100 pg/mL)
amphotericin B (0.25 pg/mL) amphotericin B (0.25 pg/mL) amphotericin B (0.25 pg/mL)
L-glutamine (2 mM) L-glutamine (2 mM) L-glutamine (2 mM)
puromycin (1 pg/ml) puromycin (1 pg/ml) puromycin (1 pg/ml)
10% v/v FCS 1% v/v FCS
FCS = foetal calf serum, EMEM = Eagle's minimum essential medium,
DMEM = Dulbecco's modified Eagle's medium, HKGS = human keratinocyte growth supplement
Table 4.2 Stock solutions of the dextrin-rhEGF conjugate
Cell line [dextrin-rhEGF] ng/mL Cell culture medium +/- a-amylase
(rhEGF-equivalent) (i.u./L)
Human epidermoid 50 H-SFM 29-521
carcinoma (HEp2)
HaCaT 400 K-SFM 93
keratinocyte
Normal dermal 400 F-SCM1% 93
fibroblasts
Chronic wound 400 F-SCM 1% 93
fibroblasts
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On commencing the proliferation assay, either the dextrin-rhEGF conjugate, 
without prior a-amylase exposure or dextrin-rhEGF conjugate, exposed to a-amylase 
(and in one experimental run, trypsin-EDTA, 0.025%), were added to the each cell- 
type, and serially diluted. Cell cultures were maintained at 37 °C/5% CO2, for 72 h, 
upon which cell proliferation was assayed, using the MTT assay (Section 2.6.3.7). In 
additional experiments, similar cell proliferation assays were performed with HEp2 
cells, seeded at 2.5 x 103 cells/well, with the addition of dextrin-rhEGF (50 ng/mL 
rhEGF equivalent) and a-amylase (521 i.u./L). However, in this case cell 
proliferation was assessed daily, over 8  days to investigate any sustained rhEGF 
release effects from the dextrin-rhEGF conjugate.
4.2.1.3 Controls
HEp2 cells were seeded into 96-well microtitre plates, at a cell density of 2.5 
x 103 cells/well, in H-SCM 10 %, and maintained at 37 °C/5% CO2, for 24 h. The 
cells were serum-starved in H-SFM, and maintained at 37 °C/5% CO2 , for 24 h. To 
assess possible cell proliferation induced by dextrin, succinoylated dextrin or a- 
amylase, stock solutions were also prepared:
• Dextrin (400 pg/mL in H-SFM)
• Succinoylated dextrin (400 pg/mL in H-SFM)
• a-amylase (93 i.u./mL in H-SFM)
Dextrin and succinoylated dextrin were serially diluted upon addition to cells. 
Cells were maintained at 37 °C/5% CO2 , for 72 h, upon which an MTT assay was 
performed (Section 2.6.3.7).
4.2.2 Cell migration in monolayer culture
A variety of methods have been used in the measurement of cell migration, 
including the transwell assay (Boyden, 1962), often modified by fluorescence 
quantitation (Spessotto et al, 2002). Other techniques include the under agarose 
migration assay (Nelson et al, 1975), the soft-agarose drop method (Silva et al, 
2003), and the phagokinetic track motility assay for phagocytic cell types (Albrecht- 
Buehler, 1977). Wound healing can be assessed using time-lapse video microscopy 
(Providence et al, 2000). Although the transwell assay has been applied to random 
migration (Huttenlocher et al, 1996), video time-lapse microscopy provides
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advantages by yielding actual speeds of individual cells and additional features of 
motion (Bahnson et al, 2005). The introduction of video imaging and computer- 
assisted methods of tracking, have further aided this approach (Huttenlocher et al, 
1998; Shutt et al, 2000).
4.2.2.1 Scratch wound model assay
Normal dermal fibroblast, chronic wound fibroblast and HaCaT keratinocyte 
cellular migration, on exposure to rhEGF or the dextrin-rhEGF conjugate, in the 
presence and absence of a-amylase (93 i.u./L), were assessed, using an in vitro 
“scratch wound model assay”, according to Stephens et al (2004). Following 
trypsinisation, cells were seeded in 24-well tissue culture plates, in cell-type specific 
SCM 10% (1ml), at a cell density of 2.5x104 cells/well. Cells were maintained at 
37°C/5% CO2 , for 48 h, to reach 95 -  100% confluence. A single scratch was made 
with a sterile pipette across the cell layer and following washing (x 2) in PBS, the 
SCM 10% was replaced with culture medium (1ml), containing rhEGF or the 
dextrin-rhEGF conjugate, in the presence and absence of a-amylase (93 i.u./L), and 
control media (Table 4.3). The rhEGF and the dextrin-rhEGF conjugate were added 
at optimum concentrations to respective culture media, using data obtained from the 
MTT cell proliferation assays, previously described (Section 4.2.1). All experiments 
were performed in duplicate.
4.2.2.2 Time-lapse microscopy
Cell migration was visualised over a 48 h period (in a controlled atmosphere 
at 37 °C/5% CO2), using automated time-lapse microscopy. Digital images were 
captured at 20 min intervals and image sequences saved as QuickTime® movie 
files, for further analysis (QuickTime®, version 7.1.5, Apple Computer Inc, 
Cupertino, USA).
4.2.2.3 Image analysis -  wound area estimation (HaCaT keratinocytes only)
QuickTime® movie files were opened using Openlab 5® software, and images 
at time points: Oh, 24h or 48h, selected and copied into a photo-processing package 
(Adobe Photoshop® CS3; Adobe Systems Incorporated, San Jose, USA). Files were 
processed as shown in Figure 4.1. The files were further processed using ImageJ®
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Table 4.3 Cell culture medium composition for the scratch wound model assay
Cell line Media
description
[rhEGF]
ng/mL
[dextrin-rhEGF] ng/mL 
(rhEGF-equivalent)
[Succinoylated dextrin] 
pg/mL
Cell culture 
medium
a-amyla
(i.u./L)
HaCaT rhEGF 0 - 1 0 0 0 K-SFM 0
keratinocyte
Dextrin-rhEGF 0 0- 100 0 K-SFM +/- 93
Succinoylated 
dextrin control
0 0 1.56 K-SFM 0
a-amylase
control
0 0 0 K-SFM 93
Normal dermal rhEGF 0-3.13 0 0 F-SCM 1% 0
fibroblasts
and Dextrin-rhEGF 0 0.1 0 F-SCM 1% +/- 93
chronic wound
fibroblasts Succinoylated 
dextrin control
0 0 1.56 F-SCM 1% 0
a-amylase
control
0 0 0 F-SCM 1% 93
(a)
€
1340xl020pixels; 8-bit; L3MT
hacatcontroUmystart2.jpg (SOX)
0^0  Histogram of hacat<ontrolamystart2
Count 1366600 
Mean: 165 072 
StdDev 86 926
Min: 37 
Max 255
Mode: 255 (644924)
(e)
Figure 4.1 Image analysis
(c) Wound area calculation
An image file of keratinocytes (a) was 
processed by manual selection of the 
wound area (b) and filling with a 
contrasting colour (white) (c). A 
histogram of the colours present was 
produced and the number of pixels (in 
white) detemined, allowing wound size as 
a percentage of the total, to be calculated 
(d). A 3-D representation surface plot was 
further generated (e).
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(f)
(g)
Figure 4.1 (continued)
Cell Tracking
A example still image from a movie file 
of normal dermal fibroblasts (f) was 
processed, by tracking individual cells (g) 
and the resulting vectors (h) and velocities 
calculated.
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software (ImageJ I.37v; http://reb.info.nih.gov/ij/).
4.2.2.4 Image analysis -  cell tracking (all cell types)
Image processing and cell tracking were performed with ImageJ® software, 
including MTrackJ plugin software (Erik Meijering; http://www.imagescience.org 
/meijering/ software/mtrackj/). 1 0  cells of characteristic movement were selected per 
movie, the tracks recorded and the velocities calculated, based upon total distance 
travelled/ time (1 pixel = 1.03374 pm).
4.2.3 Statistical analysis
Statistical analyses were undertaken, using GraphPad Prism®, version 4.00 
(GraphPad Software, San Diego, USA). Data were compared using a Student's t-test 
or a one-way ANOVA, with a Bonferroni post-test. Results were expressed as a 
mean and standard deviation (S.D.), or standard error of the mean (S.E.M.). 
Statistical significance was considered at a probability o fp <  0.05.
4.3 Results
4.3.1 Cell viability/proliferation
4.3.1.1 Optimisation of the cell viability/proliferation assay
The selection of optimum conditions (% FCS and the range of [rhEGF]) for 
each cell type, was based on the lowest % FCS necessary, to maintain cell 
proliferation and thus, reduce the influence of endogenous EGF, within FCS. HaCaT 
proliferation was most pronounced in response to rhEGF, in K-SCM 10%. A similar 
result was also obtained with K-SFM (p > 0.05) (Figure 4.2). Therefore, the K-SFM 
was shown to support cell proliferation, without exogenous rhEGF interference and 
was, therefore, used in subsequent experiments. Significant (p < 0.01) fibroblast 
(normal dermal and chronic wound) proliferation occurred in F-SCM 1%, in the 
fibroblast assays (Figure 4.3). HEp2 cells were observed to proliferate in serum-free 
conditions, thus free from endogenous EGF interference (Figure 4.4).
4.3.1.2 Addition of rhEGF and the dextrin-rhEGF conjugate, to all cell types
In the HEp2 model, rhEGF displayed a biphasic pattern of activity, causing 
stimulation of proliferation at lower concentrations, but inhibition of proliferation at
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HaCaT proliferation assay optimisation. Panel (a) demonstrates 
HaCaT responses to rhEGF, in K-SCM 10%, panel (b) in K-SCM 
1% and panel (c) in K-SFM (mean ± S.D., n = 6; * p  < 0.01, 
ANOVA and Bonferroni post hoc test).Panel (d) shows no 
significant difference in cell proliferation, between media 
compositions, with the addition of rhEGF (6.25 ng/mL). Normal = 
rhEGF-free control.
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Figure 4.3 Dermal fibroblast proliferation assay optimisation. Panel (a) 
demonstrates normal dermal fibroblast responses to rhEGF, in F- 
SCM 10%, panel (b) in F-SCM 1% and panel (c) in F-SFM. Panel
(d) shows a significant increase in cell proliferation in F-SCM 1%, 
with the addition of 3.13 ng/mL rhEGF (mean ± S.D., n = 6; * p  < 
0.01, ** p  < 0.001 ANOVA and Bonferroni post hoc test ). Normal 
= rhEGF-free control.
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higher concentrations (>400ng/mL; Figure 4.5). The peak concentration for activity 
with the dextrin-rhEGF conjugate, following 24 h a-amylase exposure (93 i.u./L), 
was 0.19 - 6.25 ng/mL, compared with free rhEGF, which displayed highest activity 
at 3.13 -  100 ng/mL (Figure 4.5a). In the HaCaT, normal dermal and chronic wound 
fibroblast models (Figures 4.5b and 4.6), this biphasic response was less pronounced, 
but cells were sensitive to rhEGF stimulation at a wider range of concentrations (i.e. 
HaCaT at 0.1 -  100 ng/mL and fibroblasts at 0.006 -  6400 ng/mL). The dextrin- 
rhEGF conjugate consistently stimulated proliferation at lower equivalent 
concentrations, compared to free rhEGF. In the HEp2 model, no significant increase 
in cell proliferation occurred with dextrin, succinoylated dextrin or a-amylase 
controls (Figure 4.7a).
In the HEp2 model, the dextrin-rhEGF conjugate activity (without the 
addition of a-amylase), was not significantly different to controls (p > 0.05). When 
a-amylase (93 i.u./L) was added to the incubation medium, HEp2 cell proliferation 
was restored to a level equivalent to that observed with free rhEGF, at 72 h (p < 
0.001) (Figure 4.7b). The extent of proliferation, induced by the dextrin-rhEGF 
conjugate was clearly related to the amount of a-amylase added (Figure 4.7c). In the 
study of sustained release, when HEp2 cells were exposed to rhEGF or the dextrin- 
rhEGF conjugate (± a-amylase), native rhEGF caused the greatest increase in 
proliferation, over the initial 5 days of exposure, prior to proliferation returning to 
baseline levels. In contrast, the dextrin-rhEGF conjugate promoted sustained cell 
proliferation over 8  days, initially at lower levels compared to free rhEGF, but by 
day 5, maximum proliferation was equivalent to that of free rhEGF, at day 2. RhEGF 
caused a significant increase in proliferation, compared to proliferation on day 0 , on 
days 2 to 4 (p < 0.005), whereas the dextrin-rhEGF conjugate retained a significant 
stimulation of proliferation, compared to proliferation on day 0 , until day 6 (p < 
0.005). Moreover, this stimulation was significantly more active than rhEGF on days
5, 6  and 8  (p < 0.0002) (Figure 4.8).
Following successive exposure of rhEGF or the dextrin-rhEGF conjugate, to 
trypsin-EDTA (0.025%), followed by a-amylase (93 i.u./L), activity of the free 
rhEGF was reduced to that of the control (p > 0.05), whereas dextrin-rhEGF retained 
its bioactivity and thus, exhibited resistance to proteolytic degradation (Figure 4.9).
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Figure 4.5 HEp2 and HaCaT responses to rhEGF and dextrin-rhEGF (+ a- 
amylase). Panel (a) shows proliferation of HEp2 cells, at 72 h, in the 
presence of rhEGF (— ♦ — ) and a-amylase-activated, dextrin-rhEGF (- 
-), at the rhEGF concentrations shown (mean ± S.E.M., n = 3; * p  
< 0.001, ANOVA and Bonferroni post hoc test). Panel (b) shows 
proliferation of HEp2 cells, at 72 h, in the presence of rhEGF (— ♦ — ) 
and a-amylase-activated, dextrin-rhEGF (- -■ - -), at the rhEGF 
concentrations shown (mean ± S.E.M., n = 3; * p  < 0.05, ANOVA and 
Bonferroni post hoc test). Normal = rhEGF-free control.
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Figure 4.6 Fibroblast response to rhEGF and dextrin-rhEGF (+ a-amylase).
Panel (a) shows proliferation of normal dermal fibroblasts, at 72 h, in 
the presence of rhEGF (— ♦— ) and a-amylase-activated, dextrin- 
rhEGF (- -■ - -), at the rhEGF concentrations shown (mean ± S.E.M., 
n = 3; * p  < 0.01, ANOVA and Bonferroni post hoc test). Panel (b) 
shows proliferation of chronic wound fibroblasts, at 72 h, in the 
presence of rhEGF (— ♦— ) and a-amylase-activated, dextrin-rhEGF 
(- -■ -  -), at the rhEGF concentrations shown (mean ± S.E.M., n = 3; * 
p  < 0.05, ANOVA and Bonferroni post hoc test). Normal = rhEGF- 
ffee control.
120
Ce
ll 
Pr
ol
ife
ra
tio
n 
(% 
No
rm
al
)
«  160 i
o 150 - 
% 140 - 
PJ 130 - 
120 -ro
o  110 - 
”  100 -
co
o
k_
CL
oo
90 - 
80
(a)
£
v u  —
las
e 
(9
3 
i.u
./L
)
n 
(1
.5
6 
ng
/m
L)
s  E
"2 to
is •» 
2 =
_i
E
o>3.
T3
>. 'E k. .E 'E .E 'EE n >< 8 «< o 0> 3 °ro o o w<=> w Q
160 
150 - 
140 - 
130 - 
120 -  
110 -  
100 -  
90 - 
80
rhEGF D extrin-rhEG F Dextrin-rhEG F 
(50 ng/m L) (6.25 ng/m L (6.25 ng/mL 
E quivalent) equiv.
+ a -am y la se , 
93 i.u./L)
(c)
20
JL
43 521
[a-Amylase] (i.u./L)
Figure 4.7 Controls and "masking/unmasking" in HEp2 cells. Panel (a)
shows controls have no significant effect (p > 0.05, ANOVA and 
Bonferroni post hoc test) on cell proliferation. Panel (b) compares 
the proliferation of HEp2 cells, at 72 h, in the presence of rhEGF 
and the dextrin-rhEGF conjugate, in the presence and absence of a 
-amylase (93 i.u./L) (mean ± S.E.M.; n = 3; * p  = 0.0035, 
ANOVA and Bonferroni post hoc test). Panel (c) shows 
restoration of rhEGF activity was related to the concentration of a 
-amylase added (mean ± S.D., n = 6, * /? < 0.01, ** p  < 0.001, 
ANOVA and Bonferroni post hoc test). Normal = rhEGF-free 
control.
121
0.9 
^  0.8
J  0 7
S  0.6 -I
8  0.5 
c
ja 0.4-1
8  0.3 H.Q
<  0.2
0.1 -I 
0.0
(a) dextrin-rhEGF 
4" + a-amylase
' %
* control
I I I "I  I " ' I I  T
0 1 2 3 4 5 6 7 8  
Time (Days)
160
(0 150Ekoz
0s
dextrin-rhEGF 
+ a-amylase140 rhEGF
130co 120
110
oh.0L 100
8 90-
0 1 2 3 4 5 6 7 8
Time (Days)
Figure 4.8 Sustained release effects of dextrin-rhEGF. Panel (a) shows HEp2 
proliferation curves over 8 days, when HEp2 cells were grown in 
serum-free conditions (control), or in the presence of rhEGF (50 
ng/mL) or dextrin-rhEGF (6.25 ng/mL rhEGF equivalent), following 
exposure to a-amylase (521 i.u./L). Panel (b) shows sustained 
proliferation of HEp2 cells, compared to controls (mean ± S.E.M., n 
= 4; * p  < 0.001, ANOVA and Bonferroni post hoc test). Normal = 
rhEGF-free control.
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Dextrin-rhEGF conjugate resistance to proteolysis. Proliferation 
of HEp2 cells, in response to rhEGF, following trypsin exposure, 
was reduced to that of rhEGF-free controls, whereas dextrin-rhEGF 
retained bioactivity, compared to rhEGF-free controls (mean ± S.D., 
n = 6, * p  < 0.001, ** p  < 0.05, ANOVA and Bonferroni post hoc 
test). Normal = rhEGF-free control.
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4.3*2 Cell migration
4.3.2.1 Image analysis -  wound area estimation (HaCaT keratinocytes only)
Under rhEGF-free conditions, wound closure did not occur over 48 h (Figure 
4.10). Optimum wound closure occurred in the presence of rhEGF (6.25 ng/mL). At 
a higher concentration of rhEGF (10 ng/mL), complete wound closure was 
suppressed. Under a-amylase-free conditions, the dextrin-rhEGF conjugate did not 
cause complete wound closure, resulting in wounds of a similar area to rhEGF-free 
controls, (dextrin-rhEGF = 20.8 ± 1.5 %, K-SFM = 25.3 ± 7.9 %; mean ± S.D., n = 2; 
p  > 0.05). Upon the addition of a-amylase (93 i.u./L), rhEGF activity was restored, 
resulting in wound closure. Again, at higher concentrations of rhEGF (>10 ng/mL), 
wound closure was suppressed (Figure 4.11). 3-D surface plots illustrated the time 
course of a typical wound closing, in response to dextrin-rhEGF conjugate, following 
the addition of a-amylase (frill movies can be found in Appendix - DVD).
4.3.2.2 Image analysis -  cel) tracking (all cell types)
HaCaT cell migration velocity was increased, in response to the dextrin- 
rhEGF conjugate, following a-amylase exposure (93 i.u./L) (p = 0.0001). There was 
no significant difference in cell velocity between free rhEGF and “unmasked” 
dextrin-rhEGF (p > 0.05) (Figure 4.12). Both normal dermal fibroblast and chronic 
wound fibroblast migration velocity was increased, in response to the dextrin-rhEGF 
conjugate, following a-amylase exposure (93 i.u./L), and rhEGF (Figures 4.13 - 
4.15). Normal dermal fibroblasts migrated at a greater velocity, in response to rhEGF 
(both free and that released from the dextrin-rhEGF conjugate, p  = 0.0098). Chronic 
wound fibroblasts migrated at a similar velocity to their patient-matched normal 
dermal fibroblast counterparts, 15.6 ± 2.2 pm/h (chronic) versus 14 ± 3.3 pm/h 
(normal) (mean ± S.D., n=10, p  > 0.05). Again, cell migration velocity was 
increased, in response to the dextrin-rhEGF conjugate, following a-amylase 
exposure (93 i.u./L) (p = 0.0012). HaCaT migration velocity increased by over 
300%, in response to rhEGF (released from the dextrin-rhEGF conjugate, upon a- 
amylase exposure, 93 i.u./L), whilst both normal dermal and chronic wound 
fibroblasts increased by just over 50%.
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Figure 4.10 HaCaT cell migration (i). Cellular migration over a 48 h period, in 
response to (a) rhEGF-free media, (b) succinoylated dextrin (1.56 p 
g/mL), (c) a-amylase alone (93 i.u./L), (d) rhEGF (6.25 ng/mL) and 
(e) rhEGF (10 ng/mL). Healing was optimum, in response to rhEGF 
6.25 ng/mL.
De
xt
rin
-rh
EG
F
+ a-Amylase (93 i.u./L)
Figure 4.11 HaCaT cell migration (ii). Cellular migration, over a 48 h period, in 
response to (a) dextrin-rhEGF (0.1 ng/mL rhEGF equivalent), in the 
absence of a-amylase, and dextrin-rhEGF, following 24 h exposure 
to a-amylase (93 i.u./L) (b) 0.1 ng/mL, (c) 1 ng/mL, (d) 10 ng/mL 
and (e) 100 ng/mL (rhEGF equivalent).
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Figure 4.12 HaCaT cell migration (iii). Panel (a) shows 3-D representative 
surface plots of wound healing over 48 h, in response to dextrin- 
rhEGF (0.1 ng/mL equivalent), in the presence of a-amylase (93 
i.u./L). Panel (b) shows surface plots of positive and negative 
control samples, as described above. Panel (c) shows HaCaT cell 
migration velocity, in response to rhEGF-free conditions, dextrin- 
rhEGF (0.1 ng/mL equivalent), in the presence and absence of a- 
amylase (93 i.u./L), and rhEGF (6.25 ng/mL) (mean ± S.D., n = 
10; * p  = 0.0001, Student's t-test).
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Figure 4.13 Normal dermal fibroblast migration. Cell tracking for 10 typical 
dermal fibroblasts per movie, over a 48 h period. Panel (a) shows 
control cells in F-SCM 1%, panel (b) shows a typical response to 
the addition of dextrin-rhEGF (0.1 ng/mL rhEGF equivalent), in the 
absence of a-amylase, panel (c) shows increased migration, in 
response to dextrin-rhEGF (0.1 ng/mL rhEGF equivalent), 
following the addition of a-amylase (93 i.u/L) and panel (d) shows 
fibroblast migration, in response to free rhEGF (3.125 ng/mL).
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Figure 4.14 Chronic wound fibroblast migration. Cell tracking for 10 typical 
chronic wound fibroblasts per movie, over a 48 h period. Panel (a) 
shows control cells in F-SCM 1%, panel (b) shows a typical 
response to the addition of dextrin-rhEGF (0.1 ng/mL rhEGF 
equivalent), in the absence of a-amylase, panel (c) shows increased 
migration, in response to dextrin-rhEGF (0.1 ng/mL rhEGF 
equivalent), following the addition of a-amylase (93 i.u/L) and 
panel (d) shows fibroblast migration, in response to free rhEGF 
(3.125 ng/mL).
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Fibroblast migration velocities. Panel (a) shows normal dermal 
fibroblast migration velocities, in response to dextrin-rhEGF (0.1 
ng/mL equivalent), dextrin-rhEGF, in the presence of a-amylase (93
i.u./L) and rhEGF (3.125 ng/mL) (mean ± S.D., n = 10; * p  =
0.0098, Student's t-test). Panel (b) shows chronic wound fibroblast 
migration velocities, under the same conditions (mean ± S.D., n = 
10; * p  = 0.0012, Student's t-test).
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4.4 Discussion
This chapter aimed to investigate the bioactivity of rhEGF and dextrin-rhEGF 
in in vitro models of wound healing. The in vitro models of wound healing, 
described herein, have demonstrated the effects that rhEGF has on normal cells and 
those derived from chronic wounds. This promotion of cell proliferation and 
migration was evident using well-established assays, and appears highly 
reproducible. Although the HEp2 cell line is only a model for the subsequent work, it 
was reliable and predictable with the cellular proliferation responses induced, and 
importantly, was able to be successfully cultured, in rhEGF-free conditions. Thus, 
this facilitated the analysis of the action of rhEGF and the dextrin-rhEGF conjugate 
without interference from the action of endogenous rhEGF, within the culture media.
4.4.1 Cell viability/proliferation
The dermal fibroblasts and keratinocytes required rhEGF in normal culture 
medium, for successful culture and sub-culture. Data from the HEp2 model, in 
combination with data from the normal dermal fibroblasts, chronic wound fibroblasts 
and HaCaT keratinocytes, provided evidence to support the “proof of concept”, that 
rhEGF could be successfully conjugated to succinoylated dextrin, released in a 
controlled manner upon succinoylated dextrin degradation by a-amylase, and further 
retain the bioactivity upon release (equivalent to that of the unmodified rhEGF)* The 
concentration of a-amylase used in the majority of these studies was within the range 
found in normal human serum (Branca et al, 2001) and chronic wounds (Chapter 6).
Whilst the bioactivity of rhEGF was effectively “masked” when conjugated 
to succinoylated dextrin, these Studies demonstrated that the rhEGF activity was 
restored upon “unmasking” of the dextrin, by the application of a-amylase, at human 
physiological concentrations, it showed an increase in bioavailability. This was 
evident in cell proliferation experiments at lower equivalent concentrations of 
rhEGF, compared to unmodified, “free” rhEGF and protein stabilisation in the 
presence of a model proteinase. Thus, the need for high concentration of rhEGF was 
reduced.
Current products that are available in the wound healing field that contain 
rhEGF are at a high rhEGF concentration (ReGenD150; 150pg rhEGF/g of carrier 
matrix, resulting in mg quantities of rhEGF being applied to a large wound area), to
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account for the protein degradation in chronic wounds (Krishna-Mohan, 2007). At 
such high levels of rhEGF administration, the systemic uptake may be increased, 
potentially leading to peripheral side effects, due to rhEGF. EGF promotes tumour 
invasion in EGFR positive cancer cells (Zolfaghari and Djakiew, 1996; Kondapaka 
et al, 1997; Angelucci et al, 2006). These Endings highlight the potential of the 
dextrin-rhEGF conjugate, to effectively deliver a bioactive dosage of rhEGF. Indeed, 
stimulation of cells in these experiments occurred at pg/L concentrations; at levels 
which are similar to that of normal serum EGF levels (317 pg/mL ±31 pg/mL; 
Savage et al, 1986). The dextrin-rhEGF conjugate affords the opportunity to 
effectively deliver a bioactive dosing at normal physiological levels.
The biphasic response identified at various concentration of rhEGF, with 
suppression at high concentrations, has been previously reported in both in vitro and 
in vivo studies (Lai et al, 1989; Breuing et al, 1997). It has been postulated that 
down-regulation of the EGFR in the presence of high concentrations of EGF may 
account for this (Lai et al, 1989). In the cell proliferation studies described here 
(particularly in the HEp2 cell line), the effects of high concentrations (400 ng/mL) of 
rhEGF were most pronounced.
The conjugation to the degradable polymer, succinoylated dextrin, also 
permitted the controlled release of rhEGF, into the “wound environment”. Over an 8- 
day period, rhEGF activity was prolonged after conjugation, when compared to 
unmodified, free rhEGF. With sustained release, rhEGF could be released, whilst still 
remaining within the narrow therapeutic range, to promote cell proliferation. In a 
clinical setting, this may reduce the need for repeated applications, and reduce the 
amount of rhEGF applied to a wound.
4.4.2 Cell migration
The migration of fibroblasts and keratinocytes was enhanced by rhEGF (in 
both free and conjugated forms, following a-amylase exposure). The action of 
conjugation caused “masking” of the rhEGF bioactivity, which was restored upon 
“unmasking”, by polymer degradation, by a-amylase.
Fibroblasts and keratinocytes exhibit very distinct morphological 
characteristics, both in appearance and cell motility (Desmoulliere and Gabbiani, 
1996; Zhao et al, 2003). As such, the analysis by time-lapse microscopy had to be
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adapted to account for these differences. The presence of very little inter-cellular 
space, and reduced contact inhibition between keratinocytes in vitro, is related to 
their structural dynamics in the epidermis, in vivo, where they form a waterproof, 
protective barrier (Werner et al, 2007). The most appropriate methods of image 
analysis were based around the subtraction of cell-free background (the in vitro 
scratch wound) and the analysis of the mass movement of the body of cells, which 
act together to form a “sliding sheet” of cell movement to rapidly repair wounds 
(Zhao et al, 2003).
In contrast, fibroblasts in cell culture, have a much larger amount of inter­
cellular space than keratinocytes. As such, the most appropriate method to examine 
fibroblast cell migration in vitro, was time-lapse microscopy, which focuses on 
individual cells, rather than a cohort of cells. Therefore, individual fibroblast cell 
tracking and velocity calculations, were implemented. Indeed, it is recognised that 
the motility of fibroblasts is an indirect measure of their ability to produce and re­
organise the ECM (Grinnell et al, 2003).
Both fibroblasts and keratinocytes were responsive to the action of free 
rhEGF. Keratinocyte wound healing and migration velocity were markedly increased 
in response to rhEGF, when compared to rhEGF-ffee controls. Although normal and 
chronic wound fibroblasts did show increased migration velocity, when stimulated 
by rhEGF (both free rhEGF, and that released from the dextrin-rhEGF conjugate, 
following a-amylase exposure), the magnitude of the effects on keratinocyte average 
migration velocity was marked (up to 300% increase over rhEGF-free controls). This 
may reflect that the activity of the HaCaT keratinocyte cell line was more dependent 
upon rhEGF alone, compared to fibroblasts, whose activity is known to be more 
closely regulated in vivo by other growth factors (e.g. TGF-P) (Hinz, 2007; Hinz et 
al, 2007).
4.5 Conclusions
The in vitro data, detailed in this Chapter, obtained from cells involved in 
normal and pathological wound healing, demonstrated that rhEGF significantly 
stimulated both cellular proliferation and migration of all the target cell populations. 
The cellular proliferation data (from cells leaving Go of the cell cycle and increasing 
the metabolic activity), exhibited increased cellular activity and migration, both of
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which are essential to normal wound healing. The present Chapter has shown that the 
dextrin-rhEGF conjugate can “mask” the activity of rhEGF, which can be fully 
restored, following polymer degradation by a-amylase (“unmasking”), under 
physiological conditions. With this established “proof of concept”, further in vitro 
studies were undertaken to investigate the intracellular mechanisms by which rhEGF 
signalling in the cell types was induced.
/
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5.1 Introduction
The epidermal growth factor receptor (EGFR; erbB-1), belongs to the family 
of ErbB receptor tyrosine kinases (Bazley and Gullick, 2005), which also includes c- 
erbB-2/HER2, c-erbB3-/HER3 and c-erbB4/HER4. The 11 mammalian ligands 
currently identified for these receptors are epidermal growth factor (EGF), 
transforming growth factor-a (TGF-a), HB-EGF (heparin binding-EGF), 
betacellulin, amphiregulin, epiregulin, epigen and the neuregulins (NRGs) 1-4 
(Olayioye et al, 2000).
EGFR is a 170,000 g/mol transmembrane glycoprotein, that normally plays 
important roles in cell proliferation, differentiation and growth, and was the first 
receptor tyrosine kinase (RTK) to be discovered (Carpenter et al, 1978). The study of 
RTKs has subsequently yielded an insight into the underlying mechanisms by which 
these kinases function (Schlessinger 2000), including the recruitment and activation 
of secondary messengers (Jorissen et al, 2003). Each member of the ErbB family 
comprises a conserved protein tyrosine kinase domain, that resides within the 
cytoplasmic domain, a transmembrane domain and a glycosylated, extracellular 
ligand-binding domain (Marques et al, 1999; Bazley and Gullick, 2005) (Figure 5.1).
5.1.1 EGFR activation
In the absence of ligand, monomeric receptors reside within the cell 
membrane in an inactive state, distributed fairly evenly over the cell membrane 
(Bazley and Gullick, 2005). However, when ligand is present in the surrounding 
milieu, the receptor sites become occupied by monomeric EGF. The EGF sidechain 
of leucine 47 (next to lysine 48, the potential conjugation site for succinoylated 
dextrin, Chapter 3), projects into a hydrophobic domain, consisting of leucine 382, 
phenylalanine 412, isoleucine 438 and alanine 415, at it’s base (Jorissen et al, 2003). 
Provided two stable 1:1 EGF:EGFR intermediate complexes persist, sequential 
receptor dimerisation and oligomerisation ensue (Ferguson et al, 2003). Receptor 
dimers, which have greater stability and ligand-binding affinity than their 
corresponding monomers (Ben-Levy et al, 1992; Zhou et al, 1993), are increasingly 
considered to be necessary for activation (Alroy and Yarden, 1997). Ligand binding 
and receptor dimerisation, subsequently, induce intracellular tyrosine kinase catalytic 
activity (Hubbard and Till, 2000; Dibb et al, 2004).
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Figure 5.1 Schematic representation of the EGFR monomer. The extra­
cellular domain consists of two ligand-binding subdomains (LI, L2) 
and two cysteine-rich domains (SI, S2). SI permits EGFR 
dimerisation. SH1 is the protein tryrosine-kinase and exist above the 
six tyrosine residues available for phosphorylation. The trans­
membrane and juxtamembrane (JM) domains target the EGFR to 
caveolae (adapted from Bazley and Gullick, 2005).
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5.1.1.1 EGFR phosphorylation
Subsequent to the transphosphorylation of the receptor dimer, at Y1173, 
secondary messenger proteins, possessing one of the two main classes of domains 
that recognise site-specific phosphorylation (“docking sites”), can interact with the 
receptors (Bazley and Gullick, 2005). An example of a well-characterised secondary 
messenger/receptor interaction, is the recruitment of the enzyme phospholipase C 
gamma (PLCy) (Wang et al, 2001). In its inactive state, PLCy is normally found in 
the cytosol. However, upon phosphorylation of the EGFR, PLCy is able to interact 
with the phosphorylated receptor. This causes tyrosine phosphorylation by the 
activated receptor and its relocation to the plasma membrane, where it ultimately 
generates the second messengers, inositol 1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG) (Falasca et al, 1998), required for calcium/calmodulin-dependent kinases and 
the stimulation of protein kinase C. Additional targets o f signaling are the JAK- 
STAT pathway (Janus kinases -  Signal Transducers and Activators o f Transcription; 
Schindler et al, 2007). These transduce the signal carried by extracellular 
polypeptides (e.g. growth factors) to the cell nucleus, where activated STAT proteins 
modify gene expression (Henson and Gibson, 2006). This pathway plays a central 
role in principal cell fate decisions, regulating the processes o f cell proliferation, 
differentiation and apoptosis (Bazley and Gullick, 2005).
5.1.1.2 Signal transducers and activators of transcription (STATs)
Seven STATs have been identified in mammals (Sano et al, 1999). Each of 
these is differentially activated by various extracellular ligands. Many investigators 
have demonstrated that growth factors, including EGF, TGF-a and platelet-derived 
growth factor (PDGF), activate members of the STAT family, including STAT1 and 
STAT3 (Hemandez-Sotomayor and Carpenter, 1992; Ihle, 1996; Darnell, 1997). 
EGF has been shown to activate STAT1 and STAT3, in EGFR over-expressing cells 
(e.g. HEp2 cells) (Sadowski et al, 1993, Zhong et al, 1994; Park et al, 1996). The 
EGFR can activate STATs, in a JAK-independent manner, due to the presence of an 
intrinsic tyrosine kinase (Ihle, 1996). The phosphorylated STAT then forms 
dimmers, which translocate to the nucleus, where it binds to DNA-response elements 
in promoter regions, thus regulating growth factor/cytokine-directed gene expression 
(Zhong et al, 1994; Ihle, 1996; Darnell, 1997). Strategies which down-regulate
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EGFR can inhibit cell proliferation and abrogate STAT3 activation (Song and 
Grandis, 2000). Indeed, studies which have demonstrated that STAT3 gene 
disruption leads to mutant mice with no apparent abnormalities; with normal 
epidermal and hair follicle development. In this model, however, wound healing was 
markedly retarded. An in vitro study with cultured keratinocytes, revealed that this 
phenotype was attributed to impaired migration, as a consequence of impaired 
STAT3 activation (Kira et al, 2002; Sano et al, 2008).
5.1.2 Intracellular studies
For the study of the EGF-activation pathway, many techniques have been 
employed, including immunocytochemistry, Northern blotting, Western blot 
analysis, microarrays and bioinformatics (Harper et al, 2002; Liu et al, 2005; 
Hurtado et al, 2007). In this Chapter, the presence and activation of the EGFR, by 
rhEGF and the “unmasked” dextrin-rhEGF conjugate, were examined using 
fluorescence and chemiluminescence techniques. Fluorophores are functional groups 
within molecules that absorb energy at a specific wavelength (excitation), and re- 
emit it, again at a specific wavelength (Lichtman and Conchello, 2005). These are 
used widely in cell biology, but some are sensitive to pH, resulting in quenching of 
the fluorescence (Lattanzio, 1990; Takahashi et al, 1999). Alexa488 is a green 
emitting fluorophore (absorption = 495 nm, emission = 519 nm), which has been 
reported to fluoresce, in a pH-independent manner (Thom and Parker, 2004).
5.1.3 Experimental aims
A series of assays were developed to examine the mechanism of action of 
rhEGF and rhEGF, released from the dextrin-rhEGF conjugate, in response to a- 
amylase. The distribution of EGFR and EGF-endocytosis, in the HEp2 epidermoid 
carcinoma cells, HaCaT keratinocytes, normal dermal fibroblasts and chronic wound 
fibroblasts, were established, using fluorescence-labelled EGF, in conjunction with 
fluorescence-activated cell sorting (FACS) and fluorescence microscopy techniques. 
EGFR-activation and intracellular secondary messenger activation were examined, 
using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(Section 2.6.22), and Western blot analysis.
i
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The aims of this chapter were the:
1. Detection of EGFR in the different cell lines.
2. Optical imaging of EGFR, using confocal microscopy.
3. Quantification of relative EGFR density between the different cell lines using 
FACS analysis.
4. Analysis of EGFR activation, by the dextrin-rhEGF conjugate, following a- 
amylase exposure.
5.2 Methods
A number of general methods (Chapter 2) were utilised in the present 
Chapter, including the SDS-PAGE (Section 2.6.2.2), the BioRad protein assay 
(Section 2.6.2.4), cell culture (Section 2.6.3.1) and FACS analysis (Section 2.6.3.8).
To assess the pH-dependent quenching of Alexa488, EGF-Alexa488 was 
diluted to a range of concentrations (0 -1 0 0  pg/mL) in a range of phosphate buffers 
(Table 5.1), and fluorescence was recorded using a Fluostar Optima microplate 
reader, equipped with a 520 nm filter.
5.2.1 Confocal microscopy
HEp2 cells, HaCaT cells and normal dermal and chronic wound fibroblasts, 
from subculture, were seeded at a density of 5 x 103 cells/well on CultureSlides in 
cell-specific, 10 % serum-containing media (SCM 10%; 200pL). After 24 h, cells 
were serum-starved, in cell-specific, serum-free media (SFM; 200 pL) for a further 
24 h. Leupeptin (50 pM) was added to the media and the cells maintained at 37 °C/5 
% CO2 for 10 min. Culture media was aspirated and EGF-Alexa488 (10 pg/mL, in 
phosphate buffered saline, PBS; 100 pL), added to cells, with additional leupeptin 
(50 pM), for between 0 and 60 min, at 4 °C or 37 °C. Cells were washed (x 3) with 
PBS and fixed with 4 % paraformaldehyde (in PBS, pH 6.8; 10Q pL), for 20 min, at 
room temperature, in the dark. Slides were mounted with Vectashield™ mounting 
medium ± DAPI and examined by Confocal Microscopy (Section 2.5.2.9).
/
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Table 5.1 Phosphate buffer compositions
Buffer
molarity
(mM)
Monosodium
phosphate
monohydrate
(mg)
Disodium
phosphate
heptahydrate
(mg)
ddH20
(mL)
pH
100 1270 212 100 5.8
100 1028 684 100 6.4
100 312 2075 100 7.4
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5.2.2 Fluorescence-activated cell sorting (FACS)
HEp2 cells, HaCaT cells, normal dermal and chronic wound fibroblasts, were 
seeded at 1.5 x 105 cells, in a 75 cm2 tissue culture flask and maintained at 37 °C/5 % 
CO2 in SCM 10 % (10 mL cell-specific media) until 90 % confluent. Cells were 
washed (x 3) in PBS and serum-starved in SFM (10 mL) for 24 h. Media was then 
aspirated and EGF-Alexa488 (10 pg/mL in PBS; 1 mL) added to cells at 4 °C and 37 
°C, in the dark, for 0 to 30 min. Cells were washed (x 3) with PBS and trypsin- 
EDTA (0.025 %) added for 5 min, at 37 °C/5 % C02. When the cells had detached 
from the tissue culture flask, SCM 10 % (9 mL) was added and the cell suspensions 
aspirated and centrifuged at 1500 g  for 1 min using a Precision Durafuge 200 
centrifuge. The supernatants were removed and the resulting cell pellets re­
suspended in ice-cold PBS (1 mL), and re-centrifuged, as described above. This 
process was repeated twice more. The cells were finally re-suspended in ice-cold 
PBS (200 pL) and the samples stored on ice, until required for FACS analysis 
(Section 2.6.3.8).
5.2.3 Western blotting
5.2.3.1 Cell culture - EGFR expression
HEp2 cells, HaCaT keratinocytes, and patient-matched, normal and chronic 
wound fibroblasts, were seeded at 5 x 105 cells/100mm sterile Petri dish and 
maintained in 5mL of SCM 10 %, until 90 % confluent. Cells were serum-starved for 
24h, in SFM, prior to protein extraction.
5.2.3.2 Cell culture - EGFR and STAT3 phosphorylation
HEp2 cells and HaCaT keratinocytes were seeded at 5 x 105 cells/100 mm 
sterile Petri dish and maintained at 37 °C / 5% C 02, in 5 mL SCM 10 %, until 90 % 
confluent. Cells were serum-starved for 24 h, in SFM, prior to the addition of rhEGF 
(400 ng/mL, in H-SFM, for HEp2 cells; 6.25 ng/mL, in K-SFM, for HaCaT cells), 
the dextrin-rhEGF conjugate (400 ng/mL rhEGF equivalent, in H-SFM, for HEp2 
cells; 0.1 ng/mL rhEGF equivalent, in K-SFM, for HaCaT cells), or a-amylase- 
exposed, dextrin-rhEGF conjugate (400 ng/mL rhEGF equivalent, in H-SFM, for 
HEp2 cells; 0.1 ng/mL rhEGF equivalent, in K-SFM, for HaCaT cells; both samples 
contained a-amylase, 93 i.u./L, pre-incubated at 37°C for 24 h). Samples were
1
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selected at regular intervals between 0 and 40 min to study phosphorylated EGFR 
expression (following 2.5 min rhEGF/dextrin-rhEGF exposure and subsequently 
washed (x3) with PBS), or 0 and 24 h for analysis of phosphorylated STAT3 
expression, and the cellular proteins extracted.
5.2.3.3 Protein extraction
Cells were washed (x3) with ice-cold, PBS and the cellular proteins extracted 
by scraping into ice-cold extraction buffer (1 mL; 50 mM Tris-HCl buffer, pH 7.5, 
containing 5 mM EDTA and 1 mM dithiothreitol) and sonicated (5 x 20 s). Cell 
suspensions were harvested, centrifuged at 15,000 g  (4 °C) (Section 2.5.2), for 20 
min, and the protein content of the resulting supernatants determined, using the 
BioRad DC Protein Assay (Section 2.5.3.4). Samples (70 pg protein) were 
lyophilised, and stored at -20 °C, until required.
5.2.3.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE)
Protein samples and positive controls (A431 cell lysate for EGFR analysis; 
K562 whole cell lysate for STAT3 phosphorylation analysis) were suspended in non­
reducing, Laemmli loading buffer (lmL 0.5 M Tris-HCl, pH 6.8, containing 0.8 mL 
glycerol, 1.6 mL 10% SDS, 0.32 mL 0.05 % bromophenol blue, 4.18 mL ddH20; 
20pL) and loaded onto pre-formed, 4-15 % gradient gels, along with molecular 
weight markers (Section 2.6.2.2). Electrophoresis was performed at a constant 18 
mA, for 3 h.
5.2.3.5 Western blot analysis
SDS-PAGE gels underwent electroblotting onto PVDF membranes, using a 
Trans-Blot Semi-Dry Electrophoretic Transfer Cell System (Section 2.5.2), at a 
constant 15 V, for 30 min. On transfer, PVDF membranes were blocked with 
blocking buffer (5 % skimmed milk powder, in 0.05 % Tween 20 / PBS, pH 7.2) 
overnight.
/
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5.2.3.6 Immunodetection
The PVDF membranes were immuno-probed with primary antibodies, anti- 
EGFR (phosphoYl 173; anti-human, polyclonal IgG antibody, raised in rabbit), anti- 
STAT3 (phospho Y705; anti-human, polycloned IgG antibody, raised in rabbit), anti- 
actin (C-2; anti-human, monoclonal IgG antibody, raised in mouse), and anti-EGFR 
(F4; anti-human, monoclonal IgG, raised in mouse), all diluted 1 : 200 in blocking 
buffer, at room temperature for 1 h. The membranes were rinsed in blocking buffer 
(1x15 min, followed by 2 x 5 min), prior to incubation with horse-radish peroxidase 
conjugated secondary antibodies, anti-rabbit, polyclonal IgG antibody, raised in goat; 
and anti-mouse, polyclonal IgG antibody, raised in goat, diluted 1 : 3000 in blocking 
buffer, at room temperature, for 1 h. The membranes were rinsed in blocking buffer, 
at room temperature (1 x 15 min, followed by 2 x 5 min), prior to incubation in 
chemiluminescent reagent (ECL Plus Western Blotting Detection Reagent Kit), for 1 
min, at room temperature. Membranes were analysed with autoradiographic film 
(Hyperfilm-ECL) for 15 s to 5 min. Films were developed with an Autodeveloper 
(Section 2.5.2).
5.2.4 Statistical analysis
Statistical analyses were undertaken using GraphPad Prism®, version 4.00 
(GraphPad Software, San Diego, USA). Data were compared using a Student's t-test 
or a one-way ANOVA, with a Bonferroni post-test. Results were expressed as a 
mean and standard deviation (S.D.). Statistical significance was considered at a 
probability ofp <  0.05.
5.3 Results
5.3.1 Confocal microscopy
No significant pH-dependent quenching of Alexa488 occurred, over a pH 
range 5.8 -  7.4 (Figure 5.2). EGFR binding by EGF-Alexa488 occurred more 
efficiently at 37 °C, than at 4 °C, in HEp2 cells, over a 30 min period (Figure 5.3). 
The increase in green signal, corresponded to increased EGFR binding. At a typical 
single-cell level, EGFR binding at 37 °C, in HEp2 cells, occurred in a time- 
dependent manner, from 1 min (Figure 5.4a). Cell surface receptor binding increased, 
as did the apparent uptake of the fluorophore (conjugated to EGF). The EGFR was
!
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Figure 5.3 Confocal microscopy of HEp2 cells. The images to the left, 
demonstrate minimal receptor binding and uptake at 4 °C, whilst 
binding was increased (arrowed) in a time-dependent manner at 37 °C. 
Scale bar = 25 ^un. Blue = DAPI, green = EGF-Alexa488.
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Figure 5.4 Confocal microscopy of HEp2, HaCaT and normal dermal 
fibroblasts. Panel (a) demonstrates the typical time-dependent binding 
of EGF-Alexa488 to HEp2 cells, at 37 °C. Panel (b) demonstrates a 
typical HaCaT keratinocyte, viewed in brightfield (1) and fluorescence 
(2) at 15 min, 37 °C/5% C 02. Panel (c) demonstrates typical normal 
dermal fibroblasts, viewed in brightfield (1) and fluorescence (2) at 15 
min, 37 °C. Scale bar = 25 pm.
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also present on HaCaT keratinocytes and normal dermal fibroblasts, as indicated by 
confocal microscopy (Figures 5.4b and 5.4c).
5.3.2 Fluorescence-activated cell sorting (FACS)
FACS analysis demonstrated ligand-specific binding occurring at a maximum 
rate after only 1 minute in HEp2 cells, which was sustained over a 30 minute period. 
Dot plots (Figure 5.5a) showed the evolution of population of non-viable after 
30 min in the 4 °C control. Although specific uptake increased over 30 minutes 
(Figure 5.5b), non-specific binding also increased (Figure 5.5c), but significantly 
more binding occurred at 37 °C (p = 0.0058). Different cell types bound and 
endocytosed the EGF-Alexa488, at contrasting rates/quantities. HEp2 cells and 
HaCaT keratinocytes bound significantly more EGF, than both the normal dermal 
and chronic wound fibroblasts (p < 0.01). There was no significant difference 
between geometric mean fluorescence of the normal and chronic wound fibroblasts 
(p > 0.05) (Figure 5.6). There was also no significant difference between the 
geometric mean fluorescence of the HEp2 cells and the HaCaT keratinocytes (p > 
0.05).
5.3.3 Western blot analysis
EGFR was identified to be differentially expressed amongst the different cell 
types examined. A band was detected at approximately 170,000 Da, corresponding to 
the EGFR. There was greater expression of EGFR in the HEp2 and HaCaT 
keratinocytes, than in the normal dermal fibroblasts and chronic wound fibroblasts 
(Figure 5.7). In the HEp2 cells, the EGFR was phosphorylated at Y1173, in response 
to rhEGF (400 ng/mL), with maximal phosphorylation at 20 min (Figure 5.8a). When 
rhEGF activity was “masked” by conjugation to succinoylated dextrin (the dextrin- 
rhEGF conjugate), in the absence of a-amylase, the degree of phosphorylation was 
markedly reduced (Figure 5.8b). Upon the addition of a-amylase (93 i.u./L) and 
incubation for 24 h at 37 °C / 5% C02, rhEGF was released from the conjugate, 
causing activation and phosphorylation of EGFR, with maximal effect at 40 min 
(Figure 5.8c). Similarly, STAT3 phosphorylation (at Y705) occurred, in the presence 
of rhEGF (400 ng/mL), with a detectable band present at 92,000 Da (Figure 5.9a). 
Again, activity was “masked” by the dextrin-rhEGF conjugate, in the absence of a-
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Figure 5.5 Fluorescence-activated cell sorting (FACS) of HEp2 cells. Panel (a) 
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Figure 5.6 Fluorescence-activated cell sorting (FACS) of all cell types. Panel 
(a) shows a histogram of the fluorescence distribution amongst the 
different cell types. Panel (b) shows the geometric mean fluorescence 
amongst the different cell types: HEp2, HaCaT keratinocytes, normal 
dermal fibroblasts (NF) and chronic wound fibroblasts (CWF), (mean 
± S.D., n = 2; *p < 0.01, ANOVA and Bonferronipost hoc test).
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Figure 5.8 Western blot analysis of phosphorylated EGFR in HEp2 cells.
Panel (a) shows the presence of EGFR (phospho Y1173) at 
approximately 170 kDa with actin loading controls, in response to 
rhEGF (400 ng/mL). Panel (b) shows minimal phosphorylation in 
response to dextrin-rhEGF (400 ng/mL equivalent) in the absence 
of a-amylase and panel (c) shows the restoration of rhEGF 
activity with the dextrin-rhEGF (400 ng/mL equivalent), following 
24 h exposure to a-amylase (93 i.u./L). Actin was used as a 
loading control.
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Figure 5.9 Western blot analysis of the phosphorylated STAT3 in HEp2 
cells. Panel (a) shows the presence of STAT3 (phospho Y705) at 
approximately 92 kDa, with actin loading controls, in response to 
rhEGF (400 ng/mL). Panel (b) shows minimal phosphorylation, in 
response to dextrin-rhEGF (400 ng/mL equivalent) in the absence 
of a-amylase and panel (c) shows the restoration of rhEGF activity 
with the dextrin-rhEGF (400 ng/mL equivalent), following 24 h 
exposure to a-amylase (93 i.u./L). K562 whole cell lysate was a 
positive control (+ve). Actin was used as a loading control.
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amylase (Figure 5.9b), and “unmasked” upon the addition of a-amylase (Figure 
5.9c). In HaCaT keratinocytes, STAT3 phosphorylation was observed upon the 
addition of rhEGF and the dextrin-rhEGF conjugate, in the presence o f a-amylase 
(93 i.u./L), following 2 h exposure. EGFR phosphorylation was absent in the rhEGF- 
free control and the dextrin-rhEGF conjugate, not exposed to a-amylase (Figure 
5.10). The actin controls confirmed the equality o f loaded protein in each sample 
analysed.
5.4 Discussion
This Chapter aimed to investigate the intracellular mechanism o f action of 
rhEGF and rhEGF released from the dextrin-rhEGF conjugate. Using a variety of 
analytical techniques, it was confirmed that conjugation of rhEGF to succinoylated 
dextrin, and subsequent release, in response to a-amylase did not affect the classical 
signalling pathway of rhEGF.
Fluorescent dyes, that can be used to investigate intracellular mechanisms, 
are known to be sensitive to pH and can undergo pH-dependent quenching. The 
intracellular pH is acidic, which can cause the quenching of fluorophores (e.g. 
fluorescein isothyanate, FITC; Palmer et al, 1994; Kwon and Carson, 1998). 
Alexa488 has been reported to be resistant to such activity and was, therefore, chosen 
for the present Study (Thom and Parker, 2004). This was confirmed in the present 
Chapter (Section 5.3). Quenching of the fluorescent signal may have given 
misleading results, and any potential intracellular tracking of the fluorophore may be 
affected by this.
As already discussed in Section 3.4, rhEGF possesses only one reactive 
amine to permit conjugation, to either a fluorophore or succinoylated dextrin. With 
only one potential conjugation site, then the production o f co-conjugates, such as the 
fluorescent labelling of an EGF molecule, prior to conjugation, to permit tracking of 
the EGF molecule, following a-amylase mediated release from the polymer 
conjugate, was not be possible. A series of experiments proved this to be correct 
(data not shown). Oregon Green™ (OG)-labelled dextrin could be conjugated to 
rhEGF (via the reactive lysine group), to produce an OG-dextrin-rhEGF conjugate 
that could be potentially tracked, using fluorescence analysis (FACS, Confocal 
Microscopy). However, with only one binding site, a dextrin-rhEGF-OG conjugate
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Figure 5.10 Western blot analysis of the phosphorylated STAT3 in HaCaT 
cells, after 2 h exposure to rhEGF, dextrin-rhEGF and dextrin- 
rhEGF exposed to a-amylase. A band corresponding to STAT3 
(phospho Y705), is observed at approximately 92 kDa, in the K562 
whole cell lysate positive control. It is also observed, after 2 h, in 
the presence of free rhEGF (6.25 ng/mL), and dextrin-rhEGF (0.1 
ng/mL rhEGF equivalent), exposed to a-amylase (93 i.u./L). There 
is a weak or absent band when exposed to dextrin-rhEGF, in the 
absence of a-amylase, or rhEGF-free media, for 2 h. Actin was 
used as a loading control.
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could not be synthesised. Hie synthesis of dextrin-rhEGF-OG would have allowed 
the tracking of rhEGF whilst conjugated (as could OG-dextrin-rhEGF), but upon 
degradation and rhEGF release, die fluorescence would no longer be conjugated to 
rhEGF and traceability would be lost. The labelling of the succinoylated dextrin 
polymer was possible, as previously shown, with the labelled polymer demonstrated 
to be taken up by endocytosis and sorted, via the early endosome (Richardson et al, 
2008).
All of the studies here, involving EGF-Alexa488, confirm receptor-binding 
and cell uptake, but the bioactivity of fluorescent rhEGF was not assessed. To enable 
a fluorescent signal to be detected by Confocal Microscopy, and other fluorescence 
techniques, a high concentration of rhEGF was used (0.5 -  10 pg/mL). Cells 
involved in the process of dermal wound healing (keratinocytes and fibroblasts) have 
been shown to be sensitive to EGF-stimulation, at much lower concentrations 
ranging between 10 -  50 ng/mL (Ando and Jensen, 1993; Yang et al, 1997; 
Sutherland et al, 2005). At high a high concentrations, a cytotoxic effect can be 
observed (Gill and Lazar, 1981; Barnes, 1982). These fluorescence studies were, 
therefore, useful for the imaging of receptor binding and EGF uptake, but it must be 
emphasised that this was not a true reflection of the events may be encountered in 
vivo.
5.4.1 Epidermal growth factor distribution
The EGFR is present on the majority of cell types (Lopez et al, 1992). It is 
found at different densities upon the cell surface of these different cells (Krupp et al, 
1982; Engstrom et al, 1985; Falette et al, 1989; Lopez et al, 1992). The expression of 
EGFR may predict the behaviour of cells to EGF stimulation (Jorissen et al, 2003). 
Upon ligand-binding and receptor dimerisation, the EGFR is taken up into the cell by 
endocytosis and processed at an intracellular level, resulting in receptor recycling 
and degradation, and the up- or down-regulation of cell surface receptors (Yarden 
and Ullrich, 1988; Gruenberg and Maxfield, 1995; Levkowitz et al, 1998; Bao et al, 
2008). Cells which over-express EGFR (e.g. epithelial carcinomas) are known to be 
susceptible to EGF-stimulation, as receptor blocking can reduce the cells’ ability to 
proliferate and migrate in vivo (Bundred et al, 2001; Chan et al, 2002).
The literature reports typical cell surface EGFR densities for fibroblasts (7 x 
104 per cell; Krupp et al, 1982) and keratinocytes (9.2 x 103 to 8.5 x 104 per cell;
157
Chapter 5 Mechanistic Studies With The Dextrin-rhEGF Conjugate
Lopez et al, 1992). These numbers of cell-surface receptors represent 85 -  95 % of 
the total receptors per cell (Krupp et al, 1982). In the present Study, the EGFR was 
more significantly expressed in HaCaT keratinocytes (immortalised, adult human 
cells) than in the fibroblasts, although the receptor was still present in both the 
fibroblast cell types. Interestingly, there were no significant differences in the EGFR 
expression between the normal dermal and chronic wound fibroblasts. It has been 
suggested that cells from bum wound margins may under-express specific cell 
surface receptors (Wenczak et al, 1992), as do aged (senescent) cells (Shirahara et al, 
2000). In the proteolytic chronic wound environment, cell surface receptors may be 
prone to degradation, and whilst still being expressed, their longevity may be 
reduced. The present Study confirmed that patient-matched, fibroblasts from 
different dermal origin, expressed a similar number of receptors when removed from 
the normal dermal or chronic wound environments. Consequently, the down- 
regulation of the EGFR, or possibly, the reduced half-life of the EGFR, in the 
chronic wound environment (Wenczak et al, 1992), is not reflected, ex vivo.
5.4.2 EGFR activation and intracellular signalling
The EGFR was differentially expressed amongst the model cell line (HEp2), 
compared to the keratinocytes and normal dermal and chronic wound fibroblasts. 
The levels detected by Western blotting, were in accordance with those detected by 
FACS analysis.
Western blot analysis of specific proteins involved in the EGFR signalling 
cascade, demonstrated that the model HEp2 cell line was sensitive to rhEGF 
stimulation, with phosphorylation of the EGFR occurring within 2.5 minutes of 
exposure, with maximal stimulation after 20 minutes. This confirmed the ability of 
rhEGF to activate this specific pathway. In the wound model, involving HaCaT 
keratinocytes, STAT3 phosphorylation occurred in the presence of both free rhEGF, 
or that derived from a-amylase-exposed, dextrin-rhEGF. The activation of the EGFR 
signalling cascade was, therefore, demonstrated to occur in both cell line models. 
With the activation of this cascade in the epidermal-derived cell line, it confirms the 
observations in the in vitro models of cell proliferation and migration (Chapter 4).
In accordance with the polymer masking-unmasking protein therapy 
(PUMPT) hypothesis, the activity and ability of rhEGF to bind to the EGFR should 
be “masked” by the conjugation to the succinoylated dextrin macromolecule.
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Western blot analysis confirmed this, as minimal expression of the phosphorylated 
EGFR was evident, in response to the dextrin-rhEGF conjugate in the absence of a- 
amylase exposure, with an equivalent quantity of rhEGF present. Upon the addition 
of a-amylase (at physiological concentrations), for 24 hours, rhEGF was released, 
inducing activation (phosphorylation) of the EGFR. Interestingly, there was a slight 
delay in the induction of maximal activity (40 minutes versus 20 minutes) between 
the free rhEGF and rhEGF released (“unmasked”) from the dextrin conjugate. This 
may be a consequence of growth factor conjugation to succinoylated dextrin, 
resulting in an amide bond between the reactive residue and carboxylic side-chain, 
which would be resistant to polysaccharide degradation. Such events may lead to 
delayed receptor binding. Alternatively, the total rhEGF was not completely released 
by a-amylase exposure, as was observed by ELISA (Section 3.3.3). With potentially 
only 40 -  50 % of the available rhEGF released, a weaker, or delayed response, as 
apparent by Western blot analysis, may have resulted.
Following EGFR phosphorylation, the intracellular pathway was activated, 
resulting in STAT3 phosphorylation, which continued over a 24-hour period. In the 
presence of the “masked” dextrin-rhEGF conjugate, there was minimal activation. 
Phosphorylated STAT3 was examined, as STAT3 is normally latent within the 
cytoplasm and may not be affected by EGFR activation (Kira et al, 2002). Under all 
conditions where the EGFR had been phosphorylated, subsequent phosphorylation of 
the STAT3 was demonstrated to occur. Again, the activation of these intracellular 
pathways confirms the bioactivity of the dextrin-rhEGF conjugate observed in 
Chapter 4.
5.5 Conclusions
These preliminary in vitro studies, involving cells found in the normal and 
wound dermis and epidermis, in addition to a model cell line (HEp2), demonstrate 
that the EGFR was present upon the surface of all cells types examined. However, 
the EGFR was accessible to the binding of labelled EGF and rhEGF, both as free 
rhEGF and as that released from the dextrin-rhEGF conjugate. Following receptor- 
ligand binding, normal intracellular pathways were activated. It can, therefore, be 
concluded that rhEGF conjugation to succinoylated dextrin, and subsequent rhEGF 
release by a-amylase (at physiological concentrations) does not affect the inherent
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bioactivity o f the rhEGF. The next line of investigation involved the development 
and optimisation of an ex vivo model of wound healing, and the examination of 
rhEGF and the dextrin-rhEGF conjugate, in this ex vivo model.
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6.1 INTRODUCTION
Ex vivo organ culture is the maintenance of multiple cell types in an organ- 
specific structured manner. The majority of skin that can be cultured in vitro, is ex 
vivo derived, but is grown as an organotypic model (e.g. human skin equivalents, 
HSE). Organotypic skin culture, in vitro, can involve the development of an artificial 
matrix, seeded with multiple cell types found together in a specific organ, in vivo, to 
mimic the appearance and/or function of the organ. HSEs consist of a dermis, 
epidermis and partially differentiated, stratum corneum, but are deficient in skin 
appendages, such as pilosebaceous units and hair follicles (Godin and Touitou, 
2007). However, such skin appendages, themselves have been cultured in vitro 
(Philpott et al, 1990). In recent years, the development of organotypic skin has 
allowed advances in wound healing investigation ex vivo, prior to in vivo assessment 
(Godin and Touitou, 2007). Examples of these two subtypes o f ex vivo model and 
how they apply to wound healing and the assessment of the dextrin-recombinant 
human epidermal growth factor (dextrin-rhEGF) conjugate, are considered below.
Another ex vivo model routinely used, has involved the collection of acute 
and chronic wound fluid. Wound fluid was utilised for both , analytical and 
experimental purposes, for example to confirm the presence of a-amylase in wound 
fluid, which was essential for fulfilment of the Polymer masking-UnMasking Protein 
Therapy (PUMPT) hypothesis. Wound fluid was also used in the assessment of the 
stability of the dextrin-rhEGF conjugate, in the presence of chronic wound 
proteinases. These are vital steps, prior to the commencement o f in vivo evaluation of 
the dextrin-rhEGF conjugate.
6.1.1 Ex vivo organ culture and models of wound healing
6.1.1.1 Organotypic skin culture
The first organotypic models of skin were based upon human keratinocytes, 
cultured upon an irradiated fibroblast layer, supported on plastic (Rheinwald and 
Green, 1975). Cultured sheets of keratinocytes were first applied to bum wounds as a 
skin substitute, as opposed to autologous skin grafting, in 1981 (O’Connor et al, 
1981). Recent developments in the synthesis of artificial skin substitutes has 
involved the use of 3-D scaffolds, to mimic the extracellular matrix (ECM), on which 
cellular or dermal and/or epidermal equivalents can be cultured and applied to
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wounds. Acellular dermal equivalents can also be used in the trauma setting to 
provide a dermal template for endogenous cellular ingrowth.
With the development of tissue-engineered, skin equivalents, for in vivo 
application, these have also been applied to in vitro studies of transdermal drug 
permeation (Pasonen-SeppSnen et al, 2001; Ajani et al, 2007) and skin irritancy 
testing (Ponec, 2002), prior to in vivo assessment. With reference to cutanous wound 
healing, the development of HSEs has provided biologically meaningful 
experimental systems, to study epidermal biology and epithelial-mesenchymal cross 
talk, in an in vivo-like tissue context (Andriani et al, 2003; Abraham et al, 2004; 
Margulis et al, 2005). These 3-D tissues allow direct determination of key response 
parameters of wounded epithelium, including cell proliferation, migration, 
differentiation, growth factor responses and proteinase expression (Singer and Clark, 
1999). As such, these systems provide a valuable model to study cell interactions in 
complex tissues (Egles et al, 2008).
However, the true in vivo architecture is lost with these models, and although 
an artificial representation can be synthesized and seeded with multiple organ 
derived cell lines, these systems are not a perfect model in which to examine the 
wound healing potential of the dextrin-rhEGF conjugate. HSEs are an ideal candidate 
for skin replacement in vivo (Dini et al, 2006; Pham et al, 2007), but for the 
assessment of the dextrin-rhEGF conjugate, an established organ culture model will 
be utilised.
6.1.1.2 Corneal re-epithelialisation
Organ culture models, involving ex vivo corneas, have been successfully 
developed for the assessment of gene therapy (Mohan et al, 2005), 
immunomodulatory drugs (Flueckiger et al, 2005) and comeal wound healing (Zhao 
et al, 2006; Castro-Combs et al, 2008). Either the whole eye, or cornea alone, can be 
maintained outside if the body, resulting in the in vivo architecture of the cornea 
being retained, along with the endogenous cell types (Figure 6.1).
Comeal epithelial wound closure models have been employed by many 
investigators. They involve inducing a defined, central epithelial wound (and 
excision of the anterior stratified squamous epithelium) and characterising the 
kinetics of the wound healing response. Healing occurs in distinct phases involving 
the “sliding” of cells to cover the denuded surface, cell proliferation and stratification
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Figure 6.1 Cross-section through the murine eye. Panel (a) shows a 4 x 
magnification of a haematoxylin and eosin (H&E) stained cornea, 
with structures labelled. Panel (b) shows a 20 x magnification of the 
cornea, with structures labelled.
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(Zhao et al, 2003). Prior to the onset of these events, there is a lag phase of about five 
hours, in vivo. Cells migrate at a constant rate o f approximately 60 to 80 pm/hour, 
until wound closure is completed (Pfister, 1975; Kuwabara et al, 1976; Matsuda et 
al, 1985; Crosson et al, 1986). Agents that have selective effects on epithelial 
growth, migration, adhesion, and differentiation have been identified. These include 
topically applied growth factors, such as EGF, fibroblast growth factor (FGF), 
transforming growth factor-Pi and -fr (TGF-fSi and -P2), keratinocyte growth factor 
(KGF), hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), 
insulin-like growth factor (IGF), interleukins (IL) -1 and -6, tumour necrosis factor-a 
(TNF-a), endothelin-1 (ET-1) and retinoids (Elliott, 1980; Kandarakis et al, 1984; 
Ubels et al, 1985; Takagi et al, 1995; Imanishi et al, 2000).
Ex vivo models of corneal re-epithelialisation, include the culture of the 
whole eye (Reid et al, 2005), submerged in tissue culture medium, or models that 
mimic the in vivo arrangement of the eye, by isolating the cornea and maintenance at 
the air-fluid interface. Such models can also further imitate the in vivo situation, by 
perfusion of the anterior chamber, at a defined pressure, producing a constant tear 
film to maintain comeal moisturisation, which can also deliver experimental 
compounds to the cornea (Zhao et al, 2006). Various animal species have been used 
for these experiments, such as rat (Reid et al, 2005), cow (Zhao et al, 2006), rabbit 
(Castro-Combs et al, 2008) and pig (Flueckiger et al, 2005).
An ex vivo rat comeal model will be utilised herein, for assessment of the 
dextrin-rhEGF conjugate. Although it is a model of acute wound healing, and the 
tissue architecture is dissimilar to skin, this model will be employed, prior to the 
investigation of the dextrin-rhEGF conjugate with an in vivo model of impaired 
dermal wound healing (Chapter 7). In the pre-clinical development of the dextrin- 
rhEGF conjugate, from in vitro repopulation of a wounded monolayer culture, to ex 
vivo organ culture, these vital further steps that have established die potential of the 
dextrin-rhEGF conjugate to enhance wound healing.
6.1.2 Wound fluid
It is widely assumed that wound fluid is a reflection of the wound 
environment (Trengove et al, 1996; Mani, 1999). As such, it may provide important 
clues regarding the status of the wound itself. Wound fluids/exudates can be
167
Chapter 6 Dextrin-rhEGF Conjugate Evaluation in an Ex Vivo
Model o f Wound Healing A ik! Wound Fluid Analysis
collected using minimally invasive methods and have the potential to provide 
important biochemical information in the healing status of a wound. Numerous 
methods for wound fluid collection have been reported (Moseley et al, 2004; Yager 
et al, 2007).
6.1.2.1 Acute wound fluid
The majority of studies examining acute wound fluid have relied upon peri- 
operatively-placed suction drains, such as the Jackson-Pratt® (American Heyer 
Schulte Corp., Santa Barbara, USA), or Portavac™ drains (Howmedica International 
Incorporated, Pfizer Medical Technology Group, Shannon, Ireland), or from blister 
fluid (Ortega et al, 2000). Although drainage fluids are relatively easy to obtain, 
these will only reflect the early stages of acute wound repair. During this phase, the 
levels of cytokines and growth factors differ. Studies have shown that growth factors, 
such as EGF, PDGF and FGF are initially high, and then progressively fall, whilst 
vascular endothelial growth factor (VEGF) and IL-1 rise during the first post­
operative week. TGF-p remains relatively constant during this time, although all 
these levels vary between studies (Vogt et al, 1998; Baker et al, 2003; Di Vita et al, 
2006). This temporal variation can reflect the underlying wound healing processes. 
No studies have reported the a-amylase content in acute wound fluids.
6.1.2.2 Chronic wound fluid
Fluid obtained from chronic wounds can be aspirated from underneath 
occlusive dressings (James et al, 2003) or by extraction from wound dressing 
materials, placed upon wounds (Moseley et al, 2004). Studies that have compared the 
biomarker profile of acute and chronic wound fluids have shown, consistently, that 
pro-inflammatory cytokines, such as the interleukins; tissue proteinases, including 
the matrix metalloproteinases (MMP-2 and -9) and serine proteinases (e.g. neutrophil 
elastase); and reactive oxygen species (ROS), are present at significantly higher 
levels in non-healing wounds, as opposed to healing wounds (Moseley et al, 2004; 
Yager et al, 2007). A consensus on the levels of growth factors in acute and chronic 
wounds, has not yet been reported, with variable levels of EGF, PDGF and TGF-p, 
found in these contrasting wound fluids. Decreased levels of growth factors, or 
inappropriate localisation may also be a factor (Cooper et al, 1994; Higley et al,
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1995; Trengove et al, 2000). A consistent finding is that when acute or chronic 
wound fluid is applied to cells, acute wound fluids promote dermal fibroblast 
proliferation and ECM synthesis, whilst chronic wound fluids suppressed this 
response (Katz et al, 1991; Bucalo et al, 1993; Mendez et al; 1999). No studies have 
reported the a-amylase content within chronic wound fluids.
6.1.3 Amylase
The amylases are a group of enzymes found in all living organisms, that 
breakdown starches into disaccharides, by acting upon a-l,4-glycosidic bonds, a- 
amylase is found in humans, although not exclusively, whereas (3- and glucoamylase 
are found exclusively in plants and microorganisms (Janacek, 1997; Pandey et al, 
2000).
6.1.3.1 a-Amylase
The a-amylases act at random locations along the polysaccharide chain, 
yielding intermediate length dextrins, shorter limit dextrins, maltotetraoses and 
maltotrioses, and ultimately the dissacharides, maltose and isomaliose (isomaltose 
retains an a-l,6-glycosidic bond) (Burkart, 2004) (Figure 6.2). In humans, a- 
amylase occurs in two isoforms (pancreatic- and salivary-a-amylase), which are 
produced in the pancreas and parotid glands, respectively (Abrams et al, 1987; 
Whitcomb and Lowe, 2007). Approximately 5 - 6 % of the total protein in pancreatic 
secretions, is a-amylase (Whitcomb and Lowe, 2007). a-Amylase is a 512 amino 
acid glycoprotein, of approximately 57,600 g/mol (Abrams et al, 1987). a-Amylase 
acts at an optimum pH of 6.7 -  7.0, in the proximal ileum and, on starch hydrolysis, 
as described above, the resulting limit dextrins and disaccharides are further digested 
by intestinal brush border enzymes (maltase, isomaltase). The resulting 
monosaccharides are subsequently absorbed (Alpers, 1994). The predicted aminov 1
acid sequences of the salivary and pancreatic isoforms differ by only 6 % (Abrams et 
al, 1987). These have nearly identical crystal structures (Ramasubbu et al, 1996) and 
have the same mechanisms of action. The two isoforms can be distinguished by 
electrophoresis (Lott and Lu, 1991).
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Figure 6.2 The degradation of polysaccharides by a-amylase. Polysaccharides 
are degraded by the random hydrolysis of a-1,4 glycosidic bonds, 
initially to medium length dextrins (n = 200 - 300) and subsequently to 
oligosaccharides and component disaccharides, a-1,6 glycosidic bonds 
(< 5 % in dextrin) are not degraded by a-amylase thus, ultimately, 
resulting in isomaltose liberation. Final degradation of the disaccharides 
is mediated by maltase and isomaltase, present at the intestinal brush 
border.
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6.1.4 Experimental aims
The efficacy of the dextrin-rhEGF conjugate, has been established with in 
vitro models o f wound healing, involving cells (fibroblasts, keratinocytes) known to 
be important in the normal response to injury, as well as those derived from chronic 
wounds (Chapters 4 and 5). Prior to investigation in an in vivo model of impaired 
wound healing (Chapter 7), the dextrin-rhEGF conjugate was evaluated in an ex vivo 
organ culture model of acute wound healing. The composition of wound fluid was 
also established, with respect to a-amylase and elastase activities.
The aims of this Chapter were the:
1. Establishment of an ex vivo model of acute comeal wound healing.
2. Assessment of the effectiveness of the dextrin-rhEGF conjugate, to induce 
comeal repair, ex vivo.
3. Collection of ex vivo wound fluid from acute and chronic wounds.
4. Analysis o f wound fluids, for a-amylase and elastase activities.
6.2 Methods
6.2.1 Ex vivo corneal organ culture model of acute wound healing
6.2.1.1 Corneal wounding
Two-month old male Wistar Han rats (250-300g; Charles River Laboratories, 
Margate, UK), were sacrificed by CO2 asphyxiation, confirmed by cervical 
dislocation. A medial and lateral canthotomy was performed to allow access to the 
globe, using a surgical scalpel (15-blade). The globe was irrigated with balanced salt 
solution (1 mL, BSS Plus®), containing 0.1% ethylenediaminetetraacetic acid 
(EDTA). The irrigation remained in situ on the cornea for 5 min. Excess irrigation 
solution was removed with a cotton swab. Using a binocular Operating Microscope 
(Stemi 2000-C), at 1.25x magnification, the cornea was scored with an ultra-fine 
micro-knife (15° cutting angle, 5mm blade). A circular abrasion was developed and 
the comeal anterior epithelium denuded, to produce a fiill-thickness comeal abrasion 
of 2mm diameter (Figure 6.3). The globe was then enucleated and placed in a 12- 
well tissue culture plate, secured on a bleb of cyanoacrylate adhesive gel (Loctite 
Super Glue). Prior to the addition of culture medium, the globe was maintained in
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Figure 6.3 Ex vivo corneal wound healing - specimen preparation, (a) Male 
Wistar Han rat were sacrificed, (b) Eyes were irrigated with BSS 
Plus® solution, containing 0.1% EDTA, for 5 min. (c) The excess 
irrigation fluid was swabbed from the eyes, (d) The eyes were 
abraded with a micro-knife, to produce a scored cornea (e). (f) The 
abrasions were developed, by progressive removal o f  the epithelium 
(as indicated by the dotted line).
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BSS Plus® (3 mL) solution. 4 specimens were assigned to each Control and Study 
Group.
6.2.1.2 Addition of tissue culture medium and study compounds
Tissue culture medium, Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with penicillin G, lOOU/mL; streptomycin sulphate, lOOpg/mL; 
amphotericin B, 0.25pg/mL; puromycin, lpg/mL; L-glutamine, 2mM (serum-free 
media; SFM), was applied to the Control Group (Group 1). For the Study Groups, the 
SFM was supplemented, as follows:
• Group 2 - 10% foetal calf serum (FCS) (serum containing media; SCM).
• Group 3 - a-amylase (93 i.u./L).
• Group 4 -  rhEGF (1 pg/mL).
• Group 5 -rhEGF(10pg/mL).
• Group 6 - dextrin-rhEGF (1 pg/mL rhEGF equivalent)
• Group 7 - dextrin-rhEGF (1 pg/mL rhEGF equivalent) and a-amylase (93
i.u./L) (pre-incubated for 24 h, at 37 °C).
• Group 8 - dextrin-rhEGF (10 pg/mL rhEGF equivalent) and a-amylase (93
i.u./L) (pre-incubated for 24 h, at 37 °C).
Supplemented tissue culture medium (3 mL), as described above, was added 
to each well, containing the ex vivo globes, and the specimens maintained at 37 °C / 
5% C02, for 64 h.
6.2.1.3 Corneal imaging
Corneal wounds were recorded using digital photography. Images from the 
Operating Microscope (at 2.5x magnification), were recorded with a digital camera 
(Nikon Coolpix 4500). For each specimen, tissue culture medium was aspirated from 
the well and excess fluid removed from the cornea, using a cotton swab. Following 
imaging, the tissue culture medium was replaced, as described above. Images were 
recorded at time points between 0 and 64 h. To confirm corneal wound healing, 
fluorescein staining was performed, using a Fluorets® Sterile Ophthalmic Strip,
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activated with phosphate buffered saline (PBS), and images recorded at 1.25x 
magnification, under an ultraviolet light source, at 365nm.
6.2.1.4 Image analysis
Digital images were contrast enhanced in Adobe® Photoshop® CS3 (Adobe 
Systems Incorporated, San Jose, USA) and size-normalised. Wound edges were 
delineated in Microsoft® PowerPoint® (2004 for Mac; Microsoft Corporation, 
Washington, USA) and wound sizes (as a percentage of the image size) calculated, 
using Image J software (ImageJ 1.40g; http://rsb.info.nih.gov/ij/) (Figure 6.4).
6.2.2 Wound fluid collection
Informed consent was obtained for all procedures, which were performed 
under Local Research Ethics Committee (LREC) approval. Patient undergoing 
mastectomy surgery (acute wound fluid) or with venous leg ulcers (chronic wound 
fluid), were recruited from inpatient (Department of Surgery) and outpatient (Wound 
Healing Research Unit) populations, at the University Hospital of Wales, Cardiff, 
UK.
6.2.2.1 Acute wound fluid collection
Acute wound fluid samples (n = 5 patients) were obtained using peri- 
operatively placed, sub-cutaneous suction drains (Jackson-Pratt), over a 24 h period. 
Samples (1 mL) were clarified by centrifugation (15,000 g, 5 min at 4°C) and the 
supernatants stored at -80°C, until required.
6.2.2.2 Chronic wound fluid collection
Each venous leg ulcer or diabetic foot ulcer (n = 5 patients) was dressed with 
Release® and covered with a Bioclusive® film dressing. These dressings remained in 
situ > 4h. Upon wound dressing saturation, the Bioclusive® film was removed, the 
saturated Release® dressing removed, using sterile forceps, and placed in a sterile vial 
on dry ice, for transfer. Any non-saturated regions within the Release® dressings 
were removed with sterile scissors. In order to elute the wound fluids, dressings were 
immersed in 0.1 M Tris-HCl buffer, pH 7.4, containing 0.1% Triton X-100 (wound 
fluid elution buffer; 500 \xL buffer/cm2 dressing). Chronic wound fluids were eluted
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Figure 6.4 Corneal abrasion - image analysis, (a) The corneas were 
digitally imaged at 2.5 x magnification, (b) The wound areas 
were highlighted (as indicated by white dotted line), (c) The 
wound areas were calculated, as a percentage of the whole image 
size (black pixels : white pixels). Serial measurements were 
taken for each abrasion, at specified time points, up to 64 h.
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for 2 h, at 4°C, under constant agitation (Cullen et al, 2002). Eluted wound fluid 
samples were aliquoted (1 mL) and stored at -80°C, until required.
6.2.3 Wound fluid analysis
6.2.3.1 Protein content determination
The total protein content of each acute and chronic wound fluid sample, was 
quantified, using the Bio-Rad DC Protein Assay (Section 2.6.2.4). Total protein 
content was determined, with reference to a standard calibration curve, as described 
previously.
6.23.2 a-Amylase activity assay
The a-amylase content of each acute and chronic wound fluid sample, was 
established using a starch-dye assay (Phadebas®). A Phadebas® tablet consists of 
homogeneously interlinked starch polymers, taking the form of globular 
microspheres of defined size. When a blue dye becomes bound to the microsphere, it 
remains insoluble in water. However, in the presence of a-amylase, the microsphere 
is degraded at a speed proportional to the a-amylase activity, and the blue dye 
liberated.
Each acute and chronic wound fluid sample (200 pL) was added to double­
distilled water (ddH2<3; 4mL), in triplicate, and prewarmed at 37 °C/5 min. A 
Phadebas® tablet was added to each sample, vortexed for 10 s, and returned to 37 
°C/15 min. The reaction was terminated with 0.5 M sodium hydroxide (NaOH) (1 
mL), the sample vortexed and centrifuged (1500 g, 5 min). An aliquot of each 
supematent (200 (liL) was placed in a 96-well microtitre plate. The absorbance of 
each well was assessed using a Dynex MRX Spectrophotometer, equipped with a 
620 nm filter. Absorbance results (patient result -  blank = absorbance) were 
compared to the supplied, Phadebas® batch-matched, standard calibration curve, for 
calculation of a-amylase content. a-Amylase activities were expressed as i.u./L and 
per mg of protein, for each acute and chronic wound fluid sample.
6.2.3.3 Elastase activity assay
The elastase activity in each acute and chronic wound fluid sample was 
determined, using the EnzChek® elastase assay (Section 2.6.2.6). The activity, over a
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1 h period, was determined (relative fluorescence units (RFU)/min), as was the 
activity with reference to the protein content o f each wound fluid sample 
(RFU/min/mg protein). Activity at 1 h was established, with reference to a standard 
calibration curve, and the units (U) and concentration (ng/mL) o f elastase calculated. 
I U was defined as the amount of enzyme necessary to solubilize 1 mg of elastin in 
20 min, at pH 8.8 and at 37 °C (defined by the manufacturer).
6.2.3.4 EGF content of wound fluid
Each acute, and chronic, wound fluid sample was analysed by ELISA (200 
pL, in triplicate), and compared to a rhEGF standard curve, as previously described 
(Section 2.6.2.5).
6.2.3.5 rhEGF and dextrin-rhEGF stability, in chronic wound fluid
rhEGF (250 pg/mL) and the dextrin-rhEGF conjugate (250 pg/mL 
equivalent), were diluted in chronic wound fluid (patient C, the highest elastase 
activity; 6 mL), and incubated at 37 °C. Aliquots (600 pL) were taken at time points 
between 0 and 72 h, snap-frozen and stored at -80 °C. On termination of the 
experiment, samples defrosted and analysed by ELISA (200 p-L, in triplicate) and 
compared to a rhEGF standard curve, as described previously (Section 2.6.2.5).
6.2.4 Statistical analysis
Statistical analyses were undertaken using GraphPad Prism® version 4.00 
(GraphPad Software, San Diego, USA). Data were compared using a Student's t-test. 
Results were expressed as a mean and standard deviation (S.D.). Statistical 
significance was considered at a probability o f p <  0.05.
6.3 Results
6.3.1 Corneal wound healing
In the establishment of the ex vivo organ culture model of acute wound 
healing, wounds (2 mm) were observed to remain unhealed, when cultured in SFM 
(Group 1), but did heal, in response to media, supplemented with 10 % FCS (Group
2). Fluorescein staining confirmed the presence of a comeal abrasion in Group 1, 
after 64 h, and the absence of any unhealed area, in Group 2 at 24-48 h. Comeal
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abrasions remained in Group 3 (a-amylase alone, 93 i.u./L), Group 4 (rhEGF, 1 
pg/mL), and Group 5 (rhEGF, 10 pg/mL), at 64 h. Group 6 (dextrin-rhEGF, 1 pg/mL 
rhEGF equivalent, in the absence of a-amylase), remained unhealed at 64 h, but upon 
exposure to of a-amylase (93 i.a/L), the abrasions were observed to have healed, in 
response to the dextrin-rhEGF conjugate, at both 1 pg/mL rhEGF equivalent (Group 
7) and 10 pg/mL rhEGF equivalent (Group 8), by 48 h (Figure 6.5).
There was a significant improvement in wound healing (p -  0.0098), in 
response to SCM (Group 2), compared to the SFM (Group 1) and a-amylase (Group
3)controls, at 24 h. All wounds in the SCM group (Group 2) had fully re- 
epithelialised by 48 h, whilst the average wound areas in the serum-free controls 
(Groups 1 and 3), were 24.5 % ± 8.1 % and 31.4 % ± 5 %, respectively, of that at 
time 0 h (mean ± S.D.) (Figure 6.6a).
In the free rhEGF Groups (Groups 4 and 5), there were no significant effects 
on wound re-epithelialisation (p > 0.05), and neither resulted in total wound re- 
epithelialisation. Wound areas, at 64 h, were 5.6 % ± 11.3 % and 23.4% ± 21.4 %, of 
the total wound area at time 0 h, for the 10 pg/mL rhEGF, and 1 pg/mL rhEGF 
Groups, respectively (mean ± S.D.) (Figure 6.6b).
In the dextrin-rhEGF conjugate Study Groups (Groups 6 to 8), there was 
failed re-epithelialisation, in the absence of physiological concentrations of a- 
amylase (Group 6), with an abrasion of 23.4% ± 5.5% of that at time 0, persisting at 
64 h (mean ± S.D.). This was not significantly different to the SFM control (Group 1) 
(p > 0.05). Upon the addition of a-amylase (93 i.u./L), there was a significant 
decrease in the wound area, at 24 h, in both the 1 pg/mL rhEGF equivalent (Group 7) 
and 10 pg/mL rhEGF equivalent (Group 8) Groups (p = 0.0004). The dextrin-rhEGF 
conjugate was significantly more effective, at decreasing the wound area, at 24 h, at 
the lower dose (1 pg/mL rhEGF equivalent), than at the higher dose (10 pg/mL 
rhEGF equivalent) (p = 0.0067) (Figure 6.6c).
6.3.2 Wound fluid analysis
6.3.2.1 Protein content determination
The protein contents of the acute (4.76 ± 0.89 mg/mL) and chronic wound 
fluid (1.27 ± 0.35 mg/mL) samples (n = 5 patients for both; mean ± S.D.), were 
significantly higher in the acute wound fluid specimens (p < 0.0001, n = 5). The
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shows the corneal abrasion healed, at 48 h, in response to a-amylase (93 i.u./L) exposed dextrin-rhEGF (10 pg/mL rhEGF equivalent).
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Figure 6.6 Ex vivo corneal wound healing. Panel (a) shows comeal wound 
closure in response to controls (Groups 1-3) (* p  = 0.0098). Panel (b) 
shows comeal wound healing, in response to epidermal growth factor 
(rhEGF) (Groups 4 and 5), with no significant difference in efficacy 
(p > 0.05). Panel (c) shows comeal wound healing, in response to 
dextrin-rhEGF, in the presence and absence of a-amylase (93 i.u./L) 
(Groups 6-8) (** p = 0.0004, *** p  = 0.0067).
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protein contents, a-amylase activity and elastase activity of each acute and chronic 
wound fluid sample, is summarised in Table 6.1.
6.3.2.2 a-Amylase activity assay
a-Amylase was observed to be present in all samples of acute and chronic 
wound fluid. There was significantly greater activity in acute wound fluid samples, 
than the chronic wound fluid samples (p < 0.0001). There was also greater variation 
in activity in the acute wound fluid samples, with an average activity of 188 ± 73 
i.u./L (n = 5, mean ± S.D.). The chronic wound fluid samples had an average a- 
amylase activity o f 52 ± 5 i.u./L (n = 5, mean ± S.D.) (Figure 6.7). When the a- 
amylase activity was calculated per mg of protein, there was no significant difference 
between the acute (208 ± 88 i.u./L, mean ± S.D.) and chronic (217 ± 67 i.u./L, mean 
± S.D.) wound fluid samples (p > 0.05).
6.3.2.3 Elastase activity assay
There was no elastase activity observed in any of the acute wound fluid 
samples examined. Elastase activity was detected in the chronic wound fluid 
samples, with a mean activity of 2.1 ± 1.2 RFU/min (n = 5, mean ± S.D.). When 
activity was calculated per mg of protein analysed, the mean activity was 17 ± 8.8 
RFU/min/mg protein (n = 5, mean ± S.D.). (Table 6.1). The mean activity at 1 h was 
126 ± 74 RFU, which equated to an average elastase activity of 0.004 ± 0.002 U/mL, 
or an average elastase concentration of 30 ± 18 ng/mL.
6.3.2.4 EGF content of wound fluids
EGF was not detected by ELISA in any chronic wound fluid samples 
examined (limit o f detection is approximately 3.9 pg/mL human EGF). In the acute 
wound fluid samples, EGF was detected in all samples, except patient 1 (Figure 
6.8a), with an average of 34 ± 22 pg/mL (n = 4, mean ± S.D.).
6.3.2.5 rhEGF and dextrin-rhEGF stability, in chronic wound fluid
When rhEGF and the dextrin-rhEGF conjugate were exposed to chronic
wound fluid (Patient C; elastase activity = 30.7 RFU/min/mg protein), over a 72 h
/
period, rhEGF was degraded. As such, rhEGF was undetected by the polyclonal,
182
Table 6.1 Wound fluid analysis - a-amylase and elastase contents
Wound
fluid
Patient Protein 
content 
(mg/mL) 
(mean ± S.D.)
a-Amylase 
activity (i.u./L) 
(mean ± S.D.)
a-Amylase activity / 
mg protein 
(i.u./L/mg)* 
(mean ± S.D.)
Elastase activity 
at 60 min (RFU)
Elastase 
activity 
(RFU/min) 
(mean ± S.D.)
Elastase activity / 
mg protein 
(RFU/min/mg)** 
(mean ± S.D.)
ACUTE 1 4.28 ± 0.05 172 ±19 201 ± 22
2
3
4.13 ± 0.16 
4.47 ±0.12
166 ±34 
256 ±27
201 ±41 
286 ±30
§ 1 : :^
4 4.57 ±0.10 261 ±35 286 ±38
5 6.33 ±0.13 83 ±39 66 ± 30
CHRONIC A 1.42 ±0.01 48 ±2 168 ± 7 116 1.93 ±0.18 13.7 ±1.3
B 1.15 ±0.07 51 ± 4 221 ± 17 82 1.37 ±0.37 11.8 ±3.2
C 1.40 ±0.14 55 ±5 195 ±18 257 4.28 ±0.54 30.7 ±3.9
D 1.67 ±0.05 57 ± 3 169 ± 9 85 1.42 ±1.24 8.5 ± 7.5
E 0.74 ± 0.02 49 ± 8 332 ± 55 91 1.52 ±0.31 20.3 ± 4.2
* Measured using 200 pL samples ** Measured using 100 pL samples
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Figure 6.7 Ex vivo wound fluid analysis. Panel (a) shows the activity of a- 
amylase in samples o f acute wound fluid, from mastectomy patients (n 
= 5, mean ± S.D.). Panel (b) shows the a-amylase activity in samples 
of chronic wound fluid, derived from venous leg ulcers (n = 5, mean ± 
S.D.). Panel (c) shows a significant difference between the a-amylase 
activity in acute and chronic wound fluids (mean ± S.D., * p  < 0.0001, 
Student's t-test). Panel (d) shows a-amylase activity, when corrected 
for protein content (mg), with no significant difference (p > 0.05) 
between acute and chronic wound fluid samples (mean ± S.D.).
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Figure 6.8 EGF, rhEGF and dextrin-rhEGF conjugate stability in wound 
fluid. Panel (a) shows the concentration of EGF in acute wound fluid 
samples (n = 5, mean ± S.D.). Panel (b) shows the stability of free 
rhEGF and dextrin-rhEGF in chronic wound fluid (Patient C), as a 
percentage of the maximum concentration of rhEGF, over time 
(mean ± S.D.). There was a significant difference in the amounts of 
rhEGF detected at 72 h, between free rhEGF and rhEGF, released 
from the dextrin-rhEGF conjugate (*p  = 0.0013, Student's t-test).
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anti-EGF ELISA, with 52.7% of the maximum concentration of rhEGF remaining, at 
72h (T1/2 is approximately 76 h) (Figure 6.8b). The dextrin-rhEGF conjugate was 
degraded by endogenous a-amylase within the chronic wound fluid sample (195
i.u./L/mg protein), releasing rhEGF that was detectable by ELISA, resulting in a 
maximal rhEGF concentration, at 48 h (Figure 6.8c). There was a significant 
increase in rhEGF concentration in the chronic wound fluid, following rhEGF release 
from the dextrin-rhEGF conjugate, after 72 h, compared to free rhEGF (p = 0.0013).
6.4 Discussion
This Chapter aimed to establish an ex vivo model of wound healing in the rat 
cornea, and assess the ability of rhEGF and the dextrin-rhEGF conjugate to promote 
wound healing. Samples of acute and chronic wound fluid were also collected and 
analysed for a-amylase and elastase activity.
6.4.1 Corneal re-epithelialisation
The ex vivo model of comeal wound healing, established herein, was 
sensitive to stimulation by FCS and by rhEGF (in the form of the dextrin-rhEGF 
conjugate). Although, it was a model of acute wound healing, rather than impaired, 
chronic wound healing, valuable information about the efficacy of the dextrin-rhEGF 
conjugate was provided. In the conjugated form, the rhEGF promoted a significant 
increase in the rate of comeal wound healing, with wound closure by 48 hours, 
compared to free rhEGF, which, although was more effective than rhEGF-free 
controls, did not always permit wound closure, by 64 hours. As was shown in vitro 
(Chapter 4), in both the cellular proliferation and migration assays, the ability of 
conjugation to “mask” the activity of the rhEGF, was reproducible in this ex vivo 
model. With the addition of exogenous a-amylase, at physiological concentrations, 
rhEGF was released, or “unmasked” from the polymer, thereby restoring bioactivity.
The increased efficacy of the dextrin-rhEGF conjugate, in enhancing comeal 
wound healing, may be due to the sustained release phenomena (Chapter 4). In the ex 
vivo model described herein, the rhEGF was applied as a single dose at the outset of 
the experiment, and the free rhEGF may have been degraded, due to the short half- 
life of EGF. The half-life of EGF in the cornea (rabbit) is 78 minutes (Chan et al, 
1991), which is identical to the plasma elimination half-life (rat) (Kuo et al, 1992).
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In the ex vivo organ culture model, the pharmacokinetics of EOF will differ, but the 
sustained release of rhEGF, from the a-amylase-mediated, degradation of the 
dextrin-rhEGF conjugate (T1/2 = 55.4 hours, Chapter 3), may account for the 
enhanced wound healing in the dextrin-rhEGF Study Groups.
This ex vivo model was reproducible and allowed the assessment of the Study 
compounds. Although, it did not mimic the comeal environment as closely as air- 
fluid interface models, with topical tear-flow and controlled anterior chamber 
pressure (Zhao et al, 2006), it did allow an effective evaluation of acute wound 
healing. With complete wound closure, at approximately 48 hours, in the dextrin- 
rhEGF Study Groups, the rate of wound closure is similar to that observed in vivo 
(Pfister, 1975; Kuwabara et al, 1976; Matsuda et al, 1985; Crosson et al, 1986).
The injured comeal epithelium is sensitive to rhEGF stimulation (Pastor and 
Calonge, 1992; Lu et al, 2001; Hori et al, 2007), and therefore, this ex vivo model is 
suited to the evaluation of the dextrin-rhEGF conjugate. There are no reported ex 
vivo models of a chronic comeal abrasion, or ulcer. Thus, the present evaluation had 
to be performed in an acute wound healing model.
6.4.2 Wound fluid analysis
The acquisition of acute and chronic wound fluid samples, by standard 
clinical collection techniques, allowed the quantification of a-amylase activity within 
these fluids. There are no published reports of a-amylase activity within such body 
biofluids. In the pre-clinical development of the dextrin-rhEGF conjugate, 
degradation studies have involved the use of physiological levels of a-amylase 
(typically 93 i.u./L), based upon published serum a-amylase concentrations (Raftery, 
1998; Branca et al, 2001). Serum a-amylase activity can vary greatly, especially in 
the presence of diseases, such as acute pancreatitis or a perforated peptic ulcer 
(Raftery, 1998).
The a-amylase activity in acute wound fluids was within the normal serum 
range (50-300 i.u./L). The a-amylase activity in chronic wound fluids was 
significantly reduced, but this may be due to a dilution effect of the collection 
technique, resulting in a lower protein content in the chronic wound fluids, when 
compared to acute wound fluids (Moseley et al, 2004). The protein concentrations of 
wound fluids from non-healing wounds is lower than that from healing wounds
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(James et al, 2000), but the elution of the saturated dressings into a buffer, may have 
further resulted in a reduced total protein content. When a-amylase activity was 
corrected for protein content, there was no significant difference in the a-amylase 
activity between the acute and chronic wound fluid samples. The corrected a- 
amylase activity, in chronic wound fluids was higher than the majority of the a- 
amylase (93 i.u./L) used in the present investigation of the PUMPT concept. In can, 
therefore, be inferred that similar degradation results would be expected to be 
observed in vivo, to those observed in vitro (Chapters 3 and 4).
Elastase activity was below the limit of detection in all of the acute wound 
fluid samples analysed. This was also observed by Trengove et al (1999). There was 
a large variation in the elastase activity in the chronic wound fluids, in agreement 
with previous reports (Trengove et al, 1999; Cullen et al, 2002). The elastase activity 
reported in this Chapter (8.5 -  30.7 RFU/min/mg protein) is significantly less than 
reported by Cullen et al (2002) (13 -  49,456 RFU/min/mg protein), despite similar 
wound fluid collection and elastase assay protocols, being employed. When the 
elastase activity in the chronic wound fluid samples was referred to a standard 
calibration curve, the average concentration of elastase reported in this Chapter (30 
ng/mL), was much lower than that reported by Trengove et al (1999) (100,000 
ng/mL), although, in this incidence, different wound fluid collection and elastase 
assay techniques were utilised. Therefore, these results may not be directly 
comparable. Wound fluid composition is variable, and can be influenced by the 
presence of infection and the pathogenesis and duration of the wound (Yager et al, 
2007).
To assess the stability o f rhEGF and the dextrin-rhEGF conjugate, in a 
chronic wound environment (Section 3.2.7), the highest reported concentration of 
neutrophil elastase was utilised (100,000 ng/mL). The dextrin-rhEGF conjugate was 
shown to be more resistant to proteolytic degradation (T1/2 > 24 hours), compared to 
free-rhEGF (T1/2 < 2 hours) (Section 3.3.4). On exposure to chronic wound fluid, 
free rhEGF was degraded, but in slower manner (Jm  was approximately 76 hours) 
than when exposed to exogenous neutrophil elastase (T1/2 < 2  hours), a-Amylase 
activity in chronic wound fluids was great enough to permit degradation of the 
dextrin-rhEGF conjugate and release rhEGF, which remained stable in the chronic 
wound fluid. This was evident by a significant increase in rhEGF at 72 hours from
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7.1 Introduction
Many in vivo models of wound healing, both acute and chronic, have been 
reported in the literature (Kiritsy et al, 1993; Davidson, 1998). These have involved 
various species of animal and have been used in evaluation of different growth 
factors, in the dermal wound healing process (Kiritsy et al, 1993; LeGrand, 1998). In 
this Chapter, in vivo models will be reviewed, as will previous studies involving 
epidermal growth factor (EGF), while the model employed for the evaluation of the 
dextrin-rhEGF conjugate will be described.
7.1.1 In vivo models of wound healing
7.1.1.1 Acute wound healing models
In vivo models of acute wound healing involve the introduction of an injury 
and a relatively rapid course of repair. These are designed to mimic the response to 
injury, after surgery or trauma (Davidson, 1998). Incisional wounds can be produced 
with a surgical scalpel, laser or electrocautery, with minimal collateral damage. The 
wounds can then be closed by mechanical means (e.g. surgical sutures), referred to as 
primary closure, or left open to heal by secondary closure. Excisional wounds 
involve the removal of a volume of the target tissue, which can subsequently heal by 
secondary closure (Davidson, 1998). The larger wound void, when compared to 
incisional wounds, affords greatest ability to analyse material for biochemical or 
histological analysis. Experimental wounds can be covered by an occlusive dressing, 
allowing the collection of wound fluids. Examples of such excisional wounds (from 
superficial to deep), include the stripping of the epidermis, with adhesive tape 
(Tammi et al, 2005); the formation of sub-epidermal blisters, by mechanical suction 
devices, chemicals or heat (Saarialho-Kere et al, 2002); partial thickness (split 
thickness) dermal injury, by shaving with a blade or dermatome, or by chemical or 
thermal means (Davis et al, 2007); or full-thickness, dermal injury, by complete full­
thickness excision of an area of skin with a blade or dermatome (Nanney et al, 2008).
In animals with skin that has a panniculus carnosus (a muscular layer 
underneath and attached to the skin, e.g. rodents, rabbits, guinea pigs), excisional 
wounds can be splinted open, to reduce the effect of contraction on wound healing 
(Michaels et al, 2007). Contraction is the centripetal movement of the wound 
margins, due to the compaction of granulation tissue, within the “body” of the wound 
(Farahani and Kloth, 2008). Contraction involves the rapid shrinkage of the wound
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area by the loose skin, reducing the need for re-epitheliaiisation, as is found in tight­
skinned species (e.g. pig, human). It must be differentiated from contracture, which 
is a myofibroblast-induced, pathological process, involved in hypertrophic scarring 
(Shin and Minn, 2004). Other models of acute wound healing, include dead-space 
models, which can be used to investigate subcutaneous wound healing; wound 
chambers to allow continuous analysis of wound progression, and bums, produced 
by chemical or thermal means (Davidson, 1998).
7.1.1.2 Impaired / chronic wound healing models
The chronic non-healing wound is uncommon in laboratory animals. As such, 
there is no accurate animal model corresponding to the chronic skin wounds in 
humans (venous leg ulcer or diabetic foot ulcers), due to anatomical, postural, age 
and cultural conditions, only found in humans. Human cutaneous anatomy is also 
markedly different from most laboratory species, except the pig (tight-skinned, with 
strong fascial attachment). Whilst many animal models have been employed, the 
majority o f models of non-healing wounds are impaired or delayed acute wound 
healing models (Davidson, 1998).
7.1.1.3 Impaired wound healing
Impaired wound healing can be induced in experimental animals by 
metabolic defects, such as chemically induced diabetes mellitus, via streptozotocin or 
alloxan administration; or by genetic diabetes (db/db), or obesity (ob/ob) (Goodson 
and Hunt, 1979a; Klingbeil et al, 1991; Tsuboi et al, 1992). Malnutrition, such as 
vitamin A, vitamin C, or zinc-deficiency, has also been investigated in the rat and 
guinea pig (Levenson and Demetriou, 1992). Immunosuppression, via the 
administration o f corticosteroids, or genetically immunodeficient rodent strains 
(severe combined immune deficiency (SCID), nude mouse/rat), can further be used 
to suppress the wound healing response, or to allow human xenografting, to produce 
a humanised skin model (Escamez et al, 2004; Garcia et al, 2007). Antiproliferative 
chemotherapeutic agents (adriamycin, hydroxyurea), can impair wound healing, by 
direct inhibition o f cellular proliferation, or by indirect action on the propagation of 
immune cells (Winn et al, 1987; Curtsinger et al, 1989; Pearse and Sylvester, 1992). 
Radiation, either locally or total body irradiation, can also reduce local or systemic 
populations o f cells, critical for wound repair (Cromack et al, 1993). Local infection,
194
Chapter 7 Dextrin-rhEGF Conjugate Evaluation
in an In Vivo Model of Impaired Wound Healing
with bacterial suspensfonsirf between 106 and 109 colony-forming units/g, have also 
been used to retard wound healing (Heggers et al, 1992).
7.1.1.4 Chronic wound healing
In vivo models of chronic wound healing cannot accurately represent the 
venous ulcer or diabetic ulcer, but the ischaemia associated with all of the 
pathologies underlying chronic wounds, can be simulated. Cutaneous ischaemia has 
been demonstrated in the guinea pig, using a skin banding technique (Constantine 
and Bolton, 1986; Skrabut et al, 1996). Other models of ischaemia have involved 
vascular ligation, e.g. the rabbit ear model (Ahn and Mustoe, 1990; Mustoe et al, 
1991), and skin flap techniques (McFarlane et al, 1965; Quirinia et al, 1992; Chen et 
al, 1999). Pressure sores have also been modelled in multiple species (Hyodo et al, 
1995; Salcido et al, 2006). In addition to necrosis caused by local ischemia, 
chemicals can induce local skin necrosis and ulceration. Doxorubicin is a 
chemotherapeutic agent that can cause ulceration (Rudolph et al, 1979), and Brown 
Recluse spider (Loxosceles spp.) venom contains sphingomyelinase, which can 
induce dermal necrosis (Davidson, 1998). The various in vivo models available, are 
summarised in Table 7.1.
7.1.2 The genetically diabetic (db/db) mouse
Venous leg ulcers and diabetic foot ulcers are a significant cause of morbidity 
in the elderly population (Price and Harding, 2004). However, these pathological 
processes have no animal equivalent. The genetically diabetic mouse, although a 
model of impaired acute wound healing, can exhibit delayed healing in skin wounds, 
similar to that found in patients with diabetes, so offers a useful model for studying 
wound repair (Kawanabe et al, 2007).
The genetically diabetic mouse was developed by Hummel et al (1966), by 
discovering a Lepr db mutation on a C57BLKS background. It experiences a 
hyperinsulinaemic phase, followed by a hypoinsulinaemic phase, at 2 - 3 months of 
age. The homozygous diabetic mouse (db/db) is also obese and has several 
advantages as a compromised wound healing model. The heterozygous littermates do 
not exhibit either diabetes or obesity. The homozygous animals develop many of the 
clinical and metabolic symptoms that resemble human adult onset diabetes, including
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Table 7.1 In vivo animal models of wound healing
Acute Wound Healing Impaired Wound Healing Chronic Wound Healing
Incisional
- Primary closure (a)
- Secondary closure (b)
Excisional
- Split thickness (c)
- Full thickness (d)
Dead space models
- Sub-cutaneous healing
Wound chambers
- Serial measurements
Bums (f)
- Chemical
- Thermal (hot/cold)
(e)
m
Metabolic defects
- Chemical diabetes
- Genetic diabetes
- Obesity
- Malnutrition
Immune system
- Corticosteroids
- SCID / nude mouse
- Chemotherapeutics
- Radiation
- Local infection
m
Ischaemia
- Vessel ligation
- Skin banding
- Skin flaps
Pressure sores
- Friction
- Mechanical loading
- Plaster casts
Dermonecrosis
- Doxombicin
- Spider venom
(a) - (f) Schematic diagrams of acute 
wounding procedures, which can be 
extended into impaired healing and 
chronic wound healing animal 
models. Adapted from Davidson, 
1998.
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peripheral neuropathy, microvascular lesions, basement membrane thickening, 
glomerular filtration abnormalities, immune complex deposition, immunodeficiency, 
obesity, and severe hyperglycemia (Coleman et al, 1982). In addition, the full­
thickness wounds in these mice exhibit a marked delay in inflammatory cell 
infiltration, granulation tissue formation and wound closure, when compared with 
their non-diabetic counterparts (Greenhalgh et al, 1990).
The spontaneous diabetic mouse has advantages over drug-induced diabetes 
(as mentioned earlier), which utilize steroids or cytotoxic agents, such as alloxan or 
streptozotocin, to induce the diabetic state, as these can be toxic, not only to the 
pancreatic beta cells, but also the urinal tubules, liver and exocrine pancreas (Rerup, 
1970). In addition, alloxan and streptozotocin alter macrophage phagocytosis and 
depress T-cell function (Goodson and Hunt, 1979b).
Limitations o f the db/db model, include the presence of the panniculus 
carnosus and predilection for wound closure by contraction, rather than re- 
epithelialisation, and the underlying pathophysiology of the diabetes contrasts with 
the human. These animals are not only hyperglycemic, but also hyperinsulinaemic, 
which is dissimilar to what is observed in human diabetes, with respect to insulin. 
Often, human diabetics are hypoinsulinaemic. Elevated levels of insulin within the 
wound fluid o f  these mice could potentially interact with other exogenous growth 
factors, to yield different effects than those observed with growth factors alone 
(Kiritsy et al, 1993).
The role o f  EGF in cutaneous wound healing in the diabetic mouse has been 
studied by Choi e t  al (2008) (streptozotocin-induced diabetes), and the efficacy of 
exogenous EGF to promote wound healing in the db/db mouse has not been shown to 
be significant, w hilst other growth factors, such as platelet-derived growth factor 
(PDGF) and transforming growth factor-a (TGF-a), have been shown to improve 
wound healing in  the db/db mouse (Brown et al, 1994). Examples of studies 
involving the db/db mouse, are summarised in Table 7.2.
7.1.3 In vivo anim al studies involving EGF
EGF has been applied to wounds in various in vivo models of wound healing. 
Franklin and Lynch (1979), applied EGF suspended in a saline-albumin / Aquaphor 
ointment, to an acute wound in rabbit ears, and demonstrating apparent improvement
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Table 7.2 In vivo studies involving the genetically diabetic (db/db) mouse model
Study Active agent Age (weeks) Dressing Application Doling Regimen
Greenhalgh et al, 1990 Platelet-derived growth factor 
(PDGF-BB), fibroblast growth 
factor (FGF)
8 - 1 2 OpSite® Injection through 
dressing
Days 0 - 5  
Sacrificed day 14
Browne* al, 1994 PDGF-BB, epidermal growth 
factor (EGF*), transforming 
growth factor-p (TGF-P)
8 - 1 2 OpSite® Injection through 
dressing
Days 0 - 4  
Sacrificed day 21
Ishikawa et al, 2003 EGF-fibronectin collagen 
binding domain
9-11 Bioclusive® Injection through 
dressing
Days 0 and 3 
Sacrificed day 6
Kirchner et al, 2003 Vascular endothelial growth 
factor (VEGF)
8 - 1 2 OpSite® Injection through 
dressing
Days 0 - 4  
Sacrificed day 21
Deiters et al, 2004 Macrophage-activating 
lipopeptide-2 (MALP-2)
12-15 Hydrofilm® Injection through 
dressing
Single dose day 0 
Sacrificed day 25
Kawanabe et al, 2007 Sphingosine-1 -phosphate 8 - 1 0 None Peripheral
intradermal injection
Daily for 13 days 
Sacrificed day 14
Pietramaggiori et al, 2008 
* 10 (xg/mL
Poly-V-acetyl glucosamine 8 - 1 2 Microalgal 
nanofibre patch
Patch applied to 
wound
Patch for lh or 24h 
per day
Sacrificed day 10 or 
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in wound healing and scar maturation. A sustained-release EGF pellet was 
subcutaneously implanted into Sprague-Dawley rats (Buckley et al, 1985), leading to 
an increase in granulation tissue and collagen synthesis, in this acute wound model. 
Mustoe et al (1991), in an acute wound healing model in rabbit ears, demonstrated 
that EGF significantly promoted re-epithelialisation. The first Study involving EGF, 
in the db/db mouse, did not show any efficacy in wound closure (Brown et al, 1994). 
This may be due to growth factor instability in the in vivo diabetic wound. Different 
vehicles have been used to optimise EGF-delivery to acute wounds, such as gelatins 
(Ulubayram et al, 2001; Tanaka et al, 2005), petroleum-based ointments (Kwon et 
al, 2006), chitosan (Alemdaroglu et al, 2006), liposomes (Alemdaroglu et al, 2008), 
and nanofibres (Choi et al, 2008), using rat, rabbit, dog and diabetic mouse models 
(summarised in Table 7.3).
Dextrin conjugates have not been tested in vivo, in animal wound healing 
models, to date. The dextrin-rhEGF conjugate was applied topically (dissolved in 
phosphate buffered saline (PBS), to excisional wounds in genetically diabetic mice in 
the present Study. Although EGF application has only been reported in this model 
once before, and the impaired acute wound of the mouse is substantially different 
from a human chronic ulcer, it is a robust model for evaluation, prior to clinical 
trials. Indeed, the pre-clinical assessment of the recombinant human platelet-derived 
growth factor (rhPDGF) containing gel, Regranex® (Johnson & Johnson, Gargrave, 
UK), involved the genetically diabetic (db/db) mouse (Brown et al, 1994; LeGrand, 
1998).
In the present Study, dextrin-rhEGF conjugate application was by injection 
through an occlusive wound dressing onto the wound bed, at delayed intervals, due 
to the sustained release nature of the conjugate. Unmodified rhEGF was used in one 
of the Control Groups, at the same 1 pg per dose, as per Brown et al (1994). The 
dextrin-rhEGF was also applied at a 1 pg per dose, and also at a 0.1 pg per dose, to 
examine the increased efficacy at a lower dose, as was highlighted in previous in 
vitro Studies (Chapter 4), and ex vivo Studies (Chapter 6). The presence of a- 
amylase in mouse serum was further established, in order to “unmask” the dextrin- 
rhEGF conjugate. Mouse plasma was also analysed, to investigate any systemic 
absorption of rhEGF, from these topical applications.
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Table 7.3 In vivo assessment of epidermal growth factor (EGF), utilising various animal wound healing models
Study Animal Vehicle EGF dose Wound Dressing Dosing Regimen
Franklin & Lynch, 
1979
Rabbit
(acute wound)
Ointment 
(Aquaphor, saline- 
albumin)
0.5 pg/mL Full thickness 20 - 30 mm 
diameter 
(314 mm2 - 700 mm2)
Not reported Every 12h 
Sacrificed day 42
Buckley et al, 1985 Sprague-Dawley rat 
(acute wound)
Cholesterol-
methylcellulose-lactose
pellets
10-20  pg/day Subcutaneous implantation N/A Single dose 
Sacrificed day 3 ,7  or 
14
Mustoe et al, 1991 Rabbit
(acute wound)
Bovine collagen 
suspension
5 pg per dose Full thickness 
6 mm diameter 
(10 mm2)
Tegaderm® applied 
over wound
Single dose 
Skin biopsy day 7
Brown ef al, 1994 Genetically diabetic 
(db/db) mouse 
(impaired wound)
5 % poly-ethylene glycol 
solution
1 pg per dose Full thickness 
15 x 15 mm 
(225 mm2)
OpSite®
Injection through 
dressing
Days 0 - 4  
Sacrificed day 21
Ulubayram et al, 2001 Rabbit
(acute wound)
Gelatin microspheres 0.5 or 7.5 pg per 
dose
Full thickness 
8 mm diameter 
(50 mm2)
Gelatin applied to 
wound and covered 
with OpSite®
Every 12h 
Sacrificed day 7,14 
or 21
Tanaka et al, 2005 Hairless dog 
(acute wound)
Gelatin film 18 pg per dose Partial thickness 
30 x 30 mm 
(900 mm2)
Gelatin film 
covered with 
Perme-Aid®
Daily for 15 days 
Skin biopsy day 30
Alemdaroglu et al, Sprague-Dawley rat Chitosan gel 10 pg/mL Partial thickness bum Chitosan gel
2006 (acute wound) 20 mm diameter
(314 mm2)
Daily for 14 days 
Skin biopsy day 3 ,7  
or 14
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7.1.4 Experimental aims
The activity and mechanisms of action of the dextrin-rhEGF conjugate, has 
previously been confirmed in vitro (Chapters 4 and 5) and ex vivo (Chapter 6). The 
next stage of the pre-clinical evaluation was the assessment of the dextrin-rhEGF 
conjugate in vivo, in a model of impaired dermal wound healing.
The aims of this Chapter were the:
1. Quantification of a-amylase in mouse serum.
2. Establishment of an in vivo model of impaired dermal wound healing, 
utilising the db/db mouse model.
3. Evaluation of the dextrin-rhEGF conjugate in vivo, via gross wound and 
histological image analysis.
4. Determination of systemic rhEGF absorption in vivo.
7.2 Methods
7.2.1 Animal husbandry
70 male diabetic mice (C57BLKs/Bom db/db), aged approximately 12-13 
weeks, were used in this Study. On arrival in the UK, the mice were housed in Groups 
of 4 to 5 animals, according to Home Office Regulations. On experimental wounding, 
animals were housed in individual cages (cage dimensions 35 x 15 x 15 cm, with 
sawdust bedding, changed twice weekly), in an environment maintained at an ambient 
temperature of 23 °C, with 12-hour light/dark cycles. Mice were provided with food 
(Standard Rodent Diet, B&K Universal, Grimston, UK) and water ad libitum. To 
acclimatise the animals to their surroundings, prior to experimentation, animals were 
housed for a period of 5 days without disturbance, other than to refresh their bedding 
and to replenish their food and water provisions. Following all anaesthetic events, 
animals were placed in a warm environment and monitored until fully recovered from 
the procedure. All animal procedures were carried out in a Home Office Licensed 
Establishment, under Home Office Licences (PCD: 50/2505; PPL: 40/2650; PIL: 
50/3482; PIL: 70/4934; PIL:40/7904). The health of animals was monitored on a daily 
basis, throughout the Study.
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7.2.2 Creation of full-thickness excisional wounds
On day 0, animals were anaesthetised (isofluorane and air, National Vet 
Services, Stoke-on-Trent, UK) and the dorsum shaved and cleaned, with saline- 
soaked gauze. A single, standardised full-thickness wound (10 mm x 10 mm), was 
created in the left dorsal flank skin of each experimental animal. Wounds in all 
treatment Groups were subsequently dressed with a circumferential band of the film 
dressing, Bioclusive® (Figure 7.1). This was performed by Dr. Jeff Hart (Cica 
Biomedical, Knaresborough, UK).
7.2.3 Application of Study compounds
Animals were assigned to each Study Group, which received treatments (100 
pL, day 0), solublised in PBS. All treatments were administered through the 
Bioclusive® film, using a 27-gauge needle (Tyco Healthcare, Gosport, UK).
• Group 1 received the free succinoylated dextrin polymer (50 pg/mL, 10 
animals).
• Group 2 received rhEGF (10 pg/mL, 10 animals).
• Group 3 received the dextrin-rhEGF conjugate (1 pg/mL rhEGF equivalent, 
10 animals).
• Group 4 received the dextrin-rhEGF conjugate (10 pg/mL rhEGF equivalent, 
20 animals).
• Group 5 (no treatment) were dressed with Bioclusive® alone (20 animals).
Animals in all Groups were re-anaesthetized, their film dressings and any free 
debris removed, and their wounds cleaned, using saline-soaked sterile gauze on post- 
wounding, day 3. Following photography (see below), animals in all Groups were re­
dressed with a circumferential band of Bioclusive® and the treatments reapplied, as a 
100 pL injection through the Bioclusive® dressing. On post- wounding, day 8, 
animals from all Groups were re-anaesthetized, their film dressings removed, 
wounds cleaned (as above), wounds photographed, and the treatments reapplied, as a 
25 pL injection, through the Bioclusive® dressing.
Immediately following Wounding, and subsequently on days 3, 8, 11 and 16, 
wounds were digitally photographed (Nikon Coolpix 4500), together with an image
2 0 2
K)Ou>
V
Figure 7.1 Creation of the wound. Panel (a) shows the 10x10 mm template marked onto the shaved dorsal skin. Panel (b) shows
the full- thickness excisional wound. Panel (c) shows the circumferential Bioclusive® film dressing, overlaying the 
wound area. Each test agent was then injected through the film dressing, onto the wound bed.
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calibration scale and wound identity plate. The condition of each wound and peri- 
wound tissues were examined at each of these time points, and any effects, beneficial 
or adverse, were documented. In all cases, the condition of the dressing materials 
were examined daily throughout the Study and were replaced, as necessary. On post- 
wounding, day 16, all remaining animals were sacrificed, using CO2 asphyxiation 
(confirmed by cervical dislocation). The animals were weighed, blood samples taken 
via cardiac puncture, and the wound tissues harvested, for histological analysis. The 
protocol employed is summarised, in Figure 7.2. These procedures were performed 
on my behalf, by Dr. Jeff Hart.
7.2.4 Image analysis of wound closure
Image Pro Image Analysis Software (version 4.1.0.0, Media Cybernetics, 
Bethesda, USA), was used to calculate the wound closure from wound images, in 
each of the experimental Groups. For each wound, at each time point, open wound 
area was measured and expressed in terms of % wound area remaining, relative to 
that immediately on wounding, at day 0. As the process of wound closure results 
from the combined effects of wound contraction (the inward movement of marginal 
tissue) and re-epithelialisation (wound resurfacing by the inward the migration of 
epithelial cells), wound closure, over time, was also considered with respect to these 
components (Figure 7.3).
7.2.5 Tissue processing of wounds
Wounds and surrounding normal tissue (5 mm) were excised and fixed in 
10% buffered formalin (Bios Europe, Skelmersdale, UK), for routine histological 
assessment. Excised tissues were sandwiched between two pieces of filter paper, 
prior to being placed in fixative, to reduce the extent of tissue curling. Fixed 
specimens were trimmed and bisected, generating two half wounds, per site. Both 
halves were processed and embedded in paraffin wax. Specimens were orientated in 
such a fashion, as to ensure that appropriate transverse sections of the wound were 
taken.
7.2.6 Histological evaluation
Wax embedded tissues were sectioned (6 pm), with a microtome (Leica 
Microsystems (UK) Ltd., Milton Keynes, UK) and representative sections stained
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dextrin 
(50 fxg/mL)
Group 2
rhEGF 
(10 jxg/mL)
Group 3
Dextrin- 
rhEGF 
(1 fxg/mL)
Group 4
Dextrin- 
rhEGF 
(10 (xg/mL)
Group 5
Film dressing 
alone
n
10
10
10
10
20
20
15 Days
l.t t
DAY0
1. Animals weighed
2. Animals wounded
3. Digital photography
4. Bioclusive® dressing applied — — — —
5. Animals assigned to Study Group
6. Treatment applied (100 pL)
i
_______________DAY 3
1. Digital photography
2. Treatment applied (100 pL)
DAY 16
1. Animals sacrificed
2. Animals weighed
3. Dressing removed
4. Digital photography
5. Harvesting of blood and wound
tissue
i
DAY 8
1. Animals weighed
2. Dressing removed
3. Digital photography
4. Bioclusive® dressing applied
5. Treatment applied (25 pL)
Figure 7.2 Study protocol. The experimental steps that were applied for the evaluation of the dextrin-rhEGF conjugate, in the
genetically diabetic (db/db) mouse, impaired wound healing model. Each Group was investigated until day 16. At time- 
points of wound photography, changing of dressings, or application of treatments, the animals were anaesthetised.
re-epithelialisation
t
DO open wound area
contracted area 
D16 open wound area
Figure 7.3 Image analysis of wound closure. Panel (a) shows a typical 10 x 
10 mm dorsal excisional wound at day 0. Panel (b) shows the 
wound area highlighted (black line). Panel (c) shows the same 
wound at day 16. Panel (d) shows the wound at day 16, with the 
wound area at DO, overlaid (red line), the day 16 open wound area 
(dotted blue line), and the limit of wound contraction (dotted black 
line). The area of re-epithelialisation lies between the limit of 
contraction, and open wound area. Scale bar = 5 mm.
206
Chapter 7 Dextrin-rhEGF Conjugate Evaluation
in an In Vivo Model of Impaired Wound Healing
with haematoxyiin and eosin (H & E). A further set of sections of each wound were 
taken and immunostained for CD-31, an antigen constitutively expressed on 
endothelial cells. Tissue harvesting and histological processing was performed by Dr. 
Jeff Hart.
7.2.6.1 Assessments on haematoxyiin and eosin (H & E) stained sections
The following evaluations were undertaken, using Image Pro Image Analysis 
Software, on representative H & E sections from each wound:
(a) Quantitative assessment of granulation tissue formation (Figure 7.4).
(b) Quantitative assessment of wound maturity (Figure 7.5).
7.2.6.2 Assessments on CD31-immunostained sections
The impact of each treatment on wound angiogenesis, was assessed in terms 
of the prevalence of endothelial cells, within wound tissue sections. Sections (6 pm) 
were stained with anti-CD31. CD-31 is an antigen constitutively expressed on 
endothelial cells (Albelda et al, 1991). Angiogensis was studied in 5 high-powered 
fields of view (hpfov), from representative sections of each wound, and expressed as 
the number of CD31 positive areas counts, per hpfov. An example of CD31 staining 
and vessel counting, is shown in Figure 7.6.
7.2.7 Analysis of mouse plasma rhEGF
At sacrifice (day 16), blood samples were taken from mice in each Group, by 
cardiac puncture. Blood was centrifuged, at 15,000 g/5 min, at 4°C, the plasma 
aspirated and stored at -80 °C. At the time of analysis, samples were defrosted, and a 
human EGF ELISA performed, on each plasma sample. Results were compared to a 
rhEGF standard curve, as described previously (Section 2.62.5).
7.2.8 Analysis of mouse plasma a-amylase
A pooled sample of mouse serum (from eight mice), was kindly donated by 
Dr. Alastair Sloan, Tissue Engineering and Reparative Dentistry, School of 
Dentistry, Cardiff University. a-Amylase activity was established, using the 
Phadebas® assay (Section 6.2.3.2).
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Figure 7.4 Qualitative assessment of granulation tissue formation.
Histological sections were scored, based upon the formation of 
granulation tissue, in H & E stained sections (scale bar - 500 pm).
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Figure 7.5 Wound maturity scoring. Panel (a) shows a typical histological cross- 
section of a wound, at day 16, with areas selected for scoring, from the 
wound centre (C), and the left (L) and right (R) margins. Panel (b) 
shows the wound maturity scoring scale. During the inflammatory 
phase of wound healing, the more predominant cells are of the 
inflammatory sub-type (arrowed white). As wound healing progresses 
into the proliferative phase, the inflammatory cells are replaced (e.g. 
with fibroblasts - arrowed black).
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Figure 7.6 Assessment of CD31 stained histological sections, (a) Angiogensis 
was studied in 5 high powered fields of view (hpfov), from 
representative sections of each wound and expressed as the number of 
CD31 positive areas counts, per hpfov. Panel (b) shows an area of 
higher magnification with the areas labelled and numbered (• focal area 
ofCD31 staining).
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7.2.9 Statistical analysis
Statistical analyses were undertaken using GraphPad Prism®, version 4.00 
(GraphPad Software, San Diego, USA). Mean values (with standard errors), for all 
live and post-mortem histological assessments, were calculated for each treatment 
Group. Data was tested for normality, using the Shapiro-Wilk test. If data failed this 
normality test, non-parametric analysis (Kruskal Wallace, Multivariate Analysis 
followed by ad hoc two sample Mann Whitney U-test analysis), was used to test the 
significance of any inter-Group differences in each of the study parameters 
investigated. If data for all treatment Groups was deemed to be normal for a given 
parameter, parametric analysis (ANOVA -  Multivariate Analysis, followed by ad 
hoc two sample student t-test), was also performed. Results were expressed as a 
mean and standard deviation (S.D.), or standard error of the mean (S.E.M.). 
Statistical significance was considered at a probability ofp <  0.05.
7.3 Results
One animal was excluded from the in vivo Study due to faecal impaction, at 
day 2, post-wounding (succinoylated dextrin Control, Group 1). The remaining 69 
animals completed the Study, to day 16.
7.3.1 Wound closure
Data concerning wound closure in diabetic (C57BLKs/Bom db/db) mice, 
from two different sources (“American” C57BLKs/Bom db/db, The Jackson 
Laboratory, Bar Harbor, USA, n = 20; “European” C57BLKs/Bom db/db, M&B, Ry, 
Denmark, n = 17) and the European non-diabetic litter-mates (M&B, Ry, Denmark, n 
= 9), was kindly donated by Dr. Jeff Hart. The wound closure rates were significantly 
reduced in the American model, under control conditions (transparent wound 
dressing only), when compared to the European model (p < 0.0001), at day 16, 
under the same conditions (Figure 7.7). Both diabetic models remain unhealed at 
day 16, whilst the non-diabetic, European model healed by day 13. The European 
diabetics underwent significantly more re-epithelialisation (p = 0.0056), by day 16, 
compared to the American diabetics, whilst wound contraction analysis exhibited no 
significant difference between the two diabetic Study Groups (p > 0.05).
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Figure 7.7 In vivo wound healing in diabetic and non-diabetic mice. Panel (a) 
shows the total wound area reduction, over 16 days, compared to the 
wound size, at day 0. The American diabetic mice had significantly 
larger wounds, compared to their European counterparts, at day 16. 
Panel (b) shows the percentage of wound healing by contraction, and 
panel (c) shows the percentage of wound healing by re-epithelialisation 
(mean ± S.E.M., *p < 0.0001 **p = 0.0056, Mann-Whitney U-test).
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7.3.1.1 Animal body weights
The body weights of the animals did not significantly differ ip > 0.05), 
between day 0 and day 8, in any of the Study Groups. In Group 1, animals were 
weighed, prior to cardiac puncture, on day 16, and there was no significant change in 
the body weights, over the 16-day period (p > 0.05). In the remaining Sample 
Groups, blood samples were taken, prior to weighing, to reduce the formation of 
blood clots. This resulted in significant decreases (p < 0.05) in body weights, at day 
16, in all Groups, except Group 3 (p > 0.05).
7.3.1.2 Assessment of the dextrin-rhEGF conjugate
Typical digital wound photography demonstrated a reduction in wound area 
in response to the dextrin-rhEGF conjugate (Figure 7.8; Appendix DVD). At day 11, 
post-wounding, the dextrin-rhEGF conjugate, at both 1 and 10 pg/mL rhEGF 
equivalent (Groups 3 and 4, respectively), induced a significant reduction in wound 
area (p < 0.035), compared to the untreated Controls (Group 5) (p < 0.05) (Figure 
7.9a). Free rhEGF, 10 pg/mL (Group 2), had no significant effect on wound area 
reduction (p > 0.05), whilst free, succinoylated dextrin polymer (Group 1) retarded 
wound area reduction ip = 0.02) (Figure 7.9b). When conjugated to succinoylated 
dextrin, rhEGF significantly increased the ability to promote wound area reduction 
(Groups 3 and 4), and therefore wound closure, when compared to free rhEGF, 10 
pg/mL (Group 2) (p < 0.011). At the higher dose, 10 pg/mL rhEGF equivalent 
(Group 4), the dextrin-rhEGF was most effective ip = 0.002) (Figure 7.9c).
Wound contraction increased in response to the dextrin-rhEGF conjugate 
(Groups 3 and 4), when compared to the untreated Controls (Group 5), and was most 
effective at 1 pg/mL rhEGF equivalent (Group 3) ip = 0.012), at day 11. A 
significant increase in re-epithelialisation was observed with the dextrin-rhEGF 
conjugate, at 10 pg/mL rhEGF equivalent (Group 4) ip = 0.001), at day 11 (Figure 
7.10). At day 16, post-wounding, a significant decrease in wound area reduction was 
observed in the succinoylated dextrin polymer and free rhEGF Control Groups 
(Groups 1 and 2, respectively) ip < 0.001). The dextrin-rhEGF conjugate promoted a 
significant decrease in wound area, at 10 pg/mL rhEGF equivalent (Group 4) ip = 
0.028). The lower dose dextrin-rhEGF (1 pg/mL rhEGF equivalent; Group 3) was
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Figure 7.8 Digital wound photography. The images show the typical in vivo wound healing, 
in response to (a) free succinoylated dextrin polymer (Group 1), (b) free rhEGF (10 
pg/mL; Group 2), (c) the dextrin-rhEGF conjugate (1 pg/mL rhEGF equivalent; 
Group 3), (d) the dextrin-rhEGF conjugate (10 pg/mL rhEGF equivalent; Group 4), 
or (e) no treatment. The wound area at day 0 is represented by the black line. All 
images are included in Appendix DVD.
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Wound area reduction, in response to the dextrin-rhEGF conjugate. Panel (a) 
shows the wound area reduction, in response to the dextrin-rhEGF conjugate, the 
dosing schedule is indicated in the overlay (mean ± S.E.M., *p  = 0.035 ** p  = 0.002, 
Mann-Whitney U-test). Panel (b) shows the wound area reduction in response to the 
controls (free rhEGF and succinoylated dextrin) (mean ± S.E.M., *** p  = 0.02, Mann- 
Whitney U-test). Panel (c) compares free rhEGF with the dextrin-rhEGF conjugate, at 
1 and 10 [xg/mL rhEGF equivalents (mean ± S.E.M., § p  = 0.011, §§ p  = 0.002, Mann- 
Whitney U-test).
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Wound contraction and re-epithelialisation, in response to the 
dextrin-rhEGF conjugate. Panel (a) shows that wound contraction 
was increased, in response to the dextrin-rhEGF conjugate, at both 1 
and 10 pg/mL, compared to untreated controls (mean ± S.E.M., * p  = 
0.012, ** p  = 0.031, Mann-Whitney U-test). Panel (b) shows 
increased re-epithelialisation, in response to the 10 pg/mL dextrin- 
rhEGF conjugate (mean ± S.E.M., § p  = 0.001, Mann-Whitney U- 
test), but not 1 pg/mL dextrin-rhEGF conjugate (p > 0.05).
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not significantly different to the untreated Control (Group 5), by day 16 (p > 0.05) 
(Figure 7.11).
7.3.2 Histological analysis
7.3.2.1 Granulation tissue
Granulation tissue deposition was significantly increased in all dextrin-rhEGF 
Groups, compared to the free rhEGF and succinoylated dextrin Controls (p < 0.05). 
(Figure 7.12; Appendix DVD). In the high-dose (10 pg/mL rhEGF equivalent), 
dextrin-rhEGF conjugate Study Group 4, the granulation tissue score was 
significantly higher than the untreated Controls (Group 5) (p -  0.006), but in the low- 
dose (1 pg/mL rhEGF equivalent), dextrin-rhEGF conjugate Study Group 3, there 
was no significant difference between the dextrin-rhEGF conjugate and untreated 
Control Groups (p > 0.05). There was also no significant difference between free 
rhEGF and no treatment Control Group 5 (p > 0.05).
7.3.2.2 Wound maturity
Sections from the central wound area were consistently scored significantly 
lower (more inflammatory cells), compared to those from the wound margin (p <
0.0001), irrespective of Study Group. The maturity of the wounds were not 
significantly affected by the dextrin-rhEGF conjugate, at either concentration 
(Groups 3 and 4), compared to the untreated Controls (Group 5), at either the central 
or marginal wound areas. An inflammatory stimulus was observed in the free rhEGF 
(Group 2) and free succinoylated dextrin (Group 1) specimens, at the central wound 
area (p  < 0.004) (Figure 7.13).
7.3.2.3 Angiogenesis
Quantitative assessment of angiogenesis within the wound (at the central, 
intermediate and marginal zones), at day 16, was performed by quantifying the 
number of angiogenic events, per hpfov. The marginal and intermediate hpfovs were 
each from the right and left side o f the wound, and the mean calculated (± S.E.M.). 
In the central wound area, there was a significant difference in angiogenic events 
between the dextrin-rhEGF conjugate Group 4 (10 pg/mL rhEGF equivalent), 
compared to the untreated Controls (Group 5) (p = 0.011).
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Figure 7.11 Wound area reduction, over 16 days. Panel (a) shows the wound area reduction in all 5 Study Groups over the 
16 day, Study period. Panel (b) shows the wound area, on day 16, as a percentage of the wound size, on day 0 
(mean ± S.E.M., * p  < 0.001, ** p = 0.028, Mann-Whitney U-test).
Figure 7.12
■  Succinoylated dextrin, 50 pg/mL
■  rhEGF, 10 pg/mL 
Dextrin-rhEGF 1 pg/mL 
Dextrin-rhEGF 10 pg/mL
□  Film dressing alone
(Group 1) 
(Group 2) 
(Group 3) 
(Group 4) 
(Group 5)
2 3 4
Study Group
_L
Granulation tissue formation, at day 16. The granulation tissue 
scores for each Study Group, at day 16 (mean ± S.E.M., * p  = 0.004, 
** p  = 0.006, Mann-Whitney U-test).
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Figure 7.13
I  Succinoylated dextrin, 50 pg/mL 
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Wound maturity. Panel (a) shows the wound maturity scores for samples selected 
from the wound centre. The Table shows Group comparison with untreated controls 
(Group 5) and panel (b) from the wound margin (mean ± S.E.M.) The dextrin- 
rhEGF conjugate (at both 1 and 10 pg/mL), did not significantly effect wound 
maturity, compared to untreated controls {p > 0.05), at either the centre or wound 
margin. Free rhEGF induced an inflammatory response (low wound maturity score), 
at the wound centre (*p = 0.002, ** p = 0.004, Mann-Whitney U-test), compared to 
the dextrin-rhEGF conjugate (1 pg/mL). All wounds were significantly more mature 
at the wound margin, than the central wound (*** p  < 0.0001, Mann-Whitney U- 
test).
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In contrast, free rhEGF (Group 2) significantly reduced the number of 
angiogenic counts (p *  0.035). At the intermediate wound zone, angiogenesis was 
significantly enhanced by the dextrin-rhEGF conjugate Group 4 (10 pg/mL rhEGF 
equivalent; p  = 0.001). At the marginal wound zone, significant angiogenesis was 
also observed in the 10 pg/mL rhEGF equivalent, dextrin-rhEGF conjugate Group 4, 
compared to the untreated Controls (Group 5) ip = 0.010). Overall, angiogenic events 
in the wound were significantly increased by rhEGF, released from die dextrin- 
rhEGF conjugate (10 pg/mL rhEGF equivalent; Group 4), compared to untreated 
Controls (Group 5) (p = 0.017), or free rhEGF (10 pg/mL; Group 2) (p = 0.005) 
(Figure 7.14).
The results of the digital wound analysis and histological evaluation of the 
wounds, are summarised in Table 7.4.
7.3.3 Mouse serum rhEGF content
Analysis of the rhEGF content of mouse serum, derived from mice in each 
study group, at day 16, was performed with a human EGF ELISA, which is sensitive 
to rhEGF (Section 2.6.2.5). No rhEGF was detected in any of the samples of mouse 
serum, from any of the Study Groups.
7.3.4 Mouse serum a-amylase content
The pooled sample of mouse serum contained 1800 ± 20 i.u./L a-amylase (n 
= 3, mean ± S.D.). This was approximately ten-times the concentration of a-amylase 
in human serum, or acute or chronic wound fluids (Section 6.3.2).
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Figure 7.14 Wound angiogenesis. Panel (a) shows the number of angiogenic counts per high 
power field of view (hpfov), at the wound centre. The Table shows the significance of 
each Study Group compared to the untreated control (Group 5). Free rhEGF (Group 
2) significantly retarded angiogenesis (highlighted red). Panel (b) shows equivalent 
data from the intermediate wound, with a significant increase in angiogenic counts in 
the 10 pg/mL dextrin-rhEGF conjugate Group (Group 4; highlighted yellow). Panel 
(c) shows similar data for the wound margin, with a significant increase in angiogenic 
counts in the 10 pg/mL dextrin-rhEGF conjugate Group (Group 4). Panel (d) shows 
the average number of angiogenic counts throughout the wound, with a significant 
increase in angiogenic counts in the 10 pg/mL dextrin-rhEGF conjugate Group 
(Group 4). The dextrin-rhEGF conjugate significantly stimulated angiogenesis more 
than free rhEGF, * p = 0.005. All p  values were calculated by Mann-Whitney U-test.
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Table 7.4 Summary of the significance of the effects of the 
dextrin-rhEGF conjugate on db/db mouse wound 
healing in vivo, compared to untreated controls
Dextrin-rhEGF 
(1 ng/mL rhEGF 
equivalent)
Dextrin-rhEGF 
(10 jig/mL rhEGF 
equivalent)
Wound area 
reduction
DAY 11
DAY 16
p  -  0.035
p  > 0.05
p  = 0.002 
p  = 0.028
Wound contraction 
DAY 11 p  = 0.012 p  = 0.031
Re-epithelialisation 
DAY 11 p  > 0.05 p  = 0.001
Granulation tissue 
score
DAY 16
p  > 0.05 p  = 0.006
Wound maturity 
DAY 16
p  > 0.05 p  > 0.05
Angiogenesis 
(mean) 
DAY 16
p  > 0.05 p  = 0.017
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7.4 Discussion
This Chapter aimed to evaluate the dextrin-rhEGF conjugate in an in vivo 
model of impaired wound healing. Other biochemical parameters, such as basic 
pharmacokinetic data and mouse serum a-amylase activity, were also established.
7.4.1 Model selection
The confirmation of the presence of a-amylase within mouse serum, even 
though at a much higher level than in humans, permitted the selection of an in vivo 
murine model. Dawra et al (2007) reported similar levels of serum a-amylase, in 
C57BL/6 mice. The genetically diabetic (db/db) mouse is an established model of 
impaired dermal wound healing, and although, not a true representation of the human 
chronic wound, it has been used in studies o f wound healing, involving rhEGF 
(Browne/ al, 1994).
The db/db mice selected in the present Study, from a North American 
Supplier, showed significantly impaired wound healing, when compared to European 
db/db and non-diabetic mice, of the same strain. Wound area and re-epithelialisation 
were both slower in the North American db/db mice. Wound contraction was similar 
in both models. These findings established the North American diabetic mouse as the 
slowest model o f wound healing, from those available. Therefore, these mice were 
selected for use in the present Study. Other studies involving the North American 
db/db mouse, in the assessment of growth factors on wound healing, include 
Greenhalgh et al (1990), Brown et al (1994) and Kirchner et al (2003).
7.4.2 Wound closure
Wound area was significantly reduced by the dextrin-rhEGF conjugate 
(Groups 3 and 4), when compared to either untreated or other Control Groups 
(Groups 1, 2 and 5). The most significant wound area reduction was observed at 11 
days, with the greatest effect apparent in the high-dose (10 pg/mL), dextrin-rhEGF 
conjugate Group 4. This reduction in wound area was also observed on the 
termination of the Study (day 16), although, the degree of significance was less. The 
Control Groups (Groups 1 and 2) significantly under performed, when compared to 
the untreated, Control Group 5. Wound area was markedly greater, with both the 
succinoylated dextrin polymer and the rhEGF Controls.
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The dosing schedule (100 pL, days 0 and 3) was adapted during the 
experiment to include an extra dose (25 pL, day 8), due to the limited observed 
progression in wound healing, in the dextrin-rhEGF conjugate Groups, during the 
initial stages of the Study. Previously reported studies involving rhEGF in in vivo 
models of wound healing (Brown et al, 1994; Ulubayram et al, 2001; Tanaka et al, 
2005; Alemdaroglu et al, 2006), have involved the application of rhEGF on a 
minimum of a daily basis, via a number of delivery vehicles. The sustained-release 
data established in Chapters 3 and 4, highlighted the potential for reduced dosing of 
the dextrin-rhEGF conjugate. As high local concentrations of rhEGF must be 
prevented, if  inhibition of wound healing is to be avoided (Lai et al, 1989; Breuing et 
al, 1997), this justified the application of the Study compounds, in a staggered 
manner. The effects of the dextrin-rhEGF conjugate, on wound area reduction, began 
to decline following the final, lower-dose on day 11. The instigation of further doses 
at this stage, or earlier, during the Study, may have increased the effects observed at 
the day 16 time-point. The Study duration could also have been increased to a point 
where wounds had fully healed (in the untreated Control Group 5). Previous studies 
involving the North American db/db mouse, have continued to between days 14 to 
21, with an average of 19 days (Greenhalgh et al, 1990; Brown et al, 1994; Kirchner 
et al, 2003).
The sustained-release effect of dextrin-rhEGF appeared to be retained in the 
in vivo model. This is indeed a significant achievement, as this was the first 
experiment performed without the addition of a known quantity of exogenous a- 
amylase. As such, these findings provide further and significant support for the 
Polymer-masking UnMasking Protein Therapy (PUMPT) concept, for the first time 
in vivo. Although the a-amylase activity in mouse serum is approximately 10-times 
that of human serum, a combination of the in vitro data from Chapters 3 and 4 (at 
human physiological levels of a-amylase), and the in vivo findings reported herein, 
appear to suggest that the PUMPT concept would be a viable proposition in the 
human. rhEGF was not detected in any sera of the Study Groups, at day 16, so one 
must assume that even in the conjugated form, the rhEGF has been metabolised and 
excreted. This may have occurred at a local wound level, with proteolytic 
degradation of the rhEGF, or the conjugate may not have been absorbed 
systemically. Even, if absorbed into the lymphatic or systemic circulation, further
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degradation may have occurred in these environments. Additional urine collection, 
throughout the course of the Study, would have revealed more pharmacokinetic 
information and potentially resolved some of the clearance issues.
The significant detrimental effect of the succinoylated dextrin and free rhEGF 
Controls (Groups 1 and 2, respectively) on retarding wound healing, may have been 
due to a series of factors. The effects approached significance at day 11, and by day 
16, is pronounced. The dextrin polymer undergoes a series of purification steps, 
following succinoylation, by dialysis (Chapter 3), to remove excess reactants, but as 
has been shown, by fast protein liquid chromatography (FPLC) (Chapter 3), a 
quantity of dimethylaminopyridine (DMAP) remains. This is subsequently removed 
during the conjugation reaction and purification, by ultrafiltration, and hence is not 
present in the dextrin-rhEGF conjugate. However, unconjugated succinoylated 
dextrin does not undergo these purification procedures. Additionally, the pH of 
succinoylated dextrin is acidic, due to the incorporation the of the carboxylic groups. 
Therefore, a combination of potentially cytotoxic DMAP and the acidic pH, which 
are inherent in succinoylated dextrin, may explain the deleterious effects that have 
been observed with succinoylated dextrin, in the present Study (even at a low dose). 
Thus, the succinoylated dextrin, may not have acted as a true negative Control. 
Further purification of the succinoylated dextrin polymer, for example, by anion 
exchange chromatography, may result in a less toxic polymer Control.
In the Study by Brown et al (1994), rhEGF was applied to excisional wounds 
in North American db/db mice. The dose applied was 1 pg, in a 5% polyethylene 
glycol vehicle, applied daily, for 5 days. Wound healing was measured as 
“percentage wound closure”, the inverse of percentage wound area reduction, as 
described in the present Study. rhEGF was consistently slower to heal wounds, but 
never to a level of significance, compared to the vehicle alone, over 21 days. In 
combination with 10 pg PDGF, the effect on wound closure was increased, but not to 
the levels of PDGF alone. It is this report that the choice of rhEGF concentrations 
employed in the present Study, were based upon. The suppression of wound healing 
in the free rhEGF Control Group (Group 2) may be a consequence of the down- 
regulation of EGF receptors (EGFR), on cells involved in the normal wound healing 
process. Indeed, this suppression of activity at high concentrations of rhEGF was 
identified in Chapter 4. In vitro, rhEGF had maximal activity at ng/mL concentration,
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rather than the pg/mL concentrations, previously utilised in vivo. Indeed, the 
previously reported in vivo studies have all applied EGF at the pg/mL concentration 
(Franklin and Lynch, 1979; Buckley et al, 1985; Mustoe et al, 1991; Ulubayram et 
al, 2001; Tanaka et al, 2005; Alemdaroglu et al, 2006), of which the majority did not 
exhibit any suppression of wound healing. Even though the half-life of EGF is of the 
order of 1-2 hours, in animal tissues (Chan et al, 1991; Prats et al, 2002), any 
suppression caused by EGF in the early stages of wound healing, would cause a 
significant lasting effect on wound area reduction. Pruss and Herschman (1977) 
demonstrated that the interaction between EGF, and its receptor, had to be 
maintained for 10-12 hours, in order to obtain effective cellular responses, in terms 
of better organised granulation tissue, greater DNA and protein content, and a higher 
rate of cell proliferation. The conjugation of rhEGF to succinoylated dextrin, not 
only reduced any toxicity caused by either component, but enhanced wound healing, 
significantly more than the untreated Control Group, possibly through this controlled 
release effect. Based on these findings, a change to the dosing regimen may further 
enhance the beneficial effects observed. Further studies may also include other 
groups such as a 1 pg/mL rhEGF control, and continuation of the study to the point 
of wound closure.
7.4,3 Histology
Histological analysis of the wounds from each Study Group, confirmed the 
macroscopic findings, from the digital wound photography. Granulation tissue 
formation was significantly increased by the dextrin-rhEGF conjugate (10 pg/mL 
rhEGF equivalent, Group 4), compared to free rhEGF (Group 2) or untreated 
Controls (Group 5). Granulation tissue depth was reported by Nanney (1990), to be 
significantly increased in a porcine acute partial thickness wound models, 
proportional to the concentration of free rhEGF applied (10 or 30 pg/mL), although 
toxicity occurred at higher rhEGF doses (50 pg/mL). Interestingly, EGF is more 
commonly associated with increased rates of re-epithelialisation in vivo, rather than 
granulation tissue formation (Franklin and Lynch, 1979; Brown et al, 1989; Martin, 
1997). Brown et al (1994) did not report any significant difference in granulation 
tissue formation, by rhEGF, in the genetically diabetic (db/db) mouse. However, the 
present Study demonstrated the controlled release of rhEGF, from the dextrin-rhEGF
227
Chapter 7 Dextrin-rhEGF Conjugate Evaluation
in an In Vivo Model o f Impaired Wound Healing
conjugate, into the chronic wound environment, resulted in similar improved effects 
on granulation tissue formation, in a comparable manner to those observed in acute 
wounds.
A feature associated with the formation of granulation tissue, is the discrete 
increase in the number of angiogenic events, in response to growth factors, such as 
vascular endothelial growth factor (VEGF) (Roy et al, 2006, Bao et al, 2008). rhEGF 
(10 pg/mL) has been shown to increase the capillary area and number of blood 
vessels, in acute partial-thickness, porcine wounds (Roesel and Nanney, 1995). This 
mechanism of angiogenesis is dependent upon the expression of the epidermal 
growth factor receptor (EGFR), which is involved in multiple facets of the normal 
wound healing response, including inflammation, wound contraction, proliferation, 
migration and angiogenesis (Repertinger et al, 2004). In the present Study, 
angiogenesis was most marked at the wound centre, with diminishing activity 
towards the wound margin, in the untreated Control Group. Stimulation of 
angiogenesis, by the dextrin-rhEGF conjugate, was most pronounced at the wound 
margin, which may be due to the multiple actions of EGF, acting via the EGFR. The 
EGFR expression is reduced at the wound margin, in bum wounds, in the late post­
bum period. Subsequently, increased activation may lead to the promotion of re- 
epithelialisation and granulation tissue formation (Wenczak et al, 1992). Again, the 
controlled release of bioactive rhEGF, from the dextrin-rhEGF conjugate, appears to 
modulate the temporal sequence of normal wound healing, whereas free rhEGF has a 
detrimental effect on wound healing, in the impaired dermal wound model.
The maturity of the wounds was judged by the relative distributions of 
inflammatory and proliferative cells, such as fibroblasts. In the normal wound 
healing response, the sequential transition from the inflammatory phase, to a 
proliferative phase, is pivotal to avoid the adoption of a chronic wound phenotype 
(Harding et al, 2002). If an overwhelming inflammatory reaction occurred, in 
response to the dextrin-rhEGF conjugate, or any of the conjugate components, then 
successful wound closure may not occur. In the present Study, wound maturity was 
significantly increased, in all Groups, at the wound margins, compared to the central 
wounds. Dextrin-rhEGF did not significantly affect wound maturity, but free rhEGF 
and free succinoylated dextrin, did induce an inflammatory response, at the wound 
centre. This effect was lost at the wound margin. As the wound re-epithelialises from 
the edge, the wound progresses from an inflammatory, to a proliferative wound.
i
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Therefore, as the central wound area would be the final region to exhibit this 
progression, this may explain the delayed resolution of inflammation at the wound 
centre. Successful wound closure must occur, prior to the progression to a 
proliferative, or maturing, wound (Martin, 1997).
7.5 Conclusions
In summary, treatment with the dextrin-rhEGF conjugate was found to 
accelerate the closure of full-thickness, excisional wounds, in the diabetic (db/db) 
mouse, relative to wounds in receipt of no treatment, free succinoylated dextrin 
polymer alone, or rhEGF alone. This effect appeared to be associated with a 
combination of both enhanced wound contraction and accelerated re- 
epithelialisation. No significant differences (p > 0.05) were observed between the 
two dextrin-rhEGF conjugate treatment dosing regimes, in terms of wound closure, 
contraction or re-epithelialisation, although a non-significant trend, suggesting a 
dose-dependent increase in wound re-epithelialisation, was observed. The most 
significant effects were apparent in the “high-dose” (10 pg/mL rhEGF equivalent), 
dextrin-rhEGF conjugate Group, when compared to untreated Controls, which were 
markedly better, than the free rhEGF Group, at equivalent concentrations. These 
effects may be due to a combination of the sustained release of rhEGF, from the 
dextrin-rhEGF conjugate, in addition to the increased resistance of the dextrin-rhEGF 
conjugate to proteolytic degradation, or inactivation, in the impaired wound healing 
environment. In addition to this effect on wound closure, the dextrin-rhEGF 
conjugate was determined to significantly promote the initiation of wound healing 
processes, in the diabetic (db/db) mouse model.
Upon histological assessment, the dextrin-rhEGF conjugate was 
demonstrated to: (i) Display a tendency to promote the caudo-cranial contraction of 
the excisional wounds, (ii) increase granulation tissue deposition (in a potentially, 
dose-dependent manner), (iii) display a tendency to promote the cellular maturation 
of neo-dermal wound tissues, and (iv) increase wound angiogenesis (in a potentially, 
dose- dependent manner), relative to untreated Controls.
Further refinement of the dosing schedule may improve the efficacy of the 
dextrin-rhEGF conjugate, although in the present Study, the observations, thus far, 
have been the first to report an improvement in wound healing, using rhEGF, in this
impaired wound healing model. The total dose of rhEGF applied, as a component of
/
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the dextrin-rhEGF conjugate, was also much less than in previous studies, involving 
free rhEGF, which have usually been applied on a daily basis. It is evident that the 
dextrin-rhEGF conjugate allows the application of a much lower dose of rhEGF, but 
has the enhanced stability and release effects, required to preferentially modulate the 
wound healing responses. Further studies may investigate the pharmacokinetics of 
the dextrin-rhEGF conjugate, in vivo, but the baseline investigations reported in the 
present Study, identified no detectable systemic absorption of rhEGF, from the 
topical application of the dextrin-rhEGF conjugate.
/
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Chapter 8 General Discussion
8.1 General Discussion
This is the first Study to investigate the potential o f polymer therapeutics in 
dermal wound healing. It has highlighted key areas, such as dextrin-recombinant 
human epidermal growth factor (dextrin-rhEGF) conjugate synthesis, 
characterisation and purification, in addition to the development of appropriate 
assays, in which to evaluate wound healing responses, including in vitro, ex vivo and 
in vivo models.
8.2 General comments: Dextrin-rhEGF as a bioresponsive nanomedicine to
improve wound healing in vitro
The dextrin-rhEGF conjugates synthesised herein contained, on average, 16 
weight percent (wt %) protein, which corresponded to approximately 2 rhEGF 
molecules per polymer chain. Heterogeneity of the product was unavoidable (evident 
by SDS-PAGE electrophoresis; Chapter 3), which may be attributable to the 
polydisperse nature of the dextrin fraction used for conjugation. A narrower 
molecular weight dextrin fraction could be used to improve conjugate homogeneity, 
if necessary, for clinical evaluation. However, this dextrin of average molecular 
weight of 42,000 g/mol, with approximately 19 mol % succinoylation was chosen 
based on previous studies (Duncan et al, 2008), that suggested this would maximise 
steric “masking” of rhEGF, whilst allowing a sufficiently slow rate of dextrin 
degradation, by a-amylase, to liberate rhEGF, at an optimal rate for sustained 
bioactivity. In addition, although a-amylase will degrade the glycosidic bonds within 
the succinoylated dextrin polymer, the degradation is slowed by the presence of 
carboxylic groups and amide bonds, within the polymer-protein conjugate (Hreczuk- 
Hirst et al, 2001a). Full degradation of the conjugate would require proteinase 
activity. It was confirmed that the conjugation of succinoylated dextrin to rhEGF, 
significantly increased its stability towards proteolysis, by the clinically most 
important protease in chronic wound fluid, neutrophil elastase (Trengove et al, 1999; 
Cullen et al, 2002) (Chapter 3).
As anticipated, succinoylated dextrin polymer conjugation also reduced the 
biological activity of rhEGF. However, consistent with the Polymer masking 
UnMasking Protein Therapy (PUMPT) concept, it was demonstrated that a-amylase, 
when added a concentrations known to be present in human serum and chronic
/
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wound fluid, was able to “unmask’Vrelease rhEGF. a-Amylase-triggered rhEGF 
liberation was confirmed by both FPLC and ELISA (Chapter 3). Polymer 
degradation would, at least initially, be expected to leave oligosaccharides and/or 
maltose, linked to the rhEGF surface. However, the fact that the liberated rhEGF was 
clearly identifiable by EGF immunoassay, and moreover, able to stimulate the 
clinically-relevant parameter of EGF-mediated cell proliferation, underlined the 
effectiveness o f the dextrin-rhEGF conjugate.
HEp2 cells were chosen for the cell viability/proliferation assays, as this cell 
line has high levels of epidermal growth factor receptor (EGFR), and their relatively 
rapid doubling time, made it possible to explore the effect of dextrin-rhEGF 
conjugate, over the more clinically relevant time frame of 8 days. The importance of 
a-amylase, as a trigger for the dextrin-rhEGF conjugate activation was clear 
throughout all the cell viability/proliferation studies performed. Furthermore, it was 
apparent that the stimulation of HEp2 cell proliferation by the dextrin-rhEGF 
conjugate, was directly related to the units of a-amylase present (Chapter 4). In the 
extended HEp2 cell viability/proliferation assay, it was evident that the initial 
delayed release of rhEGF, from the dextrin-rhEGF conjugate, led to a lag phase of 
approximately 24 hours in cellular response, compared to that observed with free 
rhEGF. However, the sustained rhEGF release from the conjugate led to enhanced 
activity, far beyond that achieved with rhEGF alone. This is even more impressive 
given that the EGF ELISA assay, determined a total release of only approximately 60 
% rhEGF, at 168 hours (Chapter 3).
The value of a slow, sustained introduction of bioactive rhEGF is underlined 
by the biphasic, concentration-dependence of rhEGF-induced proliferation (Chapter 
4). Clearly, high local concentrations of rhEGF must be prevented if inhibition of 
wound healing is to be avoided (Lai et al, 1989; Breuing et al, 1997). More clinically 
relevant cells, HaCaT keratinocytes and fibroblasts, derived from both normal 
dermal and chronic wound origin, also demonstrated enhanced proliferation, in the 
presence of the dextrin-rhEGF conjugate, activated by physiological levels of a- 
amylase. Furthermore, it was identified that dextrin-rhEGF conjugates exposed to 
trypsin (as a model proteinase), prior to a-amylase exposure, retained the ability to 
promote cell proliferation. Experiments to investigate the cellular mechanism of 
action of the dextrin-rhEGF conjugate, in HEp2 cells, identified that the conjugate
/
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exposed to a-amylase was able to induce EGFR and STAT3 phosphorylation 
(Chapter 5). This suggested a direct effect on the EGFR and a promotion on signal 
transduction. Such stimulatory effects on migration and wound repopulation would 
be key features o f chronic wound repair in vivo.
8.3 General comments: Dextrin-rhEGF as a bioresponsive nanomedicine to
improve wound healing in vivo
The dextrin-rhEGF conjugate, described herein, was synthesised with the aim 
of protecting the growth factor from the proteolytic chronic wound environment, 
whilst permitting the restoration of bioactivity, with time, when exposed to 
physiological concentrations of a-amylase, using the PUMPT concept (Duncan et al, 
2008). Normal serum a-amylase concentrations occur between a range of 30-300
i.u./L (Raftery, 1998; Branca et a/, 2001), whilst levels in chronic wound fluids occur 
in a similar range (Chapter 6). In this way, a-amylase levels in the chronic wound 
environment would be anticipated to generate novel therapeutics for improved 
wound repair. Traditional wound therapy involves the use of topical agents to clean, 
disinfect and stimulate healing (Menke et al, 2007). This can be a protracted, painful 
process, that is often associated with high levels of morbidity (Harding et al, 2002). 
In contrast to acute wounds, chronic wounds fail to show the controlled 
inflammatory, proliferative and remodelling phases of normal wound healing 
(Mustoe et al, 2006). Numerous factors can be responsible for this malfunction, 
including wound infection, tissue hypoxia, failed angiogenesis and the underlying 
uncoupling o f the normal growth factor cascade. Many attempts have been made to 
find more effective therapies for chronic wounds, but there has been little success 
(Mekkes et al, 2003). Natural and synthetic polymers have been explored as 
biodegradable matrices or hydrogels for the controlled release of growth factors 
(Saltzman and Olbricht, 2002). However, although their topical application in 
conjugation with rhEGF, can increase the rate of re-epithelialisation, in acute wounds 
(Tanaka et al, 2005), little or no significant clinical improvement in chronic wound 
healing has ever been demonstrated (Falanga et al, 1992; Danilenko et al, 1995). 
Consequently, rhEGF remains an experimental protein and its fate seems to depend 
upon a reappraisal of delivery strategies (Prats et al, 2002).
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With the implementation of two independent models o f wound healing 
(Chapters 6 and 7), involving two different species of animal (a rat, ex vivo 
organotypic model of acute wound healing and a mouse, in vivo model of impaired 
dermal wound healing), a significant step-forward in the pre-clinical assessment of 
the dextrin-rhEGF conjugate, was achieved. The data obtained from the in vitro 
models o f wound healing, involving the stimulation of cellular proliferation and 
migration o f cells associated with the normal and pathological wound healing 
response, was reproduced in both animal models. Similar findings were obtained 
both in vitro, ex vivo and in vivo, including the concentration-dependent toxicity of 
high rhEGF concentration and the enhanced effect on wound healing by rhEGF, 
following release from the dextrin-rhEGF conjugate, by physiological levels of a- 
amylase.
The ex vivo model, by design, was similar to the in vitro model of cell 
migration. The experiments were performed over a similar time-scale, and the tissue 
culture medium used for the fibroblasts in vitro and the corneas ex vivo, was of the 
same composition. The exogenous a-amylase (93 i.u./L) utilised, was from the same 
source and prepared in an identical fashion. Although different batches of the 
dextrin-rhEGF were utilised in these experiments, similar results were observed, 
namely enhanced wound healing with the dextrin-rhEGF conjugate, “masking” and 
“unmasking” of the dextrin-rhEGF conjugate, in response to physiological levels of 
a-amylase, and the absence of wound healing, with individual component Controls.
Previous in vivo and clinical studies involving rhEGF have failed to 
demonstrate a significant clinical effect on wound area reduction, in impaired wound 
healing models (Falanga et al, 1992; Tsang et al, 2003; Choi et al, 2007). 
Suppression of the healing response, by free rhEGF, was reported by Choi et al 
(2008), in a similar fashion to the findings in the present Study. In acute wound 
models and clinical studies, rhEGF consistently reduces wound area compared to 
Controls (Brown et al, 1989; Mustoe et al, 1991; Tanaka et al, 2005; Kwon et al,
2006). However, it must be,considered that these small sample number trials have 
not yet resulted in a USA/UK licensed product for use in humans.
Current products that are available in the wound healing field that contain 
rhEGF are at a high rhEGF concentration (ReGenD150; 150pg rhEGF per g of 
carrier matrix, resulting in mg quantities o f rhEGF being applied to a large wound
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area), to account for the protein degradation in chronic wounds (Krishna-Mohan,
2007). At high levels, the systemic uptake may be increased, potentially leading to 
peripheral side effects, due to rhEGF. EGF promotes tumour invasion in EGFR 
positive cancer cells (Zolfaghari and Djakiew, 1996; Kondapaka et al, 1997; 
Angelucci et al, 2006). Therefore, based upon the findings herein, the dextrin-rhEGF 
conjugate, containing rhEGF at a much lower concentration, would need less rhEGF 
for the manufacture of dextrin-rhEGF, and a less concentrated formulation will need 
to be applied. Indeed, stimulation of cells in these experiments occurred at pg/L 
concentrations, at levels that are similar to normal serum EGF levels (317 pg/mL ± 
31 pg/mL; Savage et al, 1986). Thus, any systemic absorption, or release of rhEGF, 
from dextrin-rhEGF, would be at physiological levels. The most advanced clinical 
trial, involving rhEGF application to chronic wounds, has involved 135 participants 
in a multi-centre phase IV, post-marketing surveillance Study, which reported 
enhanced wound healing, with no significant side-effects, although some elements of 
the Study design and report may be questioned (Krishna-Mohan, 2007).
The reasons for the limited success of growth factor therapy has been 
attributed to (i) an inappropriate release profile in the clinical setting, (ii) the lack of 
stability of the protein in the delivery system or post-delivery, (iii) rapid protein 
degradation of rhEGF, by chronic wound proteinases or denaturation by reactive 
oxygen species (ROS) (James et al, 2003; Moseley et al, 2004), (iv) the lack of 
stability of the protein in the delivery vehicle used for application, and/or the toxicity 
of the polymeric carrier used (e.g. a polyethyleinimine-nitric oxide adduct; Bauer et 
al, 1998). It should be noted, however, that one approach, Regranex®, which is a 
topically-applied gel, containing recombinant human, platelet derived growth factor 
(rhPDGF), recently became the first recombinant growth factor to be approved by the 
US Food and Drug Administration (FDA), for the acceleration of wound healing and 
it is currently used in the treatment of diabetic foot ulcers. However, even in this 
case, Regranex® has been shown to be only effective in selected wounds (< 1.5 cm2), 
in conjunction with good wound care, with no reduction in ulcer recurrence, when 
compared to good wound care alone (Steed, 2006). More recently, in March 2008, 
the FDA reported an ongoing safety review of Regranex®, concluding that people 
who have used three or more tubes of becaplermin gel, and who have or develop 
cancer, are more likely to die from the cancer than people who have cancer, and who
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have not used becaplermin gel (FDA, 2008). However, despite these concerns, the 
product still remains licensed for use, at present.
The improvement in wound healing, reported in the present Study (Chapter 
7), attributed to the dextrin-rhEGF conjugate, is more significant than other studies 
involving rhEGF and its application to chronic wounds in vivo (Choi et al, 2008). 
Regranex® has been reported to consistently improve the granulation tissue 
deposition, when applied in vivo, to wounds in genetically diabetic (db/db) mice, 
although wound closure is not significantly affected (Brown et al, 1994; LeGrand, 
1998; Chan et al, 2006). The dextrin-rhEGF conjugate, not only enhanced 
granulation tissue deposition in the diabetic mouse model, but also significantly 
increased wound closure rates. The aforementioned concerns about the safety of 
Regranex®, may open the door for new wound healing products, such as the dextrin- 
rhEGF conjugate, given that dextrin has an established safety profile (Day, 2003), 
which may out-perform existing products. Further pre-clinical investigation may 
result in the production of the dextrin-rhEGF conjugate that could be scaled up to an 
industrial level (such as further purification, possibly via chromatographic 
techniques, to remove any residual free polymer). It has been previously argued that 
Regranex® is a cost-effective treatment for chronic wounds (Ghatnekar et al, 2001), 
but the observed effects are marginal (Persson et al, 2000). With lower component 
costs than Regranex®, dextrin-rhEGF may represent a more cost-effective option, 
although it must be considered that further developmental costs and industrial 
production, could significantly affect the final costings.
8.4 General comments: Polymer therapeutics to modulate cellular responses
in impaired human wound healing
In conclusion, the present Study has demonstrated, for the first time, the 
potential of a bioresponsive, polymer therapeutic, as a nanomedicine for wound 
healing. For effective bioresponsive drug delivery, the system must have at least 
three components, a biosensor for detecting external signals; signal processing for 
determining when to respond; and an actuator for drug release. Many studies have 
shown that successful bioresponsive systems require additional functions, such as 
protecting the drug, until required, and releasing the drug in a timely, controlled 
manner (Park, 2008). The development of a bioresponsive polymer-drug conjugate,
/
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designed specifically to promote wound healing, opens a new possibility of 
bioresponsive drug delivery, not only for treatment of acute and chronic dermal 
wounds, but also for drug targeting, based on specific stimuli found at a target site.
The positive effects observed with the dextrin-rhEGF conjugate during in 
vitro, ex vivo and in vivo Studies, would support the further evaluation of the 
conjugate towards clinical trials. First clinical studies would certainly involve the 
local, topical application of the dextrin-rhEGF conjugate to diabetic and/or venous 
leg ulcers. These pathologies are causative of the majority of non-healing, chronic 
wounds and as such, there is real clinical need for new treatment therapies. However, 
the dextrin-rhEGF conjugate also has potential for intravenous administration, as it 
would be expected to exhibit targeted delivery to wounds developing new blood 
vessels, by angiogenesis and thus, display localised vascular hyperpermeability, for 
example, via the enhanced permeability and retention (EPR) effect (Matsumara and 
Maeda, 1986). Given that recent studies have shown that polymer conjugates can be 
tailored to deliver an anticancer combination therapy (Vicent et al, 2005), the 
approach reported here has also has the versatility to deliver other established growth 
factors (and / or their combinations), integral to the enhancement of dermal wound 
healing. This Study also verifies the broader therapeutic potential of the PUMPT 
concept, especially using the combination of dextrin and a-amylase, as the enzyme is 
widely distributed in serum and extracellular fluids (Miyasaka and Rothman, 1982).
The present Study has formed the basis for further translational research and
development of the dextrin-rhEGF conjugate, from the “bench to the bedside”,
hopefully to provide a more effective treatment strategy, for impaired dermal wound
healing, than those currently available. Given the overwhelming evidence, described
herein, to support the PUMPT concept, it could be further applied to other polymers
and bioactive proteins, in the future treatment of a variety of medical disorders. The
use of different growth factors, antimicrobial agents, or antioxidants, alone or in
combination as a co-conjugate, may be applicable to areas of regenerative medicine
involving different tissues, such as bone and cartilage, or more complex organs,
^  , 
including the kidney or brain.
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This appendix DVD contains:
1. In vitro scratch wound assay QuickTime™ movie files (.mov) of HaCaT 
keratinocytes, normal dermal fibroblasts and chronic wound fibroblasts 
(typical representative files).
Disc 2:
2. An electronic copy of this Thesis (.doc).
3. Electronic copies of publications arising from this Thesis (.pdf).
4. In vivo digital wound photography and wound histology images (all are 
PowerPoint® presentation files, .ppt).
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Chapter 1 General Introduction
follows:
• Firstly, dextrin-rhEGF conjugates will be synthesised, and characterised. To 
assess the ability of the dextrin-rhEGF conjugate to release rhEGF, in 
response to a-amylase, degradation studies will be performed under 
simulated physiological conditions, to confirm the stability of the dextrin- 
rhEGF conjugate in response to proteolysis (Chapter 3).
• In vitro studies will be used to determine the bioactivity of the dextrin-rhEGF 
conjugate, in both “masked” and “unmasked” conditions, using models of 
wound healing involving cell lines derived from normal human skin 
(keratinocytes and fibroblasts) and chronic wounds (fibroblasts). Cellular 
proliferation and migration in response to unmodified rhEGF and conjugated 
rhEGF will also be investigated (Chapter 4).
• After confirmation of rhEGF release from the polymer, in vitro assays of 
bioactivity will be performed to ensure that the modified rhEGF retains the 
ability to bind to the specific cell-surface receptor, and activate intracellular 
signalling pathways. (Chapter 5).
• Having established the bioactivity in vitro, an ex vivo model of acute wound 
healing will be developed, using rat corneas. Other ex vivo studies include the 
collection and analysis of human wound fluid from acute and chronic dermal 
wounds, to confirm the presence and activity of a-amylase (pivotal for 
dextrin-rhEGF degradation and activation) and a characteristic wound 
proteinase (neutrophil elastase) (Chapter 6).
• Having established the activity of the dextrin-rhEGF conjugate, both in vitro 
and ex vivo, an in vivo animal (mouse) model of impaired wound healing will 
be utilised for the final stage of pre-clinical assessment (Chapter 7).
Based upon this synthetic and pre-clinical assessment study of dextrin-rhEGF 
as a bioresponsive nanomedicine for dermal wound healing, future aims would be to 
expand the types of polymer and mediators of wound healing (other growth factors, 
antibiotics, anti-inflammatory agents), used in the construction of healing-promoting 
polymer therapeutics, leading to novel treatments to alleviate the increasing burden 
of chronic wounds.
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Chapter 3 Synthesis And Characterisation of Dextrin-rhEGF Conjugates
3.2.6.1 Degradation assays of dextrin, succinoylated dextrin and the dextrin- 
rhEGF conjugate, by GPC
Samples of dextrin, succinoylated dextrin and the dextrin-rhEGF conjugate (1 
mg/mL) were added to physiologically relevant a-amylase concentrations (93 i.u./L), 
in PBS. These were incubated at 37 °C, 100 pL samples (x 3) removed and snap- 
frozen in liquid nitrogen, at time points between 0 and 168 h. These samples were 
analysed in triplicate, using GPC (Section 2.6.2.1).
3.2.6.2 Degradation assays of the dextrin-rhEGF conjugate, by FPLC
The dextrin-rhEGF conjugate (1 mg/mL in PBS) was incubated at 4 °C and at 
37 °C, in a-amylase-free conditions, for 168 h. a-Amylase (93 i.u./L) was added to 
samples of the dextrin-rhEGF conjugate (1 mg/mL in PBS) and incubated at 37 °C. 
The dextrin-rhEGF conjugate was also lyophilised and stored at -20 °C for 168 h. 
Samples (100 pL) were snap-frozen in liquid nitrogen, at time points between 0 and 
168 h. The samples were thawed and analysed using FPLC (Section 2.6.1). 
Chromatogram peak areas, corresponding to the dextrin-rhEGF conjugate and free 
rhEGF, were recorded. The ratios of free rhEGF : dextrin-rhEGF were subsequently 
calculated.
3.2.6.3 Determination of rhEGF concentration by ELISA
For quantification of free rhEGF, liberated from the dextrin-rhEGF conjugate, 
in the presence and absence of physiological a-amylase levels, an ELISA was 
employed. This colorimetric assay had a range of detection of 0.7-250 pg/mL. As 
such, samples of the dextrin-rhEGF conjugate were diluted to 250 pg/mL rhEGF 
equivalent in dilution buffer (RD5E, in ELISA kit), in the presence, or absence of 
physiological a-amylase concentrations (93 i.u./L). Samples (200 pL, x 3) were 
taken at time points between 0 and 168 h and snap-frozen in liquid nitrogen. The 
ELISA was performed, as described in Section 2.6.2.5.
3.2.7 Stability of rhEGF and the dextrin-rhEGF conjugate, in response to 
proteinases
The dextrin-rhEGF conjugate (1 mg/mL) and rhEGF (1 mg/mL) were 
dissolved separately in PBS (1 mL). To assess stability to proteolytic degradation,
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human neutrophil elastase (100 pg/mL) or trypsin-EDTA (0.025 %) was added to 
these samples and incubated at 37°C. Aliquots (200 pL) were taken at time points 
between 0 and 24 h, and snap-frozen in liquid nitrogen. On completion of the 
experiment, all samples were thawed and analysed by FPLC, as described in Section 
2.6.1. Degradation of rhEGF and the dextrin-rhEGF conjugate were assessed by the 
changes in the area of the characteristic chromatogram peaks.
3.2.8 Statistical analysis
Statistical analyses were undertaken using GraphPad Prism® version 4.00 
(GraphPad Software, San Diego, USA). Data were compared using a Student's t-test 
and a one-way ANOVA, with a Bonferroni post-test. Results are expressed as a mean 
and standard deviation (S.D.), or standard error of the mean (S.E.M.). Statistical 
significance was considered at a probability ofp <  0.05.
3.3 Results
3.3.1 Synthesis and characterisation of the dextrin-rhEGF conjugate
When dextrin (51,000 g/mol) was succinoylated, the degree of modification 
was confirmed by titration to be between 19 - 21 mol %. Typically, the reaction 
conversion efficiency for succinoylation was approximately 30 - 40 % of the 
theoretical maximum.
Characterisation of dextrin by FUR (Figure 3.6) showed characteristic peaks 
at 3,640 (OH), and 1,450 cm'1 (O-CH2). On succinoylation, the ester peak at 1,720 
cm'1 was observed to increase in signal strength, in relation to the degree of 
modification. GPC, using pullulan standards, suggested an apparent molecular 
weight increase from 57,000 ± 500 g/mol (mean ± S.D., n = 3) to 84,000 ± 1,500 
g/mol (mean ± S.D., n = 3), following succinoylation, with little change in 
polydispersity (dextrin = 1.73, succinoylated dextrin = 1.75) (Figure 3.7).
The ninhydrin assay .estimated the mean numbers of primary amines as 1.2 ± 
0.1 (mean ± S.D., n = 3), per molecule of rhEGF for conjugation. When the 
succinoylated dextrin intermediate was conjugated to rhEGF, using EDC and sulfo- 
NHS, SDS-PAGE confirmed the presence of a high molecular weight conjugate with
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Chapter 6 Dextrin-rhEGF Conjugate Evaluation in an Ex Vivo
Model o f  Wound Healing And Wound Fluid Analysis
the dextrin-rhEGF conjugate, rather than free rhEGF. It must be considered, 
however, that the ELISA employed herein, will detect the presence of EGF, but not 
the activity of EGF. The absence of detectable EGF within chronic wound fluid is 
similar to the findings o f Wlascheck et al (1997), who described the degradation of 
growth factors in response to chronic wound fluid. The levels of EGF in acute wound 
fluids (34 ± 22 pg/mL) were lower than human plasma levels (317 ± 31 pg/mL) 
(Savage et al, 1986), which may suggest an instability of rhEGF in acute wound 
fluids, in response to other wound proteinases, other than neutrophil elastase, which 
was undetected in acute wound fluids. It may also be due to the short plasma half-life 
of EGF (Kuo etal, 1992).
6.5 Conclusions
The efficacy o f the dextrin-rhEGF conjugate, in an ex vivo model of acute 
wound healing, was established in this Chapter. Dextrin-rhEGF conjugate activity 
was dependent upon activation by a-amylase, at a physiological concentration (the 
PUMPT hypothesis), as in the inactive “masked” state; there was no significant 
rhEGF bioactivity, compared to rhEGF-free controls. The ex vivo model of comeal 
wound healing, has been shown to be reproducible, and that it is a reliable model for 
further analysis o f polymer-protein conjugates. In addition, wound fluid analysis has 
confirmed the presence o f a-amylase, equivalent to serum concentrations, in both 
acute and chronic wound fluids, relevant to dermal repair situations. This has, 
therefore, justified the use of physiological concentrations of a-amylase, in the 
characterisation and evaluation of the dextrin-rhEGF conjugate. Previous studies on 
the degradation of succinoylated dextrin and its conjugates, involved the use of non­
human, a-amylase, at much higher concentrations (Hreczuk-Hirst et al, 2001a). This 
Study has confirmed these previous findings, but in a more clinically relevant setting.
The next line o f investigation involved the establishment of an in vivo model 
of impaired dermal wound healing, and the evaluation of both rhEGF and the 
dextrin-rhEGF conjugate, in the promotion o f wound repair, in this context.
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